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Abstract
Sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) is an integral
membrane protein with known involvement in the maintenance of resting membrane
potentials, nutrient uptake, cellular signal transduction, and cell-cell adhesion. The
functional enzyme contains a catalytic alpha subunit and a glycosylated beta subunit, of
which three isoforms of each are known to exist in the central nervous system (CNS).
Altered expression and/or activity of Na+/K+-ATPase subunit isoforms has been
previously implicated in the pathophysiology of several neurological disorders. This
study characterized Na+/K+-ATPase expression and distribution in the myelin membrane,
identified its specific heterodimeric forms and binding partners, and explored its
possible involvement in demyelinating disorders, such as multiple sclerosis. For the first
time, Na+/K+-ATPase α1, α2, and α3, as well as the β1, β2, and β3 subunits, were shown to
co-express within a tissue of the CNS. These six isoforms, in addition to six isozymes
(α1β1, α2β1, α2β3, α3β1, α3β2, and α3β3), of Na+/K+-ATPase were identified in myelin
isolated from mouse brain; this expression shared both similarities and differences with
neurons, astrocytes and/or oligodendrocytes. The major isozymes of Na+/K+-ATPase
identified in myelin were α1β1, α2β3, and α3β1. Co-immunoprecipitation (co-IP) assays
demonstrated that the three alpha isoforms of Na+/K+-ATPase in the myelin sheath can
interact with other Na+/K+-ATPase alpha and beta subunit isoforms, in addition to
associating with certain myelin-specific proteins and other protein types. These protein
binding partners of Na+/K+-ATPase have known cellular functions, including RNA splicing,
involvement in cell-cell migration and adhesion, the mediation of cytoskeletal
ii

interactions, and the regulation of protein degradation and apoptosis; they also
suggested localization of Na+/K+-ATPase to the adherens junctions, tight junctions,
caveolin-1 enriched microdomains, lipid rafts and tetraspanin-enriched microdomains of
myelin. Western blot analysis indicated that Na+/K+-ATPase expression varies over postnatal development. Distinct differences in protein expression were observed between
healthy and diseased myelin. In particular, demyelinating ND4 mice exhibited severe
impairment of Na+/K+-ATPase β1 subunit maturation. Overall, this study has provided a
comprehensive look into Na+/K+-ATPase expression and interactions within the myelin
sheath, emphasizing its importance to both myelin structure and function.
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Chapter 1 – Introduction
1.1 The Nervous System
The nervous system is a complex network of cells which transmit both motor and
sensory signals between different parts of the body. It allows the body to respond to
changes in its internal and external environments [1]. The nervous system is divided into
two distinct, but mutually supporting, branches: the central nervous system (CNS) and
the peripheral nervous system (PNS). These systems, as well as their subdivisions, are
described in Figure 1.1. Consisting of the brain and spinal cord, the CNS is responsible
for higher mental functions and is recognized as the processing center for all of the
received stimuli. Alternatively, the PNS is fundamental in reacting to stimuli and uses
nerves to conduct the electrical signals between nerve cell bodies outside of the CNS,
called ganglia, with the CNS itself [1]. Collaboration between these two divisions is
critical for the conscious and unconscious processes required to sustain life.
To facilitate signal transmission throughout the body, specialized cells called
neurons receive stimuli and conduct electrochemical waves to other parts of the
system. These waves are traditionally called action potentials. Neurons, or nerve cells,
receive information via specialized processes called dendrites, which extend from its cell
body. Receipt of stimuli will trigger an electrical impulse (action potential), originating in
the cell body and propagating along the axon of the neuron. This process is typically the
longest extension of the cell, and most neurons generally only have one [1].
Neurotransmitters allow the signal to be passed from one neuron to another, via
1

specialized contact points called synapses [1]. A synapse will connect the axon of the
pre-synaptic neuron with the post-synaptic cell, often the dendrites of another neuron.
Post-synaptic cells may become excited or inhibited depending on the neurotransmitter
in effect.

Figure 1.1 The divisions of the nervous system
The nervous system is divided into the CNS and PNS. The CNS comprises the brain and spinal cord, and
processes the neural information that is transmitted. The PNS reacts to stimuli and uses nerves to conduct
the electrical signals between nerve cell bodies outside of the CNS to the spinal cord and brain. The
peripheral nervous system accommodates both motor and sensory functions; motor responses may be
either voluntary or involuntary and therefore are further divided into the somatic and autonomic systems,
respectively. Involuntary motor responses include those which prime the body to react to stressful stimuli
or trigger the activities that occur in the resting state.

The non-conductive cells of the nervous system are often designated as
supporting cells. They can provide protection of the delicate neuronal processes,
insulation of electrical impulses, and connect the nervous system to the vasculature [1].
2

In the CNS, these cells are commonly referred to as glia, or glial cells. Astrocytes are the
most abundant cell type in the nervous system and the largest of all neuroglial cells [1].
They are essential in maintenance of the blood-brain barrier, in addition to maintaining
ionic homeostasis, they provide metabolic support to neurons and respond to injurious
stimuli [2]. Interestingly, astrocytes have the ability to express voltage-gated sodium
channels, despite being classically considered inexcitable [2]. Oligodendrocytes are
another glial cell type; their PNS equivalents are called Schwann cells. Both
oligodendrocytes and Schwann cells are much smaller in size when compared with
astrocytes, and are responsible for the formation of and maintenance of the myelin
sheath. Finally, microglia and ependymal cells are two other types of neuroglia. The
former possesses phagocytic properties which are often employed in cases of disease or
tissue damage, whereas the latter forms the lining of the ventricles and canals of the
CNS [1].

1.2 The Myelin Membrane
1.2.1 Structure, Function and Morphology
The propagation of action potentials along a neuronal axon is significantly
increased when the axon has been electrically insulated [3]. This insulation can be
provided by oligodendrocytes in the CNS or Schwann cells in the PNS, in the form of
myelin; however, the formation of the myelin sheath in the CNS is more complicated, as
a single oligodendrocyte can myelinate several axons [1]. As shown in Figure 1.2,
myelination of an axon is achieved by the wrapping of cytoplasmic extensions of the
3

supporting cell to form concentric layers of oligodendrocyte or Schwann cell plasma
membrane [1;4;5]. During this process, cytoplasm within the wrapping processes of the
myelinating cell becomes extruded such that the lipid bilayers are side by side; the
intracellular space is compacted to produce the major dense line of myelin, while the
extracellular space becomes the intraperiod line of myelin [4]. Neighbouring segments
of myelin, along the same neuronal axon, are generated by different oligodendrocytes
[6]. The result of myelination is a multi-layered, lipid rich membrane, called the myelin
sheath, which protects and insulates the axons of vertebrates for rapid neural
transmission. Action potentials generated in myelinated axons are restricted to the
nodes of Ranvier; these are segments of the neuron which are not insulated by myelin.
Consequently, action potentials travel more rapidly via myelinated axons, as they do not
need to travel the full length of the axon; this phenomenon is referred to as saltatory
conduction [1].

4

Figure 1.2 The process of myelination by oligodendrocytes
Oligodendrocytes can myelinate multiple axons, and multiple segments of a single axon, by repeatedly
wrapping extensions of their cytoplasm around the neuronal axons, forming concentric layers of cell
plasma membrane. The cytoplasm and extracellular space of the myelinating cell become extruded such
that the lipid bilayers are side by side. The intracellular space is compacted to produce the major dense
line of myelin. The extracellular space becomes the intraperiod line of myelin. Image adapted from
references [1;7].

The biogenesis of oligodendrocytes begins with their conception from migratory
and mitotic precursors; these become progenitor cells, specifically oligodendrocyteastrocyte glial progenitor cells (OPCs), and mature into post-mitotic myelin-producing
cells [6;8]. The maturation of the oligodendroglial cell lineage, and differentiation into
myelin-forming cells, is accompanied by corresponding changes in protein expression; in

5

particular, cell surface antigens which can be recognized by monoclonal antibodies and
act as markers of the oligodendrocyte cell lineage [6]. The OPCs are generated in waves,
beginning in early embryonic development and continuing after birth [9]. These
progenitors migrate throughout the CNS prior to maturation; they are guided by
extracellular matrix (ECM) molecules. For example, tenascin-C has proposed inhibitory
effects on oligodendrocyte migration, as increased expression at the rat retina-optic
nerve junction coincides with an absence of oligodendrocytes [6]. Oligodendrocyte
maturation into myelinating cells predominately occurs in the early post-natal life of
mammals. Post-migration, the progenitor cells become established along the neural
tracts of the CNS that are destined to become white matter; here they differentiate
further into preoligodendrocytes [6]. These immature oligodendrocytes, or
preoligodendrocytes, express 2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNP), which
is the first myelin-specific protein that is known to be produced by oligodendrocytes.
Finally, the expression of myelin basic protein (MBP), myelin-associated glycoprotein
(MAG), and proteolipid protein (PLP) indicate fully matured oligodendrocytes [6].

1.2.2 Lipid and Protein Composition and Membrane Microdomains
The myelin sheath has a high lipid to protein ratio, with its protein composition
classically perceived as low in complexity. An estimated 70-80% of the dry weight of
myelin is lipid [10;11]. The lipid content is composed of a 2:2:1:1 molar ratio of
cholesterol to phospholipid to galactolipid to plasmalogen [11]. It is unclear how
cholesterol and these other lipids are enriched to such an unparalleled degree, in
myelin. With regards to protein content, oligodendrocytes and Schwann cells express
6

different myelin-specific proteins [1]. In the PNS, Schwann cells express myelin protein
zero (P0) and peripheral myelin protein 22 (PMP-22) during myelination; PLP, myelin
oligodendrocyte glycoprotein (MOG), oligodendrocyte myelin glycoprotein (OMgp), and
other proteins act as proxies in the CNS [1]. PLP and its isoforms represent 30-45% of
the total myelin protein in the CNS [11]. It is believed that PLP provides structural
support for the maintenance of the compact lamellar structure of myelin; though it has
also been speculated to act as an ionophore [12]. The second most abundant protein
found in CNS myelin is MBP; 22-35% of total myelin protein consists of a combination of
MBP isoforms [11]. Finally, CNP makes up 4-15% of the total protein in myelin, while the
remaining 5-25% is a combination of a variety of different proteins [11]. Transporter
proteins and ion channels have not been extensively studied in the myelin membrane.
The myelin sheath, like any biological membrane, is fluid in nature. Molecules
within the lipid bilayer are not static; instead, they are dynamic and capable of diffusion
within the membrane itself. The fluid mosaic model, proposed by Singer and Nicolson in
1972, describes the ability of proteins and lipids to move via rotational or translational
diffusion [13]. Consequently, cellular membranes are heterogeneous and exhibit phase
separation. Two coexisting phases, specifically the liquid-disordered (Ld) and liquidordered (Lo) phases, are identifiable and can be differentiated by their lipid components;
this compartmentalization is observed in the lipid bilayer of model membranes. The
liquid-disordered phase is cholesterol-poor and primarily composed of unsaturated
lipids, or those with short acyl chains, resulting in a more fluid and disordered
membrane [14;15]. In contrast, cholesterol and other sterols are intrinsic to the liquid7

ordered phase [14;15]. This phase is often enriched in sphingolipids, while containing
few transmembrane proteins. Cholesterol and sphingolipids become tightly packed,
along with saturated lipids, within the Lo phase, creating a thickened, less fluid and more
ordered membrane.
Although biological membranes, including the myelin sheath, are fluid, the lipid
bilayer is maintained by hydrophobic and hydrophilic interactions; hydrogen bonding,
electrostatic interactions, and van der Waals forces also contribute to the arrangement
of lipids and proteins in the membrane [13]. These intermolecular forces are involved in
the maintenance of Lo and Ld phases, as well as the formation of membrane
microdomains, which are basis for many membrane-associated cellular processes [15].
Membrane microdomains, often termed lipid rafts, are enriched in cholesterol and
other lipids with longer, highly saturated fatty acid chains; these are characteristic of the
Lo phase. Experimentally, in biological membranes, lipid rafts are isolated as detergent
resistant membranes (DRMs) using non-ionic detergents at 4oC. Numerous integral and
peripheral membrane proteins are incorporated amongst these lipids, and they impart
significant functional roles in biological membranes, including signal transduction,
cellular transport, secretion and endocytosis [1;14;16]. The close proximity of
interacting proteins within lipid rafts offers efficient signal transduction and has defined
these microdomains as “signaling platforms” within biological membranes [1;14].
Proteins identified in the microdomains of myelin have demonstrated developmental
regulation that is essential for maintenance of the myelin sheath; similarly, lipid rafts in
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oligodendrocyte progenitors have been noted to contain proteins that provide vital
roles in the signaling cascades necessary for their maturation and differentiation [16].

1.3 Demyelinating Diseases
1.3.1 Multiple Sclerosis
Multiple sclerosis (MS) is a chronic disease of the central nervous system. It is
characterized by the destruction of the myelin sheath; a consequence of myelin
detachment from the axon of neurons [1]. These two processes are termed
demyelination and intramyelinic edema, respectively [4]. The loss of myelin is usually
coupled with damage to the oligodendrocytes which generate and maintain the myelin
sheath [1]. Consequently, MS is a model example of a myelinopathy, in which the myelin
sheath is damaged either directly or incidentally as a result of injury to the myelinating
cells [4]. Grinker myelinopathy and Guillain-Barré syndrome are two other well-known
myelinopathies. Figure 1.3 illustrates the typical pattern of myelinopathy, in addition to
depicting other types of neurotoxic injury. The disruption of the myelin sheath, and the
fundamental changes in its protein and lipid chemistry, contributes to the presentation
of plaques which are customarily found in the white matter of individuals afflicted with
MS [1]. In general, the disease manifests in recurring episodes of neurological
insufficiency; symptoms differ according to the regions of the CNS which are affected
[1]. Ultimately, the problem remains a consequence of impaired, or non-existent,
transmission of action potentials. Schwann cells in the PNS are able to remyelinate
neuronal axons, thereby restoring the transmission of electrical impulses; unfortunately,
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remyelination in the CNS is more complicated and only occurs to a limited extent [4].
Without adequate cell division of the myelinating cells, the axon remains exposed and
can initiate undesirable cross-talk with adjacent axons [4].

Figure 1.3 Patterns of injury in the cells of the nervous system
Several different processes can result in injury to the cells of the nervous system; these include
neuronopathy, axonopathy, myelinopathy and transmission toxicity. Neuron death is termed
neuronopathy, and often causes the proliferation of astrocytes. Axonopathy occurs when the axon
degenerates, despite neuron survival; the axon is the primary site of injury. Damage to the myelin sheath
is termed myelinopathy. Myelinopathies may develop as a consequence of injury to the oligodendrocytes
in the CNS, or Schwann cells in the PNS. In cases where cells are uninjured, transmission toxicity can still
occur; excitation may be blocked, or cells may become excessively stimulated. Communication between
neurons and their post-synaptic cells is disrupted. Image adapted from reference [4].

MS varies in its presentation of symptoms; as such, it has been clinically divided
into four different types. Relapsing-remitting MS (RRMS) is diagnosed in individuals who
experience random episodes of symptom flare-ups, followed by periods of recovery or
remission [18;19]. These so-called attacks may introduce new symptoms or simply a
worsening of existing ones. Both symptomatic episodes and remission periods can last
anywhere from a few hours to several months. RRMS is most common in MS patients,
with more than 80% of cases initially presenting as this type [19]. Two subgroups of
10

RRMS exist; benign MS and clinically isolated syndrome. Cases in which remission
reaches near completion, and in which there is limited progression in physical disability
15-20 years post-diagnosis, are described as benign MS [18]. Alternatively, patients who
experience only single episodes of neurological symptoms are often diagnosed with
clinically isolated syndrome (CIS), sometimes called ‘probable MS’ [18]. The second main
classification is primary progressive MS (PPMS). It affects roughly 10-15% of MS patients
and is characterized by the continued advancement of symptoms and escalation of
physical disability [18;19]. This form of the disease often presents later in life, and is the
only type of MS which equally affects both men and women [18]. In all other types,
women appear to be most vulnerable to the manifestation of MS. Secondary
progressive MS (SPMS) initially presents as RRMS, with distinct episodes and periods of
remission; unfortunately, over time the disease evolves such that the disability no
longer improves but continues to gradually worsen [18;19]. Approximately 50% of
patients with RRMS will progress to SPMS within 10 years of their initial diagnosis [18].
Finally, progressive-relapsing MS (PRMS) is a rare diagnosis, in which the patient
experiences a persistent worsening of symptoms combined with acute attacks of
greater severity [18;19]. Although RRMS, PPMS, SPMS and PRMS are clinically discrete,
the development and symptoms of multiple sclerosis range over a spectrum which can
ultimately make for a challenging diagnosis. Disease-modifying treatments, in addition
to those for symptom management, are available; however, the etiology of MS remains
unclear and there is no known cure.
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1.3.2 Models for Demyelination
An animal model utilizes non-human organisms as a representation of the
pathology, symptoms, and/or prognosis of a human disease. Animal models have been
developed not only as tools for investigating human diseases and disorders, but are key
to the advancement of therapeutics. They provide a means for examining and
manipulating disease processes, such as the development of MS, without unnecessarily
harming actual humans. Although it would be ideal to directly study MS in people, tissue
samples are hard to come by since patients are rarely biopsied [20]. Samples collected
post-mortem provide limited information, as they are often representative of late-stage
lesions and the chronic effects of MS; they do not provide much information regarding
the generation and development of lesions or mechanisms of demyelination [20].
Typical models of MS demonstrate (1) immune-mediated demyelination, (2) viralinduced demyelination, (3) genetic defects leading to demyelination, or (4) toxininduced demyelination [21;22]. Well-known examples of each include experimental
autoimmune encephalomyelitis (EAE), Theiler’s murine encephalomyelitis virus (TMEV),
DM-20 (deletion mutant of PLP), and the cuprizone model, respectively.
Pelizaeus Merzbacher Disease (PMD) is an X-linked dysmyelinating disorder of
the CNS that is characterized by hypomyelination and a reduction in the total number of
mature oligodendrocytes. This human leukodystrophy has been successfully modelled in
mice, rats, rabbits, and dogs; each exhibiting spontaneous mutations [21]. More
specifically, it was discovered that roughly 25% of patients with PMD possess a mutation
in the DM-20 gene which codes for a myelin PLP. DM-20 has proposed roles in
12

myelinogenesis; its expression has been shown in the normal embryonic development
of mice, despite being a minor myelin protein in mature adults [23]. Individuals with
increased protein expression demonstrated a more severe phenotype [21]. This
discovery guided the development of ND4 transgenic mice, which are now used to
model MS. The transgenic ND4 mice contain 70 copies of the DM-20 gene [23]. These
mice are clinically normal up to 3 months of age; however, they develop neurological
deficits which increase in severity as the animals mature. The transgenic mice die shortly
after 8-10 months of age, when neurological symptoms are marked and include tremors
and unsteady gait [23]. It is postulated that as the myelin membrane matures in ND4
mice, the overexpression of DM-20 impedes the formation of compact myelin and
triggers spontaneous demyelination.

1.4 Sodium-Potassium Adenosine Triphosphatase
1.4.1 Structure, Function, and Localization
Sodium-potassium adenosine triphosphatase (Na+/K+-ATPase), also known as the
sodium-potassium pump, is an integral plasma membrane protein responsible for the
maintenance of the resting potential of cells, including oligodendrocytes, astrocytes,
and microglia [24;25]. It belongs to the P-type ATPase family [26]. It specifically utilizes
the energy generated from the hydrolysis of adenosine triphosphate (ATP), in order to
import two potassium ions into the cell for every three sodium ions the enzyme exports
out of the cell [24;27]. The resultant sodium ion gradient produced by the enzyme has
been associated with the cellular uptake of nutrients, such as sugars and amino acids
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[24]. At rest, the sodium-potassium pump utilizes 20-30% of ATP generated [28]. This
active transport of sodium and potassium ions, performed by Na+/K+-ATPase, is a Mg2+dependent process [29]. Like other P-type ATPases, Na+/K+-ATPase forms an acyl
phosphate intermediate; ATP binds to an aspartate residue in the enzyme, via the
terminal phosphate of ATP [27]. All P-type ATPase family members contain a 7 amino
acid motif that include the necessary aspartate residue; this sequence follows the
format of D-K-T-G-T-[LIVM]-[TIS] [27]. The most common version of this DKTG motif is
DKTGTLT [27]. P-type ATPases can be further classified according to their structure and
function. P1-ATPases transport alkali metal cations, and P2-ATPases transport transition
metals or metalloid cations [27]. The P3-ATPase subfamily only has a single member;
KdpB is a protein which specifically transports K+ ions [27;30]. Members of each of these
subfamilies vary in their arrangement of three key amino acid motifs; the DKTG, TGES,
and GDGXNDXP sequences. The TGES motif is located in front of phosphorylation site of
the protein, while the GDGXNDXP motif directly follows the ATP binding domain [27].
Generally there are three protein subunits which assemble together via noncovalent bonds to produce the active form of the sodium-potassium pump [29]. These
include a catalytic α subunit, a glycosylated β subunit, and a proteolipid γ subunit [29].
The subunits are roughly 110 kDa, 45-55 kDa, and 10 kDa, respectively [29]. The α
subunit is polytopic, whereas the β subunit is a type II membrane protein [26].
Alternatively, the γ subunit is a transmembrane protein belonging to the FXYD family
[25]. It is not required for functional expression of Na+/K+-ATPase; as a result, Na+/K+ATPase is commonly identified as a heterodimeric enzyme, composed of a αβ complex.
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Several isoforms of the α and β Na+/K+-ATPase subunits exist. Each isoform may
demonstrate variations in ion, ATP or ligand affinities [24]. Likewise, particular isoforms
can be distinguished according to their location in the plasma membrane, their ability to
couple with other transporters, or the way in which they are regulated [24].
In mammalian cells, studies have successfully identified four isoforms of the α
subunit [24]. Each of these isoforms is roughly 1000 amino acid residues in length [27].
The divergence in amino acid sequences between the isoforms is minor, and it is unclear
how these changes influence the functional roles of the subunits [27]. The amino acid
sequences of Na+/K+-ATPase α1, α2, and α3 are available in Appendix B. The α1 subunit is
the most prominent isoform, with ubiquitous expression in mammalian cells, and it is
typically the dominant or exclusive isoform found in epithelia and kidney cells [24;27].
Alternatively, the α2 subunit is found in specific tissues including brain, muscle, adipose,
osteoblasts, retina, choroid plexus, lung, and the optic nerve [24]. It regulates muscle
contractility, and is involved in responding to stress by adjusting blood pressure [31].
The α3 and α4 subunits demonstrate significant tissue specificity. The α3 subunit is
expressed in the neural tissue of most animals, though it has also been identified in
human cardiac tissue [24]. With restriction to the testis, the α4 subunit has only been
identified in spermatogonia and sperm [24;27]. It was demonstrated that inhibition of
the α4 subunit results in immotile sperm, and mutations can ultimately impair fertility
[27;31]. Diversity in Na+, K+, ATP and cardiac glycoside affinity has been noted among
the α subunit isoforms [24]. For example, the rat α3 isoform has demonstrated a
reduced affinity for Na+ in comparison to α1 and α2, whereas α1 exhibits a greater K+
15

affinity than its α2 and α3 counterparts [24]. The isoforms of the α subunit have
displayed a minimum of 85% conserved sequences, across species [32]. Neurological
diseases such as familial hemiplegic migraine type 2 and rapid-onset dystoniaparkinsonism have been associated with human mutations of the α1- and α2-subunits
[31].
The C- and N-termini of the α subunit are both intracellular, and the subunit also
possesses five extracellular and four intracellular loops [27]. Consequently, the α
subunit of Na+/K+-ATPase has 10 transmembrane domains, as shown in Figure 1.4. This
observation is consistent with other P-type ATPases, as all family members have at least
six transmembrane helices (M1-M6); also, the P2-type ATPase subclass, of which Na+/K+ATPase belongs, have 10 transmembrane helices (M1-M10) [33]. These transmembrane
regions accommodate the ion binding sites for Na+ and K+ [32]. Three major cytoplasmic
domains have also been identified in the α subunits; these include the actuator (A-),
nucleotide binding (N-), and phosphorylation (P-) domains [32]. The actuator domain is
composed of the N-terminal and second cytoplasmic domain (CD2) connecting helices
M2 and M3; it contains the TGES motif [27]. Alternatively, the third cytoplasmic domain
(CD3) connecting M4 and M5 accommodates the nucleotide binding and
phosphorylation domains, with the N-domain being inserted in the P-domain [32]. The
conserved aspartate residue, and its associated DKTG sequence, is located within the Pdomain [27].
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Figure 1.4 The typical structure of the α subunit of Na+/K+-ATPase
+

+

The α subunit of Na /K -ATPase has 10 transmembrane domains, with both N and C-termini located on
the cytoplasmic side of the plasma membrane. Image modified from reference [27].

To date, four isoforms of the 370 amino acid long β subunit have been
discovered [27]. Only three of the isoforms (β1, β2, β3) have been shown to occur in
mammalian cells [24]. Limited information is available regarding the β4 subunit, at this
time. Similar to the α1 subunit, the β1 subunit is found in most tissues [24]. It is
intimately involved in the intracellular adhesion of epithelial cells [31]. Alternatively, the
β2 subunit is limited primarily to neural tissue, whereas the β3 subunit can be found in a
broader range of tissues [27;34]. The β2 subunit, sometimes referred to as the adhesion
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molecule on glia (AMOG), plays an important role in the adhesion and subsequent
migration of neurons on glial cells [31]. The N-terminus of the β subunit and roughly 30
amino acid residues reside in the cytoplasm [27]. All isoforms of the β subunit are
heavily glycosylated, with the extracellular portion of the β subunit containing N-linked
glycosylation sites, either NXS or NXT [3;27]. Each isoform varies in its number of
potential N-glycosylation sequences; this value also depends on the species of origin.
For example, the mammalian β1 subunit has three possible extracellular N-glycosylation
sites; alternatively, the β2 subunit may have eight or nine potential N-glycosylation sites
if derived from a human or mouse, respectively [3]. The β1 subunit extracellular domain
is also the site of several disulfide bridges; enzyme activity is lost if these disulfide
bridges are disrupted [3;27]. The structure of the mammalian β1 subunit is illustrated in
Figure 1.5. Conservation of amino acid sequences is much lower for the isoforms of the
β subunit when compared to the α subunit, with β3 subunits being as low as 50%
identical across species [32]. The amino acid sequences of Na+/K+-ATPase β1, β2, and β3
are available in Appendix B. A decrease in β1 subunit expression has been linked to
certain forms of cancer, whereas disturbances in β2 subunit expression and distribution
within cells and/or tissues have been associated with gliomas and epilepsy [31].
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Figure 1.5 The structure of the mammalian β1 subunit of Na+/K+-ATPase
+

+

The β1 subunit of Na /K -ATPase has a single transmembrane segment, with a large extracellular region.
The N-terminal is located with the cytoplasm, while the C-terminal, 3 N-glycosylation sequences and 3
disulfide bridges are found on the extracellular portion of the protein. Image modified from reference
[27].

1.4.2 Altered and Proposed Functions
Both α and β subunits are vital for cardiac glycoside-sensitive Na+/K+-ATPase
activity; separation of these components results in a loss of enzymatic activity [27]. It
has been unmistakably shown that the β subunit is responsible for the transport and
placement of the α subunit into the plasma membrane; nonetheless, the β subunit can
be expressed in the membrane without α expression [27]. These components are
combined in the endoplasmic reticulum, where independent production of the subunits
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also occurs [27]. Despite the obvious tissue-specific distribution of both the α and β
isoforms of Na+/K+-ATPase, little is known regarding specific αβ heterodimers [31].
Members of the FXYD family have been closely associated with Na+/K+-ATPase;
these proteins modulate the kinetic activity of the enzyme [25]. Currently, all
crystallized structures of the αβ complex of Na+/K+-ATPase have been shown to
associate with an FXYD protein; nonetheless this γ subunit is not essential for the
functional expression of the αβ complex [32]. It is for this reason that the sodium
potassium pump is commonly classified as a heterodimeric protein. Regardless, it is
important to recognize the influence these proteins have on the enzymatic activity of
Na+/K+-ATPase. The various isoforms of the γ subunit, FXYD1-7, are summarized in Table
1.1. These variants differ in their localization and have distinct structural divergence in
their N-terminal sequences [25]. The γ subunit has been shown to influence the catalytic
function of Na+/K+-ATPase in two distinct ways; it increases the affinity between ATP
and the enzyme, in addition to increasing antagonism between sodium and potassium
ions [35]. The sodium and potassium ions will compete for Na+ activation sites on the
cytoplasmic side of the plasma membrane [25].
Table 1.1 FYXD Proteins

+

+

This table provides the distribution of FXYD proteins which associate with Na /K -ATPase, in addition to
providing the known effects that these proteins have on its enzymatic activity. Table modified from
reference [36].

Isoform


FXYD1




Distribution
Known to combine with
Na+/K+-ATPase α1,α2, and α3
in the cerebellum
Most abundant in Purkinje
cells, choroid plexus and
ependymal cells
Present in neurons and glia
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Function



Decreased affinity of Na+/K+ATPase for Na+ and K+



FXYD2
FXYD3
FXYD4
FXYD5





Limited expression identified
in Allan Atlas rat brain



Abundant expression
identified in Allan Atlas rat
brain
Almost exclusive to brain
Abundant expression
identified in Allan Atlas rat
brain

FXYD6

FXYD7

Limited expression identified
in Allan Atlas rat brain
Moderate expression
identified in Allan Atlas rat
brain
No expression in Allan Atlas
rat brain
No expression in Allan Atlas
rat brain






Decreased affinity of Na+/K+ATPase for Na+ and K+



Decreased affinity of Na+/K+ATPase for Na+ and K+
Decreased affinity of Na+/K+ATPase for Na+ and K+
Increased Na+/K+-ATPase
maximum enzyme inhibition
(Imax)






Decreased affinity of Na+/K+ATPase for Na+ and K+



Decreased affinity of Na+/K+ATPase for Na+ and K+

The general reaction mechanism for Na+/K+-ATPase is depicted in Figure 1.6.
Na+/K+-ATPase exists largely in two enzymatic states. These states, E1 and E2, are due to
extreme conformational changes which occur during the catalytic process [33]. E1 is the
high affinity state for the primary transported ion (Na+ in this case), whereas E2 is the
low affinity state for sodium ions [33]. It has been suggested that a minimum of four of
these steps are voltage-dependent. In particular, the cytoplasmic Na+ binding, the E1 to
E2 conformational change, the extracellular release of Na+, and the extracellular binding
of K+, are all thought to be voltage dependent [37].
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Figure 1.6 The Na+/K+-ATPase reaction cycle
Sodium and potassium ions are represented by purple and green dots, respectively. The E1 state has a
high affinity for sodium ions, while the E2 state has a low affinity for sodium ions. Sodium and potassium
+ +
ions are exchanged across the plasma membrane by Na /K -ATPase, using the energy captured from the
hydrolysis of ATP. Image adapted from reference [27].

There are two main categories within which Na+/K+-ATPase inhibitors can be
classified; these include glycoside inhibitors and non-glycoside inhibitors. Glycoside
inhibitors, otherwise known as cardiac glycosides, are characterized by the union of an
aglycone, or genin, and one to four sugars [38]. The aglycone is pharmacologically
active, with a chemical structure similar to steroids or bile acids; conversely, the sugars
determine the potency and duration of action of the inhibitor by managing its solubility
[38]. Examples of cardiac glycosides include digoxin and ouabain. Like all cardiac
glycosides, these compounds can be further divided into two classes of glycoside
inhibitors: the cardenolides and the bufadienolides. In contrast, non-glycoside inhibitors
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have distinctive chemical structures from the glycosides, or have a modified aglycone
component. For example, cassaine is a non-glycoside inhibitor, in which the steroid ring
is broken [38].
Though ion transport is the primary function of Na+/K+-ATPase, several unrelated
functions have been proposed. It has demonstrated a role in cellular signalling
pathways. Exposure to low levels of the glycoside inhibitor ouabain, at concentrations
which do not affect ion gradients, has been associated with increased cellular growth
[24]. Na+/K+-ATPase appears to be involved in two Ras-dependent signalling cascades,
which are activated by ouabain inhibition of the enzyme. In the first pathway, Ras
promotes the formation of reactive oxygen species which in turn activate nuclear factor
kappa light-chain-enhancer of activated B cells (NF-κB); while in the second pathway,
the induced Ras protein initiates a Raf/MEK/MAPK cascade [24]. MAPK refers to the
mitogen-activated protein kinase, and MEK is the MAPK kinase. It is unclear if the
induction of these signalling cascades is due to the inhibition of a specific α subunit, or if
several isoforms are affected. The effect has been demonstrated in kidney and HeLa
cells which only express the α1 subunit; however, ouabain-induced signalling and cell
growth has also been witnessed in cardiac myocytes and smooth muscle cells which
express both α1 and α2 subunits [24].

1.5 Purpose of the Study
Disrupted Na+/K+-ATPase activity has already been implicated in a variety of
disorders, such as male infertility, rapid onset dystonia Parkinsonism, essential
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hypertension, migraine headaches, and epilepsy [24;27;39;40]. Decreased Na+/K+ATPase expression has also been previously recognized in bladder, kidney, colon, breast
and pancreatic cancers [41]. Changes in the activity or expression of Na+/K+-ATPase
within the central nervous system may designate this protein as a biomarker of certain
neurological conditions, including MS. The three CNS neural cell types, specifically
neurons, astrocytes and oligodendrocytes, do not demonstrate equivalent expression of
either the α or β isoforms of Na+/K+-ATPase [36]. In addition, neither the α4 or β4
isoforms are known to exist in the central nervous system of humans. The role of
Na+/K+-ATPase in the myelin membrane, and its potential as a biomarker of MS, has not
been previously investigated. MS affects people of all age demographics, emphasizing
the value in successfully treating this condition. Likewise, it is one of the main causes of
permanent disability in not only paediatric and elderly populations, but also young
adults [17].
The main purpose of this study was to characterize sodium-potassium adenosine
triphosphatase in the myelin membrane, using a mouse model. In order to achieve this
feat, three primary objectives were defined:


The first objective of this study was to identify which Na+/K+-ATPase
subunit isoforms exist in mouse myelin, determine how they are
distributed among the various microdomains, and to characterize their
expression.



The second objective was to determine:
o The heterodimeric forms of Na+/K+-ATPase in mouse myelin.
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o The specific binding partners of Na+/K+-ATPase in mouse myelin.


The third objective was to evaluate any differences in the expression of
Na+/K+-ATPase, and its individual subunit isoforms, in healthy mouse
myelin and in diseased mouse myelin, specifically using ND4 mice to
model MS.

The realization of these objectives will provide insight into the structural and
functional roles of Na+/K+-ATPase within the myelin sheath. Establishing the normal
protein interactions of Na+/K+-ATPase and its expression in healthy, intact myelin will
provide the basis for its comparison in models of myelinopathies such as MS. Although
Na+/K+-ATPase is an integral membrane protein, making its use as a biomarker more
challenging, understanding its role in demyelination will also provide crucial information
for the development of therapies for neurological diseases. Determining the
contribution of Na+/K+-ATPase to either demyelination or remyelination processes, and
identifying its binding partners, will indicate possible ways that the protein can be
manipulated for preventative or therapeutic purposes.
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Chapter 2 – Materials, Experimental Techniques, and
Methodology
2.1 Materials
Mouse brains, collected from CD1 strain mice, were purchased from Rockland
Inc. (Gilbertsville, PA, USA) and Bioreclamation LLC (Liverpool, NY, USA). The transgenic
ND4 mouse brains were provided by Dr. George Harauz, from the University of Guelph
(Guelph, ON, Canada). All animal tissues were stored at -80oC. The Pierce Micro
Bicinchoninic acid (BCA) Protein Assay Kit used in this study was from ThermoScientific
(Rockford, IL, USA). Protease Inhibitor Cocktail (PIC) and Phosphatase Inhibitor Cocktail
(PhosSTOP) tablets were from Roche (Mannheim, Germany). Grade 703 blotting paper
was from VWR International (Mississauga, ON, Canada), while 0.45 μm nitrocellulose
membrane was purchased from both Bio-Rad Laboratories Ltd. (Mississauga, ON,
Canada) and Santa Cruz Biotechnology (Dallas, TX, USA).
Ethyl ether and ammonium bicarbonate were purchased from EMD Chemicals
(Gibbstown, NJ, USA). Anhydrous alcohol and acetonitrile were from Mallinckrodt Baker,
Inc. (Philipsburg, NJ, USA). Methanol was from Fischer Scientific (Fair Lawn, NJ, USA) and
acetone was purchased from Caledon Laboratories Ltd. (Georgetown, ON, Canada).
Sodium thiosulfate, silver nitrate, 37% formaldehyde, sodium carbonate, triton X-100
(TX-100), and 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)
detergent were purchased from Sigma-Aldrich (St. Louis, MO, USA). TX-100 10% (w/v)
solution was also purchased from ThermoScientific (Rockford, IL, USA) as Surfact-Amps
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X-100. Sodium dodecyl sulfate (SDS) was purchased from Bio Basic Inc. (USA) and Fluka
Chemie (Switzerland). Additionally, AccuGENE 10% (w/v) SDS was obtained from Lonza
(Rockland, ME, USA). Tetramethylethylenediamine (TEMED) was from both Fisher
Scientific (Fair Lawn, NJ, USA) and Bio-Rad Laboratories, Inc. (Hercules, CA, USA).
Acrylamide/bis 30% solution (37.5:1) was purchased from Bio-Rad Laboratories, Inc.
(Japan). Tween-20 10% solution, Precision Plus Protein Dual Color Standards, and
Coomassie G-250 BioSafe stain were from Bio-Rad Laboratories, Inc. (Hercules, CA,
USA). Hydrochloric acid (HCl) was purchased from VWR Scientific Products (West
Chester, PA, USA) and from EM Science (Darmstadt, Germany). Glacial acetic acid was
also purchased from EM Science (Darmstadt, Germany). Ammonium persulfate (APS),
glycerol and trypsin gold, mass spectrometry grade, were from MD Biochemicals, LLC
(Solon, OH, USA), Sigma-Aldrich (St. Louis, MO, USA) and Promega Corporation
(Madison, WI, USA), respectively.
Tris base was obtained from both BioBasic Inc. (USA) and Sigma-Aldrich (St.
Louis, MO, USA). Sucrose was purchased from Fischer Scientific (Fair Lawn, NJ, USA) and
Sigma-Aldrich (St. Louis, MO, USA). Potassium chloride (KCl), magnesium chloride
(MgCl2), sodium chloride (NaCl), ethylene diamine tetraacetic acid (EDTA), ethylene
glycol tetraacetic acid (EGTA), dithiothreitol (DTT), iodoacetamide, 2-mercaptoethanol,
sodium orthovanadate (Na3VO4), phenylmethanesulfonylfluoride (PMSF), and 2-[4-(2hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) were also from Sigma-Aldrich.
Bromophenol blue sodium salt was obtained from Fisher Scientific (Fair Lawn, NJ, USA).
Percoll was from GE Healthcare (Uppsala, Sweden). Skim milk powder was from Metro
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Selection (Toronto, ON, Canada). Glycine was purchased from Fischer Scientific (Fair
Lawn, NJ, USA). Formic acid was purchased under the Fluka brand of Sigma-Aldrich
(Steinheim, Germany). D-mannitol was from Acros Organics (Geel, Belgium). Choleratoxin B subunit peroxidase conjugate was from Sigma-Aldrich (St. Louis, MO, USA).
Table 2.1 Primary antibodies used in this study
Primary antibodies were obtained from EM Millipore (Temecula, CA, USA), Santa Cruz Biotechnology
(Dallas, TX, USA), Sigma-Aldrich (St. Louis, MO, USA) and ThermoScientific (Rockford, IL, USA).

Antibody

Type

Specificity/Epitope

Host

Supplier

β-Actin
Na+/K+ATPase α

Monoclonal

N-terminal
aa 551-850 of
Na+/K+-ATPase α
Purified renal
outer medulla of
rabbit origin
Peptide mapping
within a
cytoplasmic
domain of Na+/K+ATPase α2 of
human origin

Mouse

Sigma-Aldrich

Product
Identifier
A-1978

Mouse

Santa Cruz

SC-48345

Mouse

Santa Cruz

SC-21712

Goat

Santa Cruz

SC-31391

Na+/K+-ATPase α3

Mouse

ThermoScientific

XVIF9-G10,
MA3-951

Mouse

Santa Cruz

SC-58626

Rabbit

ThermoScientific

PA5-26279

Goat

Santa Cruz

SC-66343

Rat
Rabbit

Millipore
ThermoScientific

MAB386
PA5-12335

Rabbit

ThermoScientific

PA5-19624

Rabbit

Millipore

AB10527

Monoclonal

Na+/K+ATPase α1

Monoclonal

Na+/K+ATPase α2

Polyclonal

Na+/K+ATPase α3
Na+/K+ATPase β1
Na+/K+ATPase β2
Na+/K+ATPase β3
MBP
MCT1
NQO1
VDAC

Monoclonal

External domain of
Na+/K+-ATPase β1
aa 15-141 from the
central region of
Polyclonal
human Na+/K+ATPase β2
Internal region of
Polyclonal
Na+/K+-ATPase β3
of mouse origin
Monoclonal
aa 82-87
Polyclonal
aa 430-460
aa 200 to CPolyclonal terminus of human
NQO1
Polyclonal
Human VDAC
Monoclonal
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EZview Red Protein A and G Affinity Gels were from Sigma-Aldrich (St. Louis, MO,
USA), while the Na+/K+-ATPase α1 antibody conjugated agarose (SC-21712) was acquired
from Santa Cruz Biotechnology (Dallas, TX, USA). The antibodies, their suppliers, and
product information, used in this study, are provided in Tables 2.1 and 2.2. The two
enhanced chemiluminescent reagents, SuperSignal West Femto Substrate and VisiGlo
Select HRP Chemiluminescent Substrate, were from ThermoScientific and AMRESCO
(Solon, OH, USA), respectively. The water used throughout this study was filtered using
a Milli-Q water purification system (Millipore).
Table 2.2 Secondary antibodies used in this study
Secondary antibodies were obtained from Rockland Inc. (Gilbertsville, PA, USA), Sigma-Aldrich (St. Louis,
MO, USA) and ThermoScientific (Rockford, IL, USA).

Antibody
Anti-Goat
IgG-HRP
Anti-Mouse
IgG-HRP
Anti-Rabbit
IgG-HRP
DyLight 488
Anti-Rat IgG
DyLight 549
Anti-Rabbit
IgG
DyLight 649
Anti-Mouse
IgG

Type

Specificity/Epitope

Host

Supplier

Product
Identifier

Polyclonal

IgG

Rabbit

Sigma-Aldrich

A-5420

Polyclonal

IgG, Fc fragment

Goat

Sigma-Aldrich

A-2554

Polyclonal

IgG

Goat

Sigma-Aldrich

A-0545

Polyclonal

IgG

Goat

Rockland

612-141-120

Polyclonal

IgG

Goat

ThermoScientific

35557

Polyclonal

IgG

Goat

ThermoScientific

35515

Refer to Appendix A for information regarding the structure and physical and
chemical properties of the detergents used in this study.
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2.2 Experimental Techniques
2.2.1 Electrophoretic Separation of Proteins
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a
commonly used biochemical technique, also known as Laemmli gel electrophoresis,
which separates proteins according to their molecular mass. In this technique, the
proteins are exposed to a detergent, specifically SDS, and a reducing agent, such as 2mercaptoethanol. These compounds are responsible for the disruption of tertiary and
quaternary protein structures. They denature the proteins by interacting with
hydrophobic domains and breaking disulfide bonds, respectively. SDS also imparts a
negative charge to proteins by coating their surfaces, which allows for separation using
an electrical current. When these protein samples are applied to a discontinuous
polyacrylamide gel, the now negatively charged proteins migrate towards the positive
electrode; since all the proteins are linearized, they migrate according to their overall
size and the smaller, lower molecular mass proteins will migrate the fastest.
A typical Laemmli SDS-PAGE gel system consists of a stacking gel of pH 6.8, a
resolving gel of pH 8.8, and an electrophoresis buffer containing glycine [42]. Both the
stacking and resolving gels consist of polymerized acrylamide which is formed by the
addition of APS and TEMED; these ingredients initiate the polymerization of acrylamide
by both introducing and stabilizing free radicals. The presence of bisacrylamide allows
cross-linking between polyacrylamide chains, thereby producing the gel structure.
Stacking gels generally contain a lower percentage of acrylamide; thus, they have larger
30

pores for the proteins to migrate through during electrophoresis. Alternatively, the
resolving gels have a higher acrylamide concentration, though it can vary as needed;
higher acrylamide content is necessary for the resolution of smaller molecular mass
proteins, as it produces a gel with smaller pores. During electrophoretic separation,
glycine from the running buffer migrates towards the cathode and becomes fully
deprotonated while transitioning between the stacking and resolving gels. Chloride ions
in the gel also migrate towards the cathode. In the stacking gel, glycine migrates slower,
and chloride ions migrate faster, than the negatively charged sample proteins; however,
once in the resolving gel, the newly deprotonated glycine ions become increasingly
mobile and pass the sample proteins, thereby encouraging their separation according to
molecular mass [42].
SDS-PAGE can separate proteins ranging from 20-250 kDa in size, though the
scope can be altered by increasing or decreasing the acrylamide content of the resolving
gel. Although it offers high resolution of protein separation, the Laemmli gel system can
be inconvenient due to the time consuming gel casting procedure. Preparation and
polymerization of both stacking and resolving gels can take a total of 60-90 minutes,
while the running time takes roughly an additional 80 minutes [42]. Once proteins are
separated, SDS-PAGE gels can be stained with Coomassie or silver; they can also be
transferred to a solid support for Western blot analysis.
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2.2.2 Western Blotting with Chemiluminescence and Fluorescence
Detection
Western blotting was used throughout this study to qualitatively and
quantitatively evaluate protein product expression. It allows for the identification of
specific proteins within complex biological samples; it is a useful tool for monitoring
protein expression in various tissues and under different conditions. Gel electrophoresis
is used to separate proteins according to molecular mass, and these proteins can then
be transferred to a solid support such that they can be probed with antibodies.
Nitrocellulose or polyvinylidene difluoride (PVDF) are two types of membranes which
are commonly used as the solid support in Western blotting. In this study, a wet
electrotransfer procedure was used to transfer myelin proteins to nitrocellulose
membranes; similar to electrophoresis, the proteins migrate from the gel towards the
membrane using an electrical current.
Once the solid support membrane is prepared, it is probed with a primary
antibody. Primary antibodies are designed for the unambiguous identification of a single
protein; they contain paratopes which recognize and bind unique epitopes, or antigenic
regions, of their respective protein targets. Epitopes which are not unique between two
or more different proteins may result in non-specific binding and cross-reactivity of the
antibody with other proteins in the sample or in the blocking buffer.
Antibodies can also be developed in two different ways; consequently, there are
two main types of antibodies. Monoclonal antibodies are produced using identical
immortalized B lymphocytes; they target a specific antigen or region of the molecule of
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interest. Polyclonal antibodies, on the other hand, are developed through the
immunization of animals; therefore, they are a collective of antibodies which can target
different components of the same molecule [1]. Polyclonal antibodies are produced by
many different B lymphocytes and since they recognize multiple epitopes of a single
antigen, they are far less specific than monoclonal antibodies.
After a primary antibody has been applied, Western blots are subsequently
exposed to a secondary antibody that is designed to bind the primary antibodies which
are securely adhered to the proteins of interest on the solid support. Secondary
antibodies may be fluorescently tagged or conjugated to an enzyme, thereby allowing
the antibody bound regions of the membrane to be visualized. Alternatively,
chemiluminescent blots take advantage of secondary antibodies which are conjugated
to an enzyme such as horseradish peroxidase (HRP) or alkaline phosphatase [43]. These
blots are incubated in a detection reagent prior to imaging; this reagent contains the
substrate for these enzymes and light is emitted as a by-product of the reaction. Both
fluorescent and chemiluminescent detection methods produce a signal which can be
measured by densitometric analysis and used to quantify protein expression. The
intensity of the measured signal is proportional to the amount of protein bound by
antibody. The two methods provide extremely sensitive protein detection; for example,
2-4 pg of transferrin protein can be detected using fluorescence, whereas little as 1 pg is
detectable with chemiluminescence [44].
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2.2.3 Individual Protein and Protein Complex Immunoprecipitation
Individual protein, or immunoprecipitation (IP), assays are used for the
purification of a specific protein from a complex mixture. Alternatively, protein complex,
or co-immunoprecipitation (co-IP), studies are used for the purification of a group of
interacting proteins; it is also an effective way to examine indirect protein-protein
interactions [45]. Co-IP procedures use an antibody to specifically isolate a bait protein
and its respective targets. The bait is the protein of interest, while its binding partners or
associated proteins are the targets [45]. In contrast, IP studies directly capture only the
target protein. In either scenario, a solid support, such as agarose or other polymeric
beads which are covalently bonded to Protein A or G, are used to bind an antibody
specific for the protein of interest; Protein A and G bind antibodies at either the Fc
portion or Fab fragments of Immunoglobulin G (IgG) [46]. Protein A and G are able to
interact with antibodies of various species and subclasses; however, not every antibody
is capable of immunoprecipitation and therefore may require use of a polyclonal
antibody or the addition of a bridging antibody which is reactive with the primary
antibody but also has a higher affinity for Protein A or G.
When the biological sample (i.e., complex mixture) is introduced to the beads,
the target or bait/target protein complexes will bind to the antibody and become
immobilized. Unbound proteins can then be washed away, and the bait and/or targets
can be eluted using detergents or by boiling. Non-specific binding by undesirable
proteins can be prevented by altering the wash buffer; salt or detergent content will
affect the stringency of IP/co-IP studies. The antibody may also co-elute, resulting in
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immunoglobulin light and heavy chains appearing in the final product. Softer elution
methods, which avoid boiling, can be developed; these may reduce the likelihood of
antibody contamination. In situations where IP/co-IP experiments are paired with
Western blotting, antibody contamination poses a problem since many secondary
antibodies are raised against immunoglobulins. The signal may become overwhelmingly
high if the IP/co-IP capture antibody and the Western primary antibodies were
produced in the same species; thus, it is important to use antibodies from different
species or minimize contamination [45]. Similarly, the light and heavy immunoglobulin
chains of the antibody may mask unique protein bands in the eluted product, if
examined using Coomassie or silver staining.

2.2.4 Protein Identification by Mass Spectrometry
Mass spectrometry is a popular analytical technique for the identification of
biological molecules. It is highly sensitive and allows for the identification of compounds
based on their mass spectrum. A mass spectrum is a graph of ion intensity versus massto-charge ratio (m/z); in essence, it illustrates the distribution of ions, generated from a
sample, according to their mass. All mass spectrometers are made up of three distinct
part components: the source in which ions are produced from the input sample, an
analyzer which separates the ions according to their m/z, and a detector which turns the
ions into a signal.
Ion sources vary depending on the chemical properties of the analytes under
investigation; for protein identification, electrospray ionization (ESI) is typically used. It
is a soft ionization method, which minimizes fragmentation of the molecular or parent
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ions generated. Furthermore, it permits the detection of high mass compounds and is
easily coupled to liquid chromatography. Matrix-assisted laser desorption ionization
(MALDI) is another ionization technique that is effective for the analysis of peptides,
proteins, and other biological molecules. The analyzed sample is co-crystallized with an
excess of a solid matrix, which absorbs light from a pulsed laser; unfortunately, the
matrix-related ions generate an increased background signal which impairs the analysis
of smaller molecules. In addition, it cannot be readily coupled with liquid
chromatography for chemical separation.
Mass analyzers have three major features: a mass limit which represents the
highest m/z that is measurable, its ability to successfully transmit ions from the source
to the detector, and the resolving power to distinguish between ions of minimal mass
difference. Quadrupole mass analyzers are commonly paired with ESI, while time-offlight (TOF) mass spectrometers are matched with MALDI. The quadrupole mass
spectrometer can operate in a scanning mode which allows a range of m/z ratios to be
monitored; alternatively, it can monitor for selected ions, thereby targeting only a few
m/z ratios. Selected ion monitoring is possible when analyte masses are known in
advance, and this allows for more rapid detection. TOF systems provide higher
resolution, superior ion transmission and can analyze a greater range of masses;
however, TOF is limited when compared with quadrupole mass analyzers, as it does not
have tandem mass spectrometry capabilities.
Protein identification is often achieved by following a bottom-up approach;
proteins are digested with proteolytic enzymes and then the resultant peptides are
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separated and analyzed by liquid chromatography coupled with tandem mass
spectrometry (LC-MS/MS) [47]. The identified peptides can then be compared with
protein databases and/or peptide libraries; alternatively, programs are available that
perform de novo sequencing on LC-MS/MS data, and search the results against specific
databases. Collision-induced dissociation of digested peptides is commonly used to
generate fragment ions for the database searches; the primary fragments are b-ions
which represent the N-terminus of the peptide, and y-ions that are generated from the
C-terminus [47]. The fragment b- and y-ions can be used to obtain the actual amino acid
sequence of the peptides being analyzed (refer to Appendix F). Unfortunately, the
bottom-up approach can result in the loss of post-translational modifications during
fragmentation, and sequence coverage is often between 5-70% [47].
When using a top-down approach for proteomic analysis, intact proteins are
directly examined using mass spectrometry. The direct measurement of the intact
molecular protein species allows its molecular form to be established. Use of alternative
dissociation techniques, such as electron-capture dissociation, allows for the generation
of c- and z-ions from cleavage of the N-C(R) bond; this type of fragmentation preserves
post-translational modifications [47]. Post-translational modifications of particular
importance include glycosylation and phosphorylation; however, ubiquitylation,
deamidation, acetylation and methylation also occur in proteins. These modifications
are critically important to the structural and functional features of proteins, and can
control biological processes. The top-down approach can provide 100% sequence
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coverage, including these modifications, but it is not readily coupled to liquid
chromatography; all protein purification must be performed offline [47].

2.3 Methodology
2.3.1 Myelin Isolation
Myelin was isolated from mouse brains using a modified version of the method
developed by Norton [48]. Whole brains were homogenized with a Dounce
homogenizer, on ice, in 10.5% sucrose in TNE (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5
mM EDTA) containing 1 mM Na3VO4, 1X PIC, 1X PhosSTOP and 1 mM PMSF. The
homogenate was overlaid on top of an equal volume of 30% sucrose in TNE, in 5 mL
centrifuge tubes. In order to separate the myelin from the remaining brain tissue, the
homogenate was subjected to a series of centrifugation steps using the Optima Max
Ultracentrifuge (Beckman Coulter). The MLS-50 rotor for this ultracentrifuge was used.
First, the sucrose gradient was centrifuged for 60 minutes at 35,000 rpm. The middle
myelin layer, at the 10.5%-30% sucrose interface, was removed. This fraction was
diluted with an equal volume of ice cold water and gently vortexed. Centrifugation for
30 minutes at 35,000 rpm was subsequently used to pellet the myelin membranes.
Pellets were osmotically shocked by the addition of 10 volumes of ice cold water, gentle
vortexing and incubation for 10 minutes on ice. The myelin was pelleted at 23,000 rpm
for 20 minutes, and then resuspended in 10.5% sucrose in TNE containing Na3VO4, PIC,
PhosSTOP and PMSF. This mixture was overlaid onto an equal volume of 30% sucrose in
TNE, and all of the centrifugation steps were repeated. The final myelin pellet was
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resuspended in myelin storage buffer (25 mM Tris-HCl, pH 7.5, 140 mM NaCl, 2 mM
EDTA) containing 2 mM Na3VO4, 1X PIC, 1X PhosSTOP and 2 mM PMSF. The isolated
myelin was aliquoted and stored at -80oC until needed. The protein concentration of the
isolated myelin was determined, after each preparation, using the Micro BCA Protein
Assay Kit from ThermoScientific. The manufacturer’s instructions were followed, using
bovine albumin standard (BSA) as the standard, and the microplate spectrophotometer
was set to measure absorbance at a wavelength of 562 nm.
A second method for isolating myelin was also used in this study. This method,
based on the protocol developed by Kristian, isolates mitochondria from the central
nervous system; myelin and synaptosomes are isolated by-products of this protocol
[49]. Rather than using a sucrose gradient, this method applies the brain homogenate to
a Percoll gradient. The two types of gradients are depicted in Figure 2.1. Percoll is made
of colloidal silica particles which have been coated with polyvinylpyrrolidone, and it has
a low viscosity. As a result, the use of Percoll, rather than sucrose, allows for the use of
lower centrifugal forces, and accelerates sedimentation rates [50]. Whole mouse brains
were homogenized with a Dounce homogenizer, on ice, in isolation medium (225 mM
sucrose, 75 mM mannitol, 1 mM EGTA, 5 mM HEPES, pH 7.4); more specifically, two
brains were homogenized in 1 mL of isolation medium, and then brought to a total
volume of 10 mL using the isolation medium. This protocol used a total of four mouse
brains, in contrast to the eight used by the sucrose gradient method. The homogenate
was centrifuged for three minutes at 1,300xg at 4oC using a F1010 fixed-angle rotor in
the Allegra 64R centrifuge (Beckman Coulter). The supernatant was set aside, and the
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pellet was resuspended in 5 mL of isolation medium and centrifuged again. The pooled
supernatant was then centrifuged at 21,000xg for 10 minutes, and the resultant pellet
was resuspended in 3.5 mL of 15% Percoll containing 225 mM sucrose, 75 mM
mannitol, 1 mM EGTA, and 5 mM HEPES, pH 7.4. A Percoll gradient was prepared by
overlaying the 15% Percoll on 24% and 40% Percoll. The discontinuous gradient was
subsequently centrifuged for eight minutes at 30,700xg, using slow acceleration and
deceleration. The very top layer, above the gradient, contained the myelin. It was
collected, resuspended in 15% Percoll, and the discontinuous gradient was prepared a
second time and centrifuged as before. This time the myelin layer was removed, diluted
with 3-4 mL of ice cold water, vortexed, and centrifuged for 10 minutes at 30,700xg. The
pellet was resuspended in myelin storage buffer, aliquoted and stored at -80oC. The BCA
protein assay was performed, exactly as done for the myelin prepared using the sucrose
gradient method.
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Figure 2.1 Schematic of sucrose and Percoll gradient myelin isolation methods
A) The sucrose gradient method; myelin membranes accumulate at the 10.5%-30% sucrose interface after
60 minutes of centrifugation at 100,000xg using the Beckman Coulter Optima Max Ultracentrifuge. B) The
Percoll gradient method; myelin membranes accumulate in the very top layer, above the gradient, while
synaptosomes and mitochondria accumulate at the 15%-24% and 24%-40% Percoll interfaces,
respectively, after 8 minutes of centrifugation at 30,700xg with the Beckman Coulter Allegra 64R
centrifuge.

2.3.2 Partial Delipidation of Whole Myelin
Myelin prepared using each isolation protocol, was compared by Western blot
analysis. Both preparations of whole myelin were partially delipidated prior to
electrophoretic separation, for enhanced detection. For each, 500 μg of myelin protein
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was brought to a total volume of 200 μL with water. The samples were then extracted
using a 2:1 mixture of ether to ethanol. They were incubated on ice for 10 minutes, then
centrifuged at 13,000 rpm for another 10 minutes, at 4oC, using an Eppendorf centrifuge
5415 D. The supernatant was discarded, and the remaining pellets were air-dried at
room temperature and resuspended in pellet resuspension buffer (10 mM Tris-HCl, 1%
SDS, pH 8.0).

2.3.3 Detergent Extraction of Myelin
Mouse myelin, isolated from CD1 mice, was subjected to two different detergent
extraction protocols. First, a differential detergent extraction with CHAPS and TX-100
was performed. For each extraction, 500 µg of myelin protein was brought to a total of 1
mL in Tris-buffered saline (TBS; 25 mM Tris-HCl, pH 7.5, 140 mM NaCl, 2 mM EDTA),
with a final concentration of 1.5% CHAPS. This mixture, which represents the initial 1.5%
CHAPS homogenate (I), was incubated on ice for 30 minutes with occasional mixing. This
incubation was followed by centrifugation at 5,000xg for 10 minutes, at 4 oC, using the
Eppendorf centrifuge 5415 D. The supernatant (S1) was set aside while the pellet (P1)
was resuspended in 1 mL of 2% TX-100 in TBS. Once again, the mixture was incubated
on ice for 30 minutes, with occasional mixing, and then centrifuged at 14,000xg for 15
minutes at room temperature using the Microfuge 18 Centrifuge (Beckman Coulter).
The supernatant (S2) was carefully removed, and the pellet (P2) was resuspended in 1
mL of 3% TX-100 in TBS. In some instances, the initial pellet (P1) was resuspended in 1
mL of 3% TX-100 in TBS, at which point the S1 and P1 fractions were directly examined;
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the second extraction was completely eliminated in this case. All myelin extracts were
stored at -20oC until required.
A different detergent extraction followed by isopycnic centrifugation was
performed to isolate the DRMs, or lipid rafts, from myelin isolated from CD1 mice; this
protocol was previously described by DeBruin et al. [16;51;52]. Initially, 500 µg of myelin
protein was brought to a total of 1 mL in 1.5% CHAPS in TBS with 10 mM Na3VO4, 10
mM PMSF, and 1X PIC solution; the myelin was added last, after 10 minutes of
incubation on ice. Once added, the myelin mixture was vortexed and incubated on ice
for 30 minutes, with occasional mixing, followed by centrifugation at 5,000xg for 10
minutes, at 4oC, using the Eppendorf centrifuge 5415 D. The pellet was resuspended in
pellet resuspension buffer, while the supernatant was combined with an equal volume
of 80% sucrose in 25 mM Tris-HCl, pH 7.5, 140 mM NaCl (Tris-buffered saline). The
resultant sample in 40% sucrose was overlaid with 30% sucrose and 5% sucrose. The
discontinuous gradients were centrifuged at 35,000 rpm for 16-18 hours, at 4oC, using
the MLS-50 rotor in the Optima Max Ultracentrifuge (Beckman Coulter). Afterwards,
samples were fractionated into approximately ten 340-µL fractions from the top of the
tube. The lipid rafts fractions were identified by GM1 dot blot. Cholera-toxin B subunit
peroxidase conjugate was used in conjunction with SuperSignal West Femto Substrate
for visualization by enhanced chemiluminescence, and imaging with the VersaDoc 4000
(Bio-Rad). Lipid raft fractions destined for analysis by Western blotting were precipitated
with acetone. A 4:1 ratio of ice-cold acetone to sample was combined, vortexed and
incubated overnight at -80oC. Later on, the acetone precipitated samples were
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centrifuged at 16,100xg for 20 minutes, at 4oC, using the Eppendorf centrifuge 5415 D.
Pellets were air-dried and resuspended in 10 µL of pellet resuspension buffer. These
samples were prepared for SDS-PAGE by the addition of 5 µL of 5X sample loading
buffer (0.5 M Tris-HCl, pH 6.8, glycerol, 10% w/v SDS, 0.5% w/v bromophenol blue).

2.3.4 SDS-PAGE
In this study, protein samples were electrophoretically separated using SDSPAGE mini-gels, with the Mini-Protean 3 cell (Bio-Rad). Either 12% or 14% freshly cast, 1mm thick, resolving gels were used for protein separation. Each protein sample was
prepared for separation by combining the sample with 5X sample loading buffer in a 1:4
ratio, and heating the mixture to 65oC, unless otherwise specified. They were then run
at 90V as they passed through the stacking gel, and the voltage was increased to 120V
until separation was completed and the tracking dye had run off the gel. The gels were
often transferred to nitrocellulose for Western blot analysis, or stained with Coomassie.
For each gel, Precision Plus Protein Dual Color Standard (Bio-Rad) was used as a
molecular mass marker.

2.3.5 Coomassie and Silver Staining
In this study, protein visualization in SDS-PAGE gels was achieved with
Coomassie G-250 BioSafe Stain (Bio-Rad), as per the manufacturer’s directions, or by
silver staining. The silver staining protocol was based on the original method developed
by Switzer et al. [53]. First, the polyacrylamide gels were fixed in 50% methanol, 10%
acetic acid for 30 minutes, with occasional shaking, and then incubated in 5% methanol,
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1% acetic acid for 15 minutes. The gels were subsequently rinsed in 50% methanol and
washed with ultrapure water three times, five minutes each time. After removing the
water, the gels were incubated in 0.02 g/100 mL sodium thiosulfate for 90 seconds; this
step was followed by three 30 second rinses with water. Next, the gels were incubated
for 45 minutes in 0.2 g/100 mL ice cold silver nitrate. The gels were rinsed again in
water, three times, for 60 seconds each time. Lastly, each gel was developed in 100 mL
of a developing solution which contained 6.0 g of sodium carbonate, 50 µL of 37%
formaldehyde, and 0.4 mg of sodium thiosulfate. Development was ceased when
protein bands became stained light brown; often requiring 5 to 20 minutes of
incubation. The development solution was decanted and gels were covered in 6% acetic
acid, for 10 minutes, to stop development. Gels were rinsed several times with water
prior to imaging.

2.3.6 Western Blotting
In this study SDS-PAGE gels were electrotransferred to nitrocellulose for 90
minutes, at 200 mA, in cold transfer buffer (25 mM Tris-HCl, pH 8.3, 192 mM glycine,
20% methanol). The membranes were subsequently blocked with 5% skim milk solution
in Tris-buffered saline with Tween-20 (247 mM Tris-HCl, pH 7.6, 27 mM KCl, 1.37 mM
NaCl, 0.5% Tween-20; TTBS), for at least 2 hours. After blocking, the membranes were
washed for 1 minute, and again for 5 minutes, in TTBS. The specific primary antibody
was then applied to the membranes, for the specified incubation period, as listed in
Table 2.3. To reduce non-specific binding, membranes were washed for 1 minute,
followed by three 5 minute washes, in TTBS. The corresponding secondary antibody was
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subsequently applied to the membranes, as per Table 2.3. Once again, membranes were
washed for 1 minute, followed by three 5 minute washes, in TTBS, post-antibody
incubation. Detection of HRP-tagged, chemiluminescent proteins was performed by
incubating the membranes in either SuperSignal West Femto Substrate or VisiGlo Select
HRP Chemiluminescent Substrate for 5 minutes, followed by immediate imaging with
the VersaDoc 4000 (Bio-Rad). Alternatively, proteins bound to fluorescently tagged
antibodies could be imaged directly after the final wash step using specific filters on the
VersaDoc 4000; a blue LED excitation source and 530BP emission filter, or a red LED
excitation source and a 695BP emission filter, was used for the detection of the various
DyLight conjugated secondary antibodies. For all Western blots, Precision Plus Protein
Dual Color Standard was used as a molecular mass marker.
Table 2.3 Antibody dilutions used for Western blotting
This table summarizes the dilutions and incubation periods of primary antibodies used in this study, in
addition to the dilutions and incubation periods of their corresponding secondary antibodies.

Primary
Antibody

Dilution

Incubation
Time

β-Actin

1:2,000

2-3 hours

1:2,000

4-5 hours

1:500

4-5 hours

1:500

4-5 hours

1:3,000

4-5 hours

1:500

4-5 hours

1:500

4-5 hours

1:500

4-5 hours

1:500

4-5 hours

Na+/K+-ATPase
α
+ +
Na /K -ATPase
α1
+ +
Na /K -ATPase
α2
+ +
Na /K -ATPase
α3
+ +
Na /K -ATPase
β1
+ +
Na /K -ATPase
β2
Na+/K+-ATPase
β3
MBP

Secondary
Antibody
DyLight 649
Anti-Mouse IgG
Anti-Mouse
IgG-HRP
Anti-Mouse
IgG-HRP
Anti-Goat IgGHRP
Anti-Mouse
IgG-HRP
Anti-Mouse
IgG-HRP
Anti-Rabbit IgGHRP
Anti-Goat IgGHRP
DyLight 488
46

Dilution

Incubation
Time

1:12,000

1 hour

1:80,000

30 minutes

1:80,000

30 minutes

1:80,000

30 minutes

1:80,000

30 minutes

1:80,000

30 minutes

1:80,000

30 minutes

1:80,000

30 minutes

1:12,000

1 hour

MCT1

1:100

4-5 hours

NQO1

1:100

4-5 hours

VDAC

1:1,000

4-5 hours

Anti-Rat IgG
Anti-Rabbit IgGHRP
Anti-Rabbit IgGHRP
Anti-Rabbit IgGHRP

1:80,000

30 minutes

1:80,000

30 minutes

1:80,000

30 minutes

When β-actin was used as a protein loading control for Western blots, the
membranes were stripped after imaging of the target protein. Each membrane was
stripped twice, 5 minutes each time, in stripping buffer (25 mM glycine-HCl, pH 2.2, 1%
SDS). The membranes were rinsed several times with water, and then washed in TTBS
for 5 minutes. The nitrocellulose membranes were then reblocked with 5% skim milk
solution, for 2 hours. The primary and secondary antibodies used for the detection of βactin are specified in Table 2.3. The same antibody incubation procedure, as described
earlier, was followed.

2.3.7 Quantification of Protein Expression by Densitometric Analysis
Protein expression levels in myelin samples were quantified by densitometric
analysis of prepared Western blots, using Image Lab Version 5.0 (Bio-Rad). Volumes for
each fluorescent or chemiluminescent signal were measured and compared with
corresponding samples of equivalent area (mm2). Volume was adjusted using local
background subtraction.
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2.3.8 Immunoprecipitation Assays
An individual protein immunoprecipitation assay was used to identify the
heterodimeric forms, or isozymes, of Na+/K+-ATPase. This IP method used the antibodies
for each β isoform, to capture the αβ complexes present in mouse myelin. EZview Red
Protein A and/or G affinity gels were used as the antibody binding matrix for these IPs;
the affinity gel and amount of each antibody used are summarized in Table 2.4. For each
IP, 25 µL of the corresponding 50% slurry suspension of the affinity gel was washed and
equilibrated in 50 mM Tris-HCl, pH 7.6, on ice. Isolated CD1 mouse myelin was extracted
with 1.5% CHAPS, as per first step of the differential detergent extraction protocol. A
sample of the initial 1.5% CHAPS homogenate (I) was set aside for comparison, while 2
µg of the β1, β2 and β3 antibodies were each added to separate 100 µL aliquots of the
1.5% CHAPS supernatant (S1). These antibody-sample mixtures were rotated for 2-4
hours, at 4oC, after which they were introduced to their respective affinity gels and
rotated, at 4oC, overnight. Each sample was subsequently centrifuged for 30 seconds at
1,500xg using the Microfuge 18 Centrifuge (Beckman Coulter). The unretained material
was removed and the affinity gels were washed with 50 mM Tris-HCl, pH 7.6. The αβ
complexes were eluted from the affinity gel by the addition of 10 µL of pellet
resuspension buffer and 10 µL of 5X sample loading buffer. The eluted material was
heated to 50oC for 5 minutes, and then cooled, pulse centrifuged, and examined using
Western blotting. Specifically, 20 µL of each β subunit IP elution were
electrophoretically separated on 12% SDS-PAGE gels, along with 20 µL of the initial 1.5%
CHAPS homogenate in sample loading buffer. Eluted material was otherwise stored at
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-20oC until required.
Table 2.4 Affinity gel and antibodies for individual protein immunoprecipitations.
Amount of
Antibody
Target
Sample
Antibody
Affinity Gel Used
Introduced
Used
Mouse
50/50 mixture of
1.5% CHAPS
β1
monoclonal
2 µg
EZview Red Protein
supernatant (S1)
Na+/K+-ATPase β1
A and Protein G
β2

1.5% CHAPS
supernatant (S1)

Rabbit polyclonal
Na+/K+-ATPase β2

2 µg

EZview Red Protein
A

β3

1.5% CHAPS
supernatant (S1)

Goat polyclonal
Na+/K+-ATPase β3

2 µg

EZview Red Protein
G

Protein complex immunoprecipitations were used to identify the specific binding
partners of Na+/K+-ATPase in the myelin membrane. Similar to the beta subunit IP, this
co-IP used the antibodies for each α isoform to capture the protein complexes which
include the catalytic component of Na+/K+-ATPase. A non-specific binding control was
also used to identify which proteins interact with the affinity gel, without the presence
of an antibody. For these co-IPs, EZview Red Protein G Affinity Gel was used as the
antibody binding matrix, in addition to use of an α1 antibody-conjugated agarose for the
α1 subunit co-IP; the affinity gel and amount of each antibody used are summarized in
Table 2.5. The EZview Red Protein G Affinity Gel was prepared as above with the beta
subunit IPs. The antibodies mentioned in Table 2.5 were each combined with 150 µL of
the 1.5% CHAPS supernatant and rotated for 2-4 hours, at 4oC; no antibody was added
to the control sample. For the α1 subunit co-IP, this step was omitted as the antibody
was conjugated to the agarose beads prior to use. Afterwards, the antibody-sample
mixtures were added to their respective affinity gels, and 150 µL of the 1.5% CHAPS
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supernatant was combined with the α1 antibody-conjugated agarose; these samples
were then rotated, at 4oC, overnight. Samples were spun down at 1,500xg for 30
seconds, the unretained material removed, and the matrix washed with 50 mM Tris-HCl,
pH 7.6, three times. After the removal of the final wash, protein complexes were eluted
from the affinity gel or agarose beads by the addition of 10 µL of pellet resuspension
buffer and 10 µL of 5X sample loading buffer. The eluted material was heated to 50 oC
for 5 minutes, and then cooled and pulse centrifuged. The initial CHAPS homogenate (I)
was combined with sample loading buffer and 5 µL of it, and 20 µL of the non-specific
binding control and sample elutions, was run on a 12% SDS-PAGE gel and stained with
Coomassie G-250 BioSafe Stain, as per the manufacturer’s directions.
Table 2.5 Affinity gel and antibodies for complex protein immunoprecipitations.
Amount of
Antibody Used

Affinity
Gel/Agarose
Beads Used

N/A

EZview Red
Protein G

Target

Sample

Antibody
Introduced

Control

1.5% CHAPS
supernatant (S1)

None

α1

1.5% CHAPS
supernatant (S1)

Mouse
monoclonal
Na+/K+-ATPase
α1

N/A

Na+/K+-ATPase α1
antibodyconjugated
agarose

α2

1.5% CHAPS
supernatant (S1)

Goat polyclonal
Na+/K+-ATPase
α2

2 µg

EZview Red
Protein G

50

α3

1.5% CHAPS
supernatant (S1

Mouse
monoclonal
Na+/K+-ATPase
α3

2 µg

EZview Red
Protein G

2.3.9 Trypsin Digestion and Proteomic Analysis
Unique protein bands from the α subunit co-IPs, identified on the Coomassie
stained SDS-PAGE, were cut from the gels and digested with trypsin for protein
identification by mass spectrometry. A negative control band was also cut and trypsin
digested. The in-gel trypsin digestion was performed as outlined by the SPARC BioCentre
at the Hospital for Sick Children (Toronto, ON, Canada). The predicted trypsin cleavage
sites of Na+/K+-ATPase α1, α2, and α3, and β1, β2, and β3, are available in Appendix B.
Excised protein bands were washed with 50 µL of 50 mM ammonium bicarbonate, for 5
minutes. The gel was shrunk with 50 µL of 50% acetonitrile/25 mM ammonium
bicarbonate for 10 minutes, and dried to completeness at ambient temperature in a
Labconco CentriVap Benchtop Concentrator. Each band was then reduced with 30 µL of
10 mM DTT for 30 minutes, at 56oC, alkylated with 30 µL of 100 mM iodoacetamide for
15 minutes, at room temperature, in the dark, shrunk with 50 µL of 50% acetonitrile/25
mM ammonium bicarbonate for 15 minutes, and then completely dried again in the
vacuum centrifuge at ambient temperature. Gel pieces were covered in 13 ng/µL trypsin
in 50 mM ammonium bicarbonate, and incubated on ice for 30-45 minutes. After that,
any remaining solution was removed and 50 mM ammonium bicarbonate was added to
cover the gel pieces while they were incubated, at 37oC, for 16-18 hours. The peptide
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extraction was performed after incubation; first, by sonicating the samples for 5 minutes
in cool water. The supernatant of each gel piece was collected and combined with the
supernatants from the following incubation steps. Each gel piece was incubated in 20 µL
of 25 mM ammonium bicarbonate for 10 minutes, then 20 µL of 5% formic acid for 10
minutes, 20 µL of 100% acetonitrile for 10 minutes, 20 µL of 5% formic acid for 10
minutes, and finally 20 µL of 100% acetonitrile for 10 minutes. The final solution was
evaporated to dryness in the vacuum centrifuge, at 44-48oC. The samples were stored at
-20oC until sent for analysis by LC-MS/MS.
The LC-MS/MS samples were analyzed using both Sequest version 1.4.0.288
(ThermoFisher Scientific, San Jose, CA, USA) and X!Tandem version CYCLONE (The GPM,
thegpm.org). Sequest was set up to search Mouse-UniProt-Jan-09-2013.fasta (unknown
version, 50272 entries) assuming the digestion enzyme trypsin. X!Tandem was set up to
search the Uniprot_Mus_musculus_May222014.fasta database (unknown version,
43362 entries) also assuming trypsin digestion. Sequest and X!Tandem were searched
with a fragment ion mass tolerance of 0.60 Da and a parent ion tolerance of 2.0 Da.
Deamidation of asparagine and glutamine, oxidation of methionine and
carbamidomethyl of cysteine were specified in Sequest as variable modifications. Glu>pyro-Glu of the N-terminus, ammonia-loss of the N-terminus, Gln->pyro-Glu of the Nterminus, deamidation of asparagine and glutamine, oxidation of methionine and
carbamidomethylation of cysteine were specified in X!Tandem as variable modifications.
Mass spectrometry peptide and protein identifications were validated using
Scaffold, version 4.3.2, proteome software (Proteome Software Inc., Portland, OR, USA).
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Peptide identifications were accepted if they could be established at greater than 20.0%
probability to achieve a false detection rate (FDR) less than 1.0%. Peptide Probabilities
from Sequest were assigned by the Scaffold Local FDR algorithm. Peptide probabilities
from X!Tandem were assigned by the Peptide Prophet algorithm with Scaffold deltamass correction [54]. Protein identifications were accepted if they could be established
at greater than 95.0% probability to achieve an FDR less than 1.0% and contained at
least 2 identified peptides. Protein probabilities were assigned by the Protein Prophet
algorithm [55]. Proteins that contained similar peptides and could not be differentiated
based on LC-MS/MS analysis alone were grouped to satisfy the principles of parsimony.
Proteins sharing significant peptide evidence were grouped into clusters.

53

Chapter 3 – Results
3.1 Identification of Na+/K+-ATPase in the Myelin Membrane
3.1.1 Expression of Na+/K+-ATPase Subunit Isoforms
Understanding the distribution of proteins within tissues, as well as identifying
changes in their expression over a lifespan, is central to comprehending their
involvement in both developmental and disease processes [56]. Many methods exist for
the identification of temporal and spatial gene or protein expression; in this study,
protein expression of each Na+/K+-ATPase subunit isoform, present in the myelin
membrane, was evaluated by the Western blot analysis of myelin from mouse brain.
Myelin was isolated from brains of euthanized mice from different age groups, thereby
allowing examination of changes in protein expression during post-natal development.
The myelin produced in mature CD1 mice was also investigated; this initial survey of
protein expression was informative and outlined which Na+/K+-ATPase subunit isoforms
exist in mouse myelin, and should therefore be further examined.
The products of both sucrose-gradient and Percoll-gradient isolated CD1 mouse
myelin were partially delipidated, and subsequently examined by Western blot analysis.
Ultimately, it was shown that Na+/K+-ATPase is expressed in the myelin membrane, and
can be successfully detected using this analysis technique. As illustrated in Figure 3.1,
Na+/K+-ATPase α1, α2, and α3, as well as the complementary β1, β2, and β3 subunits, were
readily detected in both myelin preparations. These three alpha and three beta subunits
represent all known isoforms of Na+/K+-ATPase in the CNS.
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All subsequent analyses of Na+/K+-ATPase were performed using myelin isolated
by the sucrose-gradient method. Both the sucrose-gradient and Percoll-gradient
isolation protocols generated myelin with detectable levels of each subunit isoform, in
addition to MBP, voltage-dependent anion channel (VDAC), monocarboxylate
transporter 1 (MCT1) and NAD(P)H quinone oxidoreductase 1 (NQO1) (refer to Appendix
G). Nevertheless, when these myelin preparations were compared with a brain
homogenate sample, of equal protein content, the myelin produced using the Percollgradient method appeared less purified although it had a greater yield.

Figure 3.1 Detection of Na+/K+-ATPase subunit
isoforms in partially delipidated sucrose-gradient
and Percoll-gradient isolated CD1 mouse myelin
Enhanced chemiluminescent Western blot detection of each
+ +
alpha and beta isoform of Na /K -ATPase in partially
delipidated myelin samples, of equivalent protein content,
from sucrose-gradient and Percoll-gradient isolation
methods. Equal volumes (15 µL), and therefore equal
protein (approximately 60 µg of total myelin protein), of
each sample were separated on 12% SDS-PAGE and
transferred to nitrocellulose membrane. The corresponding
primary and secondary antibodies used are described in
Table 2.3. Each Western blot was imaged using the
VersaDoc 4000 (Bio-Rad) with an exposure time of 30-400
seconds, ensuring non-saturation.

3.1.2 Detergent Solubility of Na+/K+-ATPase
Non-ionic detergents, such at TX-100, have formerly proven incapable of
solubilizing certain regions, or microdomains, of plasma membranes. These DRMs are
enriched in cholesterol, sphingomyelin, and lipid-anchored proteins. They show
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similarities to the Lo phase (refer to section 1.2.2) of model membranes, and may
represent membrane microdomains such as lipid rafts, caveolae and/or cellular
junctions [14;16]. Consequently, the detergent-insolubility of these coalesced lipid rafts
became the basis for the isolation and characterization of both raft proteins and lipids
[57]. As earlier studies of Na+/K+-ATPase have demonstrated its localization within
various membrane microdomains, such as the caveolae of kidney cells, detergent
extraction has proven essential in the successful characterization of this protein in other
tissue and cell types [58].
The initial extraction of Na+/K+-ATPase from the myelin membrane using the
differential detergent extraction procedure with 1.5% CHAPS, followed by 2% TX-100,
indicated that limited protein was detectable in the TX-100 supernatant (S2) and pellet
(P2) fractions. Each of the Na+/K+-ATPase subunit isoforms was observed in the initial
pellet (P1), but preferentially partitioned into the 1.5% CHAPS supernatant (S1) fraction;
refer to Figure 3.2. Densitometric data indicated that Na+/K+-ATPase α1, β1, β2, and β3
were highly enriched in the CHAPS supernatant; more than 90% of all Na+/K+-ATPase α1,
β1, β2, and β3 was detected in this S1 fraction. Alternatively, the P1 fraction contained
approximately 20-30% of all Na+/K+-ATPase α2 and α3.
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Figure 3.2 Detection of Na+/K+-ATPase subunit isoforms in detergent extracted CD1
mouse myelin
+

+

A) Enhanced chemiluminescent Western blot detection of each alpha and beta isoform of Na /K -ATPase
in the 1.5% CHAPS supernatant (S1), pellet (P1) and the initial CHAPS homogenate (I). Equal volumes (20
µL) of each sample were separated on 12% SDS-PAGE and transferred to nitrocellulose membrane. The
corresponding primary and secondary antibodies used are described in Table 2.3. Each Western blot was
imaged using the VersaDoc 4000 (Bio-Rad) with an exposure time of 30-200 seconds, ensuring non+ +
saturation. B) Relative intensity of each Na /K -ATPase subunit isoform in the 1.5% CHAPS supernatant
and pellet, ensuring non-saturation and subtracting background. Each value was corrected by
normalization with the initial CHAPS homogenate.

The propensity of Na+/K+-ATPase to become solubilized in 1.5% CHAPS detergent
suggested that its subunit isoforms may be present in the myelin lipid rafts. DRMs,
coalesced lipid rafts, were isolated from CD1 mouse myelin by treatment with 1.5%
CHAPS detergent, followed by separation with a discontinuous sucrose density gradient.
Larger fragments of the myelin membrane, as well as subcellular organelles, were
compacted by low speed centrifugation of the 1.5% CHAPS mixture; whereas the
resultant CHAPS supernatant contained the DRMs, as well as solubilized proteins and
lipids [52]. When this supernatant subsequently underwent ultracentrifugation on a
discontinuous sucrose density gradient, the DRMs and solubilized proteins and lipids
were separated according to buoyancy. As the DRMs are rich in cholesterol and
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glycosphingolipids, and represent the Lo phase, they are typically more buoyant and
found in the lower density fractions; in contrast, solubilized proteins and lipids are
detectable in the high density fractions of the density gradient. Ganglioside GM1 dot
blot immunodetection was used to identify specifically which fractions contained the
DRMs. All fractions were examined by Western blot analysis for each Na+/K+-ATPase
subunit isoform, and then compared to the GM1 dot blot. All three alpha and three beta
subunits of Na+/K+-ATPase were detected in the non-raft, high density fractions. Na+/K+ATPase α1, α3, β2, and β3 were also successfully identified in the low density, raft
fractions; for that reason, it is expected that these isoforms are part of the lipid rafts of
the myelin membrane. Two of these Western blots are shown in Figure 3.3 below. It is
unclear whether the α2 and β1 isoforms are also part of the DRMs, as the enhanced
chemiluminescent signal was near the limit of detection (refer to Appendix G). All the
same, Na+/K+-ATPase α2 and β1 are not highly enriched in the lipid rafts of myelin.
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Figure 3.3 Detection of Na+/K+-ATPase subunit isoforms in myelin DRMs
+

+

+

+

Enhanced chemiluminescent Western blot detection of: A) Na /K -ATPase α1 and β2; B) Na /K -ATPase α3.
Equal volumes (20 µL) of each acetone-precipitated lipid raft fraction (A1-A10 and B1-B10), isolated as
CHAPS DRMs, were separated on 12% SDS-PAGE and transferred to nitrocellulose membrane. Fractions
A3, A4, B3 and B4 represent the low density, raft fractions; alternatively, fractions A9, A10, B9 and B10
represent the non-raft, high density fractions. The red arrows indicate the low density, raft fractions. The
corresponding primary and secondary antibodies used are described in Table 2.3. Each Western blot was
imaged using the VersaDoc 4000 (Bio-Rad) with an exposure time of 30-200 seconds, ensuring nonsaturation.

3.2 Heterodimeric Forms of Na+/K+-ATPase in the Myelin Membrane
Determination of each heterodimeric form, or isozyme, of Na+/K+-ATPase in CD1
mouse myelin was performed using an IP with each beta subunit isoform. This method
captures the αβ complexes formed by each individual beta subunit isoform. Equal
volumes of each eluted fraction were then examined for all alpha subunits by Western
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blotting, using primary antibodies specific for each isoform (Figure 3.4). Six
heterodimeric forms of Na+/K+-ATPase were discovered; α1 was shown to pair with β1,
α2 dimerized with β1 and β3, and α3 was found to couple with all three beta isoforms.
These six isozymes, α1β1, α2β1, α2β3, α3β1, α3β2, and α3β3, were six of nine possible
functional Na+/K+-ATPase heterodimers; α1β2, α1β3 and α2β2 were not observed in these
myelin samples. Three major isozymes, α1β1, α2β3, and α3β1, were established; they
appeared to be the most abundant of each αβ complex according to signal intensity.

Figure 3.4 Identification of heterodimeric forms of the Na+/K+-ATPase in CD1 mouse
myelin
+

+

Enhanced chemiluminescent Western blot detection of each alpha isoform of Na /K -ATPase in the initial
CHAPS homogenate and final eluted fractions from each beta isoform immunoprecipitation. Equal
volumes (20 µL) of each sample were separated on 12% SDS-PAGE and transferred to nitrocellulose
membrane. The corresponding primary and secondary antibodies used are described in Table 2.3. Each
Western blot was imaged using the VersaDoc 4000 (Bio-Rad) with an exposure time of 30-200 seconds,
ensuring non-saturation.
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3.3 Specific Binding Partners of Na+/K+-ATPase in the Myelin
Membrane
Initial inspection of the proteins eluted from each Na+/K+-ATPase alpha subunit
isoform co-IP revealed several unique protein bands, when compared to a non-specific
binding control. Protein bands were identified using both silver and Coomassie G-250
BioSafe staining. These bands, in addition to those which became concentrated by the
co-IP, are indicated in Figure 3.5 and Figure 3.7; they suggest that Na+/K+-ATPase
interacts with several different proteins within the myelin membrane. Likewise, unique
protein bands differed between the co-IPs of each individual alpha isoform; hence each
isoform may have independent binding partners and form distinct protein complexes.
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Figure 3.5 Silver stained SDS-PAGE of eluted proteins from co-immunoprecipitations of
each Na+/K+-ATPase alpha isoform using CD1 mouse myelin
Silver stained 1-mm thick 12% SDS-PAGE, loaded with 3 µL of initial CHAPS homogenate (I) and equal
volumes (20 µL) of a non-specific binding control (C) and the final eluted fraction of each alpha isoform
co-immunoprecipitation. Precision Plus Protein Dual Color Standards (M) was used as a molecular mass
standard. The stained gel was imaged using the VersaDoc 4000 (Bio-Rad) with an exposure time of 0.1-5
seconds, ensuring non-saturation. The indicated bands are unique when compared to the non-specific
binding control, or became concentrated by the co-IP.

Each lane of the silver stain, shown in Figure 3.5, was scanned for a comparison
of protein band intensities and their corresponding rate relative to front (Rf) values. The
intensity and separation of these protein bands are illustrated in Figure 3.6. Many
proteins are shown in the initial CHAPS homogenate; however, the intensity of these
proteins is lesser, as only 3 µL of this sample was loaded onto the SDS-PAGE gel. Several
proteins can also be identified in the non-specific binding control, according to signal
intensity. By examining the separated proteins according to signal intensity, it is clear
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that there are indeed both unique and shared protein bands in each Na+/K+-ATPase
alpha subunit isoform co-IP elution. There are also non-unique protein bands which are
of greater intensity in the Na+/K+-ATPase alpha subunit isoform co-IP elutions. It is also
likely that there are a greater number of eluted proteins than identified protein bands,
as the signal intensity of one protein may be masked by the signal intensity of a protein
of similar molecular mass.
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Figure 3.6 Separation of proteins eluted from Na+/K+-ATPase co-immunoprecipitations
+

+

Separation of proteins from: A) initial CHAPS homogenate; B) non-specific binding control; C) Na /K + +
+ +
ATPase α1 co-IP elution; D) Na /K -ATPase α2 co-IP elution; E) Na /K -ATPase α3 co-IP elution. The signal
intensity corresponds to the amount of protein, while the Rf value indicates the distance travelled by the
protein from the origin. Larger Rf values correspond with proteins of smaller molecular mass. Analysis was
completed with Image Lab Version 5.0 (Bio-Rad). The symbols (*,◊,ᵻ,‡) indicate a few of the common
protein peaks observed between samples.
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The unique protein bands identified in the Na+/K+-ATPase alpha subunit isoform
co-IP elutions, by staining with Coomassie G-250 BioSafe, were examined by mass
spectrometry. Ultimately, 21 bands (Figure 3.7) were excised and digested with trypsin;
of these, 15 were analyzed by LC-MS/MS. Bands 10, 13, 14, 15, 17 and 19 were not sent
for analysis due to the similarity of their molecular masses when compared with Bands
21, 5 and 6, 9, 1 and 11, 4, and 7, respectively. It was anticipated that the three alpha
isoforms of Na+/K+-ATPase would share several binding partners; therefore, protein
bands identified in different co-IP elutions but of similar molecular mass, were digested
and stored but not sent for analysis unless necessary.

Figure 3.7 Coomassie stained SDS-PAGE of eluted proteins from coimmunoprecipitations of each Na+/K+-ATPase alpha isoform using CD1 mouse myelin
Coomassie G-250 BioSafe stained 1-mm thick 12% SDS-PAGE, loaded with 5 µL of initial CHAPS
homogenate (I) and equal volumes (20 µL) of a non-specific binding control (C) and the final eluted
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fraction of each alpha isoform co-immunoprecipitation. Precision Plus Protein Dual Color Standards (M)
was used as a molecular mass standard. The stained gel was imaged using the VersaDoc 4000 (Bio-Rad)
with an exposure time of 0.1-5 seconds, ensuring non-saturation. The indicated bands were excised and
digested with trypsin for identification by mass spectrometry.

A total of 33 proteins were identified in the 15 digested bands; however,
absolutely no proteins were detected by mass spectrometry in Band 4. Of the 33
documented proteins, positive identification was assigned to those recognized with
100% certainty using the Scaffold 4.3.2 proteome software. These proteins also required
a minimum of two unique peptides to be recognized, for confirmation of identity. After
applying these criteria, there were 13 major proteins identified; these are listed in Table
3.1. Several immunoglobulin chains from the antibodies used in the co-IPs were also
detected by mass spectrometry; these proteins are not listed.
Table 3.1 Major proteins identified in Coomassie G-250 BioSafe stained bands from
SDS-PAGE separation of Na+/K+-ATPase alpha co-immunoprecipitation elutions
Each band number corresponds to the indicated protein bands in Figure 3.7. Gel bands were trypsin
digested and analyzed by LC-MS/MS. Each major protein was identified with 100% probability using the
Scaffold 4.3.2 proteome software, in addition to having a minimum of two unique peptides identified. The
ID indicated the UniProtKB/Swiss-Prot accession number, whereas Gene represents the gene name
provided by NCBI. The number of unique peptides, the percent coverage, and molecular mass of each
protein, as identified by LC-MS/MS, is also provided.
Unique
MW
Band No.
Protein Identified
ID
Gene
% Coverage
Peptides
(kDa)
Sodium/potassiumtransporting ATPase
Q8VDN2
Atp1a1
7
19
113
subunit alpha-1
Sodium/potassium1
transporting ATPase
Q6PIC6
Atp1a3
6
19
112
subunit alpha-3
Serine/arginine
repetitive matrix
Q8BTI8
Srrm2
3
2
295
protein 2
Peripheral myelin
18858
Pmp22
3
9
57
protein 22
3
Sodium/potassiumtransporting ATPase
Q6PIC6
Atp1a3
2
3
112
subunit alpha-3
Peripheral myelin
18858
Pmp22
2
4
57
protein 22
5
SpermatogenesisQ80VP2
Spat7
2
1
66
associated protein 7
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6
7
9

11

12

18

20

21

Sodium/potassiumtransporting ATPase
subunit beta-1
2’,3’-cyclic nucleotide
3’-phosphodiesterase
Myelin proteolipid
protein
Sodium/potassiumtransporting ATPase
subunit alpha-2
Sodium/potassiumtransporting ATPase
subunit alpha-3
Cullin-associated
NEDD8-dissociated
protein 1
Sodium/potassiumtransporting ATPase
subunit beta-1
Brain acid soluble
protein 1
Protein MRVI1
Peripheral myelin
protein 22
Serine/arginine
repetitive matrix
protein 2
Myelin proteolipid
protein
Krueppel-like factor 6

P14094

Atp1b1

3

12

35

P16330

Cnp

7

16

47

P60202

Plp1

2

9

30

Q6PIE5

Atp1a2

2

6

112

Q6PIC6

Atp1a3

3

7

112

Q6ZQ38

Cand1

2

2

136

P14094

Atp1b1

4

16

35

Q91XV3

Basp1

2

16

22

Q9WUX5

Mrvi1

2

2

100

18858

Pmp22

3

5

57

Q8BTI8

Srrm2

2

1

295

P60202

Plp1

5

17

30

O08584

Klf6

2

5

32

According to the mass spectrometry results, the α1 and α2 isoforms were
confirmed to be present in their respective co-IP elutions. Similarly, Band 15 should
represent the α3 isoform, as it shares an equivalent molecular mass to Bands 1 and 11;
both of which were found to contain the Na+/K+-ATPase α3 subunit isoform. The α1
subunit isoform was shown to interact with 7 other proteins in myelin; Na+/K+-ATPase
α3, Na+/K+-ATPase β1, serine/arginine repetitive matrix protein 2 (SRRM2), PMP-22,
spermatogenesis-associated protein 7 (SPAT7), CNP, and PLP1. Each of these proteins
co-eluted with the α1 subunit. In comparison, the α2 subunit isoform was also found to
interact with Na+/K+-ATPase α3, in addition to cullin-associated NEDD8-dissociated
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protein 1 (CAND1). Lastly, the α3 subunit isoform co-eluted with 7 other identified
proteins; Na+/K+-ATPase β1, brain acid soluble protein 1 (BASP1), protein MRVI1
(MRVI1), PMP-22, SRRM2, PLP1, and krueppel-like factor 6 (KLF6). The identification of
the Na+/K+-ATPase β1 subunit isoform, within both the α1 and α3 subunit co-IP elutions,
supports the previous Western blot analysis which identified α1β1 and α3β1 as two of the
three major Na+/K+-ATPase isozymes present in the myelin membrane.
Potential protein binding partners of Na+/K+-ATPase were also identified using
the STRING database. STRING version 9.1 (http://string-db.org/) was used to integrate
the information from collections of experimental data and other resources, in order to
provide evidence-based predictions of protein-protein interactions for each of the
subunit isoforms [59]. Each alpha and beta subunit isoform was predicted to interact
with all other alpha and beta subunit isoforms of Na+/K+-ATPase. FXYD2 was also a
predicted functional partner of all Na+/K+-ATPase subunit isoforms. For a complete list of
the predicted functional partners of Na+/K+-ATPase, and illustrations of the
corresponding protein-protein interactions, refer to Appendix C.

3.4 Na+/K+-ATPase Expression in Myelin from CD1 and ND4 Mice
As previously mentioned, establishing changes in protein expression over various
life stages is imperative to understanding their role in development. This knowledge also
provides a basis for determining how protein expression may become altered in a
diseased state, thereby offering insight regarding which biological and chemical
processes could be manipulated for therapeutic benefit. In particular, ND4 transgenic
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mice provide a suitable model of multiple sclerosis. In this study, myelin isolated from
these mice was compared with the myelin of age- and sex-matched control CD1 mice.
The animals were euthanized at 3.10, 7.65, 9.00 or 13.02 months of age; and each line
was raised and sacrificed under the same conditions. Western blot analysis of equal
amounts of protein from both myelin preparations, and from each age group, was
performed for all three alpha and three beta subunit isoforms of Na+/K+-ATPase (Figure
3.8). Densitometric analysis was then carried out to evaluate changes in the expression
of each isoform, from each myelin preparation, over post-natal development. All of the
densitometric data, for both CD1 and ND4 myelin, can be found in Appendix D.
Western blots were performed in duplicate; samples from both myelin
preparations, at each age group, were examined once without a β-actin protein loading
control (refer to Appendix H) and once with a β-actin protein loading control. Without
normalization to β-actin, each data set showed distinct similarities; however, the
normalized densitometric data was the primary focus in this study. By using β-actin as
an internal control, technical artifacts, such as pipetting errors during gel loading and
inconsistent protein transfer to blotting membranes, were minimized [60]. It also
permits the comparison of two different blots, when they are otherwise not directly
comparable [61].
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Figure 3.8 Detection of Na+/K+-ATPase subunit isoforms in partially delipidated CD1
and ND4 mouse myelin of varying ages
+

+

Enhanced chemiluminescent Western blot detection of each alpha and beta isoform of Na /K -ATPase in
partially delipidated CD1 and ND4 mouse myelin. Equal volumes (15 µL), and therefore equal protein
(approximately 60 µg of total myelin protein), of each sample were separated on 12% SDS-PAGE and
transferred to nitrocellulose membrane. The corresponding primary and secondary antibodies used are
described in Table 2.3. Each Western blot was imaged using the VersaDoc 4000 (Bio-Rad) with an
exposure time of 30-200 seconds, ensuring non-saturation.
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The normalized densitometric data in this study is represented as the relative
intensities of each Na+/K+-ATPase subunit isoform. Expression levels were described in
terms of the ratios of individual Na+/K+-ATPase subunit isoform levels, to the levels of βactin in each sample; this is considered a robust normalization method for Western
blotting [62]. First, the signal intensity of each β-actin control was divided by the highest
measured intensity value of all β-actin controls; this process generated a relative
intensity factor, between 0 and 1.00. The signal intensities of each Na+/K+-ATPase
subunit isoform were subsequently divided by their respective relative intensity factor;
the result is the relative intensity for each Na+/K+-ATPase subunit isoform.

3.4.1 Age-Related Protein Expression in Healthy CD1 Mouse Myelin
All three alpha and three beta subunit isoforms of Na+/K+-ATPase were detected
at 3.10, 7.65, 9.00 and 13.02 months of age in the CD1 control mouse myelin. These
samples represent typical, healthy myelin, and are indicative of the normal age-related
changes in protein expression. Upon the measurement of protein band intensity for
each subunit isoform, in each age group, it was noted that intensities fluctuated over
the course of normal development. These changes persisted even after each
densitometric measurement was normalized to a β-actin, as a protein loading control, in
the same sample. The adjusted values, and corresponding fluxes in the expression of
each subunit isoform, are displayed in Figure 3.9. Upon inspection, each alpha isoform
consistently exhibits an increase in expression when approaching the final 13.02 month
age group. In contrast, the beta isoforms are relatively divergent. Na+/K+-ATPase β1
expression increases between 9.00 and 13.02 months but remains lesser than the initial
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measurement at 3.10 months. Alternatively, Na+/K+-ATPase β2 and β3 expression
steadily increases or decreases, respectively, over time.

Figure 3.9 Relative Na+/K+-ATPase subunit isoform expression in CD1 mouse myelin
with aging
+

+

Intensity of each Na /K -ATPase subunit isoform, ensuring non-saturation and subtracting background.
Intensity was measured at 3.10, 7.65, 9.00 and 13.02 months of age. Each value was corrected by
normalization with a β-actin protein loading control.

Beyond the observed fluctuations in the protein expression of each subunit
isoform, it was also discovered that the protein bands for each glycosylation state of
Na+/K+-ATPase β1 could be detected by Western blotting (Figure 3.8). The mammalian
Na+/K+-ATPase β1, such as that found in mice, can have three N-glycans or N-linked
glycosylation sites occupied; in addition to these three forms, Na+/K+-ATPase β1 can also
exist as a core, unglycosylated subunit [3]. This core protein is often considered its
immature form. Three β1 protein bands, that were approximately 60 kDa, 52 kDa and 48
kDa in size, represented the β1 subunit with all three N-glycans, two N-glycans, and only
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one N-glycan, respectively. The largest form of Na+/K+-ATPase β1, with the highest
molecular mass, was designated Band 1 of the Na+/K+-ATPase β1 subunit; similarly, Band
2 and Band 3 were assigned to the other glycosylated forms, from highest to lowest
molecular mass. And lastly, another small molecular mass protein band was identified
by the Na+/K+-ATPase β1 antibody; it was approximately 40 kDa in size. It was designated
as Band 4 of the Na+/K+-ATPase β1 subunit, and represents the β1 core protein.

Figure 3.10 Relative Na+/K+-ATPase β1 glycosylation state expression in CD1 mouse
myelin with aging
+

+

Intensity of each Na /K -ATPase β1 glycosylation state, ensuring non-saturation and subtracting
+ +
background. Bands 1 to 4 represent the highest molecular mass form of Na /K -ATPase β1 to the lowest
molecular mass form (core, non-glycosylated), respectively. Intensity was measured at 3.10, 7.65, 9.00
and 13.02 months of age. Each value was corrected by normalization with a β-actin protein loading
control.

Resembling the other subunit isoforms of Na+/K+-ATPase the protein expression
of the individual glycosylation states of Na+/K+-ATPase β1 varied over the course of
development. The normalized intensities of each glycosylation state, at each age, are
illustrated in Figure 3.10. It was observed that expression levels generally increased
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between 3.00 to 7.65 months, decreased after 7.65 months, and bounced back at 13.02
months of age. Band 1, the highest molecular mass form of Na+/K+-ATPase β1, was
unique in the fact that its expression continually decreased from 3.00 months onward,
until rebounding at 13.02 months of age. Bands 2 and 3 were typically found in the
greatest abundance, when compared with the fully glycosylated and core forms of
Na+/K+-ATPase β1. Additionally, the core, unglycosylated form of Na+/K+-ATPase β1, at
both 9.00 and 13.02 months of age, was extremely difficult to perceive upon visual
inspection of the blot. These Western blots indicated that expression of the immature
form of Na+/K+-ATPase β1 was extremely limited in the later months of development; it
was also the least abundant of all forms, across all four age groups.

3.4.2 Age-Related Protein Expression in Diseased ND4 Mouse Myelin
As a follow-up to studying each Na+/K+-ATPase subunit isoform in healthy CD1
control mouse myelin, the myelin isolated from ND4 mice, which represent a
demyelinating model of MS, was subsequently assessed. These mice were sacrificed at
the same time as the CD1 mice; either at 3.10, 7.65, 9.00 or 13.02 months of age.
Analogous to the examination of Na+/K+-ATPase subunit isoform expression in CD1
control mice, Western blotting in conjunction with densitometric analysis was
performed. These images are shown alongside their control counterparts in Figure 3.8.
Once again, all three alpha and three beta subunit isoforms of Na+/K+-ATPase were
successfully detected in the ND4 myelin from each age group. When normalized to a βactin protein loading control, the fluctuations in protein band intensity for each subunit
isoform closely resembled the changes which occurred in the CD1 control myelin, across
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all four age groups; refer to Figure 3.11, and compare with Figure 3.9. Na+/K+-ATPase β3
appeared to be an exception, as its expression within the ND4 myelin increased after
9.00 months; whereas the CD1 myelin showed a decrease in expression during this time
period.

Figure 3.11 Relative Na+/K+-ATPase subunit isoform expression in ND4 mouse myelin
with aging
+

+

Intensity of each Na /K -ATPase subunit isoform, ensuring non-saturation and subtracting background.
Intensity was measured at 3.10, 7.65, 9.00 and 13.02 months of age. Each value was corrected by
normalization with a β-actin protein loading control.

As with the CD1 control myelin, the three glycosylation states as well as the core,
unglycosylated form of Na+/K+-ATPase β1 were evident in the ND4 myelin. In this case,
the trends of protein expression over the course of development were once again
similar to that of the CD1 myelin, with several slight differences. As shown in Figure
3.12, the fully glycosylated form of Na+/K+-ATPase β1 (Band 1), rather than its core (Band
4), was the least abundant of all other Na+/K+-ATPase β1 proteins. The two intermediate
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molecular mass protein forms, Bands 2 and 3, remained the most abundant, as also
seen in the CD1 control myelin (Figure 3.10).

Figure 3.12 Relative Na+/K+-ATPase β1 glycosylation state expression in ND4 mouse
myelin with aging
+

+

Intensity of each Na /K -ATPase β1 glycosylation state, ensuring non-saturation and subtracting
+ +
background. Bands 1 to 4 represent the highest molecular mass form of Na /K -ATPase β1 to the lowest
molecular mass form (core, non-glycosylated), respectively. Intensity was measured at 3.10, 7.65, 9.00
and 13.02 months of age. Each value was corrected by normalization with a β-actin protein loading
control.

3.4.3 The Effect of Demyelination on Na+/K+-ATPase Protein Expression
A direct comparison of the corrected intensities for each Na+/K+-ATPase subunit
isoform as well as the various glycosylation states of Na+/K+-ATPase β1, within each
individual age group, can be found in Figure 3.13 and Figure 3.14. Certain differences
between the protein expressions of the two myelin preparations were immediately
recognized. Firstly, Na+/K+-ATPase α1 initially demonstrates increased expression within
the ND4 myelin, until 13.02 months when it is lesser than, but close to, the levels of
expression detected in the CD1 myelin. Secondly, the expression of the fully
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glycosylated form of Na+/K+-ATPase β1 (Band 1) in the ND4 myelin was strikingly lesser
than that of the CD1 myelin, across all age groups. Na+/K+-ATPase β2 also exhibited
reduced expression within the ND4 myelin at 3.00 and 7.65 months of age, but
surpassed the measured expression of the CD1 myelin at 9.00 and 13.02 months of age.
Lastly, Na+/K+-ATPase β3 was consistently elevated in the ND4 myelin, across all age
groups.

Figure 3.13 Compared relative intensities of each Na+/K+-ATPase subunit isoform,
between CD1 and ND4 myelin, in each age group
+

+

Relative intensity of each Na /K -ATPase subunit isoform, ensuring non-saturation and subtracting
background. Each value was corrected by normalization with a β-actin protein loading control.
Comparisons were for CD1 (blue) and ND4 (red) myelin at: A) 3.00 months of age; B) 7.65 months of age;
C) 9.00 months of age; D) 13.02 months of age.
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Figure 3.14 Compared relative intensities of each Na+/K+-ATPase β1 glycosylation state,
between CD1 and ND4 myelin, in each age group
+

+

Relative intensity of each Na /K -ATPase β1 glycosylation state, ensuring non-saturation and subtracting
+ +
background. Bands 1 to 4 represent the highest molecular mass form of Na /K -ATPase β1 to the lowest
molecular mass form (core, non-glycosylated), respectively. Each value was corrected by normalization
with a β-actin protein loading control. Comparisons were for CD1 (blue) and ND4 (red) myelin at: A) 3.00
months of age; B) 7.65 months of age; C) 9.00 months of age; D) 13.02 months of age.
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Chapter 4 – Discussion
4.1 Comparison of Sucrose and Percoll Gradient Isolation Methods
The biochemical analysis of specific cell types, a particular membrane, or the
subcellular organelles of certain tissues, requires the successful isolation of pure cellular
populations or subcellular fractions. The complex nature of the CNS, and its highly
interconnected cellular processes and cell types, has prompted the development of
several different isolation strategies which aid in the study of cellular neurochemistry
[63]. Firstly, the successful isolation of subcellular organelles and biological membranes,
such as myelin, requires a method of cell lysis or tissue homogenization which
maximizes yield while minimizing cellular debris and contaminants [64]. It is also
important that the procedure maintains the functional integrity of the target, as well as
preserving its structure as much as possible. In this study, whole mouse brains were
homogenized, using a Dounce homogenizer, in an isotonic sucrose solution of low ionic
strength. Under these conditions, the myelin membrane becomes detached from
neuronal axons and forms small vesicles; these myelin vesicles are similar in size to
mitochondria and nuclei [65]. The high lipid to protein ratio in myelin also confers the
lowest intrinsic density of any membrane fraction derived from the CNS, including
mitochondria and nuclei [65].
Essentially all myelin isolation protocols exploit the size and density of the myelin
vesicles generated during the homogenization of CNS tissue. Often, an isolation protocol
will use differential centrifugation at low speeds to remove bulky debris from the initial
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homogenate [49]. This process is then followed by the separation of the remaining cell
membranes and organelles using a discontinuous density gradient. Mitochondria,
synaptosomes, nuclei and other large cellular components will sediment through the
denser layer of the isolation medium, while small membrane fragments and certain
organelles will remain in the upper, less dense fraction; the myelin vesicles, however,
will gather at the density interface due to their size and buoyancy [11;65]. After
collecting the crude myelin from the interface, the sucrose is diluted out and the
vesicles are osmotically shocked. By treating the isolated myelin with ice cold purified
water, any residual microsomes, axoplasm or major impurities are released [65]. Myelin
vesicles of higher purity can be obtained by adding supplementary centrifugation and
osmotic shock steps to the methodology. A second round of density gradient
centrifugation can be introduced; by doing so, further removal of large particles, which
may become trapped in the crude myelin layer that forms at the density interface, is
achieved [66]. Continuous density gradients can also be introduced as a way of
preventing contaminating materials from becoming trapped in the crude myelin layer;
this addition may be either supplementary to, or in place of, the discontinuous gradient
centrifugation steps [66]. A range of myelin vesicles, of different sizes, densities, and
lipid to protein ratios, can be separated by the use of continuous gradients; thereby
permitting a more detailed examination of the myelin membrane to be conducted.
In this study, the myelin vesicles were separated from the remaining neural
tissue using either a discontinuous sucrose or Percoll gradient; each method offered its
own advantages and disadvantages. The method by Kristian used a discontinuous
80

Percoll gradient [49]. Percoll, like sucrose, can be prepared in an isotonic solution which
allows osmolarity to be maintained throughout the isolation [67]. It has a low viscosity,
as it is made of colloidal silica particles which have been coated with
polyvinylpyrrolidone [67]. Consequently, the use of Percoll, rather than sucrose, allows
for the use of lower centrifugal forces, and accelerates sedimentation rates [50]. More
specifically, the maximum centrifugal force applied by this method was 30,700xg, and
gradient separation took merely eight minutes. In fact, the entire procedure for isolating
myelin, mitochondria and synaptosomes is estimated to take 90 minutes [49].
The sucrose gradient isolation method developed by Norton takes slightly over
two hours to complete [48]; however, modifications used in this study increased the
isolation time to 4-5 hours total. A discontinuous density gradient was applied twice;
first to isolate the crude myelin, and a second time to obtain purified myelin. Unlike the
Percoll gradient isolation, this method excluded an initial low speed centrifugation step
to remove major debris, prior to applying the homogenized CNS tissue to a
discontinuous density gradient [48]. It also required significantly greater centrifugal
forces and separation times; the density gradient centrifugation steps depended upon
the use of an ultracentrifuge, as forces up to 100,000xg were reached. Due to the longer
isolation time, protease and phosphatase inhibitor cocktails were included in the
isolation medium of the sucrose gradient method, during homogenization; they were
not present in the isolation medium of the Percoll gradient method, though were
incorporated into the myelin storage buffer used in each procedure. These inhibitors
prevent protein denaturation which is often triggered by disturbance of the highly
81

regulated cellular environments; in so doing, total protein recovery is boosted and
enzyme activity is preserved [68]. The sucrose gradient method also took advantage of
two osmotic shock steps, which ensured removal of impurities from within the myelin
vesicles. Unfortunately, this procedure required a greater number of mouse brains to
produce an equivalent myelin yield to that generated using the Percoll method. The
additional purification steps included in the sucrose gradient isolation led to the loss of
some myelin vesicles; consequently, 8 mouse brains were needed to attain comparable
amounts of myelin protein when judged against the product of the alternate Percoll
procedure, which used only 4 mouse brains. The sucrose method was variable and
yielded 2.5-14 mg of total protein, whereas the Percoll method generated
approximately 5 mg of protein.
Preliminary tests indicated that both sucrose and Percoll gradient isolation
protocols generated myelin with measurable levels of Na+/K+-ATPase α1, α2, and α3, as
well as their complementary β1, β2, and β3 subunits. Similarly, MBP, VDAC, NQO1 and
MCT1 were successfully detected by Western blotting in the products of each myelin
preparation (refer to Appendix G). MBP is a known myelin-specific protein, while VDAC
and NQO1 are currently being investigated in the DeBruin lab as possible myelinassociated proteins. Alternatively, MCT1, MCT2 and MCT4 have all been previously
shown to localize within the CNS; MCT1 is predominately expressed in oligodendrocytes,
while MCT2 and MCT4 are expressed in neurons and astrocytes, respectively [69].
Differences in the isolated myelin samples were only observed when examined side by
side, along with a brain homogenate sample of equal protein content. VDAC and MCT1
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were more enriched in the myelin vesicles of the Percoll gradient protocol, despite
containing equivalent levels of MBP when compared with myelin isolated using a
sucrose-gradient; therefore, the myelin produced using the sucrose-gradient method
was selected for all further analyses despite being a more timely and expensive
procedure.

4.2 Role of Na+/K+-ATPase Isoforms and Heterodimers in the Myelin
Membrane
To date, four alpha and three beta isoforms of Na+/K+-ATPase have been
identified in mammalian tissues; of these, only Na+/K+-ATPase α1, α2, and α3, and β1, β2,
and β3 have been identified in CNS tissue. Each of these isoforms are encoded by
separate genes and they show a high degree of conservation, even across species
[3;70;71]. Despite any differences in sequence and/or post-translational modifications,
past studies have demonstrated that each of the four alpha subunit isoforms are
capable of forming a functional ion pump with any of the three beta subunit isoforms
[31].

4.2.1 Co-expression of Na+/K+-ATPase Isoforms and Isozymes
The isoforms of each subunit demonstrates spatial and temporal patterns of
expression; specifically, tissue-specific and developmental variations in protein
expression [70]. The α1 and β1 subunits have been classically perceived as the
“housekeeping” isoforms, as they are typically abundant and ubiquitously expressed
[24;27;31;72]. Conversely, the α2, α3, α4, β2, and β3 subunit isoforms demonstrate
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varying levels of tissue-specificity or variations in expression throughout the stages of
development; these differences suggest that each provides unique functional roles. So
far, the α2 subunit has been primarily identified in the brain, muscle, adipose,
osteoblasts, retina, choroid plexus, lung, and the optic nerve; the α3 and β2 subunits are
found in neural tissue, with Na+/K+-ATPase α3 also having been identified in human
cardiac muscle; and the α4 and β3 subunits are expressed in spermatogonia and sperm,
although Na+/K+-ATPase β3 has also been noted in the brain, kidneys, lung, spleen,
intestines, and liver [24;27;31;34]. With regards to the specific cell types of the CNS, the
α1 isoform distributes between neurons and glia, while the α2 and α3 isoforms are
primarily expressed in glia or neurons, respectively; also, the β1, β2, and β3 isoforms
predominantly exist within neurons, both astrocytes and oligodendrocytes, or
oligodendrocytes, respectively [36]. Refer to Table 4.1 and section 4.2.2 for further
discussion. In this study, it was identified that all three alpha and three beta subunit
isoforms of the mammalian CNS were expressed in the myelin membrane of both CD1
and ND4 mice; these represented healthy and diseased myelin, respectively.
Apart from the tissue- and organ-specific distribution of each subunit isoform,
the alpha and beta subunits of Na+/K+-ATPase can also exhibit subplasmalemmal
organization. Na+/K+-ATPase has the potential to reside within certain microdomains
and membrane regions; therefore, it often demonstrates targeted distribution within
the plasma membrane [32]. This phenomenon has been observed in cultured astrocytes
and neurons, both of which have a unique and complex cellular architecture (Figure
4.1). In particular, the α1, α2, and α3 subunit isoforms have demonstrated unique
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patterns of expression in these cell types. Na+/K+-ATPase α1 is expressed throughout
astrocytes, but appears limited to the cell bodies of neurons [72]. Alternatively, Na+/K+ATPase α2 localizes in regions of the plasma membrane that overlap with the cellular
distribution of the endoplasmic reticulum [72]; this pattern of expression could be an
unintentional consequence of integral membrane protein synthesis and transport from
the endoplasmic reticulum to the plasma membrane, via the Golgi complex. And lastly,
Na+/K+-ATPase α3 non-uniformly distributes throughout the processes (dendrites, axons,
and terminal fibers) and cell bodies of neurons; Na+/K+-ATPase α3 stands apart from its
α1 counterpart, as it is expressed in clusters or focused regions within neurons [72].

Figure 4.1 The basic structure of neurons and astrocytes
A typical neuron has a cell body, which contains the nucleus and other cellular organelles, as well as
dendrites to receive impulses, and axons and fibers to transmit impulses. Astrocytes are characteristically
star-shaped, and extend processes which commonly terminate on blood vessels or the axons of neurons.
Image adapted from references [1;4].

Known protein-protein interactions indicated that Na+/K+-ATPase stabilizes
components of adherens junctions and regulates the expression of proteins found in the
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tight junctions of epithelial cells [58;73;74]. These two microdomains form the apical
junctional complex, which is responsible for critical cell-cell adhesion. Na+/K+-ATPase has
been shown also to localize within the caveolar microdomain of renal epithelial cells;
this result was anticipated as both Na+/K+-ATPase and caveolae exist at the basolateral
plasma membrane of these polarized cells [32;58]. In these caveolae, oligomers of
caveolin-1, tetramers of annexin-2, and oligomers Na+/K+-ATPase formed large
multiprotein complexes [58]. Furthermore, when activity was investigated in both
caveolar and non-caveolar Na+/K+-ATPase pools, it was determined that ion transport
capabilities were retained in the caveolae; this has also been demonstrated in Na+/K+ATPase within caveolae derived from cardiac myocytes [58]. Caveolin-1 enriched
microdomains, adherens junctions and tight junctions are all found in the myelin
membrane as well; the caveolin-1 enriched microdomain and adherens junctions are
both components of the outer loops of myelin, the adherens junctions and tight
junctions are part of the paranodal loops of myelin, and the adherens junctions and
tight junctions are also found in the incisures and radial components of the myelin
membrane, respectively [16].
Ultimately, the unique subplasmalemmal distribution of each Na+/K+-ATPase
subunit isoform may confer unique physiological properties to specific cell types. On top
of these distinct localization patterns, the subunit isoforms also vary in their
comparative levels of expression. For example, neurons typically express Na+/K+-ATPase
α1, α2, and α3; however the α1 and α3 isoforms are most abundant [72]. In the same
way, all three alpha isoforms of the CNS are expressed in the myelin membrane, as
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identified in this study; however, as shown by Western blot analysis, myelin is rich in the
α3 isoform, while the α1 and α2 isoforms are less abundant. As in neurons, the α2
isoform in myelin is the least abundant. With regards to the beta subunit in myelin,
Na+/K+-ATPase β2 and β3 are more abundant than the β1 isoform. Each individual Na+/K+ATPase alpha or beta isoform, within a specific tissue or cell type, also experiences
fluctuations in their expression over the course of development.
As discussed earlier, multiple subunit isoforms are often co-expressed within a
tissue or specific cell type. The coexistence of different Na+/K+-ATPase subunit isoforms,
and in turn various isozymes, may be essential due to differences in their sensitivity to
inhibitors, substrate affinities, and varying cellular roles. Firstly, Na+/K+-ATPase is often
targeted by cardiac glycosides, such as ouabain, in the treatment of congestive heart
failure and other cardiomyopathies. These compounds can inhibit enzymatic activity by
disrupting the catalytic site of the alpha subunit. They are also naturally occurring in
biological systems. Interestingly, the α1 isoform is ouabain-resistant; Na+/K+-ATPase α2
and α3, however, are ouabain-sensitive and can be inhibited by such compounds [75].
With regards to their substrate affinities, disparity in both Na + and K+ ion affinities
between isoforms have been experimentally proven. In a rat model, the α1 isoform
exhibited a greater K+ affinity than its α2 and α3 counterparts; while the α3 isoform has
demonstrated a reduced affinity for Na+ in comparison to α1 and α2 [24]. The enzymatic
activity of each of the heterodimeric forms of Na+/K+-ATPase can also be modulated by
associations with the FXYD1 protein, which is often co-expressed [76]. Thirdly,
adaptations or isoform specific interactions are reflected in the distinct distribution of
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the Na+/K+-ATPase beta subunit isoforms within oxidative and glycolytic tissues; in
particular, the β1 isoform is found in oxidative muscle fibers whereas the β2 isoform
resides primarily in the glycolytic fibers [77]. The slight differences in these enzymatic
properties, between individual isoforms and isozymes, may support different
physiological requirements and provide adaptability to inconsistent ionic and osmotic
cellular environments [72]. Likewise, the chromosomal dispersion of the genes for each
alpha subunit isoform, as well as their individual expression patterns, suggests selection
in response to various physiological demands [72]. Negative and positive elements have
been identified for the genes of each alpha isoform; they bind transcription factors and
regulate both spatial and temporal expression. The existence of these elements also
indicates that Na+/K+-ATPase expression is strongly associated with physiological
requirements [72]. Alternative splicing has also been shown to generate truncated alpha
and beta isoforms; both have been identified in several tissue types and retain their ATP
binding and phosphorylation sites, suggesting that they maintain their ATPase activity
[3]. The expression of these truncated proteins could have significant structural or
functional importance. Finally, it is possible that co-expression may primarily offer
functional redundancy, as Na+/K+-ATPase is responsible for several critical cellular
functions and is a key regulator of homeostasis.

4.2.2 Comparison with Cell Types of the Brain
Na+/K+-ATPase α1, α2, and α3, as well as the complementary β1, β2, and β3
subunits, represent all known isoforms of Na+/K+-ATPase in the CNS. Table 4.1
summarizes the findings of this study, in addition to the known subunit isoform
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expression of the major cell types of the CNS. Myelin, unlike these cell types, is the only
component of the CNS known to express all six subunit isoforms. Although Na+/K+ATPase α3 expression has not been detected in oligodendrocytes [34;75;79;81], it is
found in the myelin sheath; thus, expression must occur post-myelination. The use of
antibodies with unique epitope binding sites, for each alpha and beta isoform, ensured
no cross-reactivity and provided confidence in the identification of each subunit
isoform. The specific epitopes for each antibody used in the study were described
previously in Table 2.1.
Table 4.1 The distribution of alpha and beta isoforms within the various cell types of
the brain
+

+

The known expression of Na /K -ATPase subunit isoforms is represented by a positive (+) sign;
+ +
alternatively, Na /K -ATPase subunit isoforms not known to exist in the specified tissue or cell type is
represented by a negative (-) sign.

Isoform
Cell Type

References
α1

α2

α3

β1

β2

β3

Neurons

+

+

+

+

+

Only in retinal
photoreceptors

[34;75;7881]

Astrocytes

+

+

-

+

+

-

[75;78-81]

Oligodendrocytes

+

+

-

+

+

+

[34;75;79;81]

Myelin

+

+

+

+

+

+

This study

Although any of the three alpha isoforms could potentially associate with any of
the three beta isoforms to produce a functional ion pump, it is atypical to observe all
possible isozymes co-expressed within a single tissue or cell type [31]. In fact, all nine
heterodimeric forms of Na+/K+-ATPase have only been noted within cartilage tissue [72].
Only six of these isozymes were revealed, by this study, to exist in the myelin membrane
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of healthy CD1 mice; these included α1β1, α2β1, α2β3, α3β1, α3β2, and α3β3. Of these,
α1β1, α2β3, and α3β1 were the most abundant heterodimeric forms of Na+/K+-ATPase in
the myelin membrane, and α2β3 and α3β3 were unique when compared with neurons
and glial cells. The isozymes found in neurons, oligodendrocytes, astrocytes and other
mammalian tissues or cell types, are specified in Table 4.2. Neurons, oligodendrocytes
and astrocytes also express Na+/K+-ATPase heterodimers which can distinguish these
cells from the myelin membrane; both α1β2 and α1β3 exist in neurons, while α1β2, α1β3,
and α2β2 have been identified in oligodendrocytes and/or astrocytes [72].
Table 4.2 The distribution of Na+/K+-ATPase isozymes within mammalian tissues
+

+

The known expression of Na /K -ATPase isozymes within various mammalian tissues and/or cell types.
This table was adapted from reference [72]. The results of this study are included; the six heterodimeric
+ +
forms of Na /K -ATPase, which were identified in the myelin membrane of CD1 mice, are listed.

Type of Tissue/Cell
Renal tubule cells
Cardiac myocytes
Gut
Alveolar epithelial cells
Liver
Neurons
Oligodendrocytes and/or astrocytes
Ciliary epithelium
Chondrocytes
Osteoblasts
Osteoclasts
Vascular endothelial cells
Skeletal muscle
Smooth muscle
Testis
Prostatic epithelial cells
Myelin

Known Na+/K+-ATPase Isozymes
α1β1
α1β1, α1β2, α1β3, α2β1, α2β2, α2β3, α3β2, α3β3
α1β1
α1β1, α1β3, α2β1, α2β3
α1β1, α1β3
α1β1, α1β2, α1β3, α3β1, α3β2
α1β1, α1β2, α1β3, α2β1, α2β2
α1β1, α1β2, α2β1, α2β2, α3β1 α3β2
α1β1, α1β2, α1β3, α2β1, α2β2, α2β3, α3β1, α3β2, α3β3
α1β1, α1β2
α1β1
α1β1, α1β2, α3β1, α3β2
α1β1, α1β2, α1β3, α2β1, α2β2, α2β3
α1β1, α2β1
α1β1, α1β2, α1β3, α4β3
α1β1, α1β2
α1β1, α2β1, α2β3, α3β1, α3β2, and α3β3

The assortment of Na+/K+-ATPase isozymes are generated by the expression of
different genes, variations in transcriptional modifications and processing, and the
successful formation of different heterodimeric combinations [3]. As noticed in Table
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4.2, α1β1 is present in all examined mammalian tissues and cell types to date; this
observation supports the role of both α1 and β1 isoforms as the “housekeeping” Na+/K+ATPase subunit isoforms [24;27;31;72]. Other isozymes have proposed functional roles
according to the known ion affinities of their corresponding subunit isoforms, as well as
known functions and physiological needs of the tissues or cell types in which they are
expressed. In particular, heterodimeric forms which incorporate the α3 isoform may
provide additional ion transport capabilities in situations or locales of major fluctuations
in ion concentration. As mentioned earlier, Na+/K+-ATPase α3 demonstrates the lowest
affinity for Na+ ions, out of all the alpha isoforms [24]. Likewise, the α3β1 isozyme has
reduced affinity for both Na+ and K+ ions, and is found primarily in excitable tissues [72].
These qualities may be interpreted as the evolutionary adaptability of Na+/K+-ATPase to
meet the requirements of excitable tissues, which experience extreme variations in their
ionic environments; for example, the extreme fluctuations observed throughout the
firing of action potentials [72]. Similarly, α3β1, α3β2, and α3β3 are expressed in cartilage
tissue or chondrocytes, where recovery from major variations in the concentration of
Na+ ions is necessary following mechanical joint loading [72]. It is therefore not
surprising that the myelin membrane expresses all α3-containing isozymes, as it is tightly
associated with neuronal axons and may be needed to support the changes in ionic
environments as action potentials are transmitted. Between the unique kinetic
properties and sensitivity in inhibitors, each expressed isozyme appears to provide the
necessary adaptations for their resident tissue requirements.
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4.3 Protein-Protein Interactions in the Myelin Membrane
Proteins are responsible for carrying out cellular processes, and although they
can have independent functions they often collaborate to maintain activity and control
their environment. Considering there is a significant number of proteins, and
exponentially more cellular functions, protein-protein interactions exhibit both
structural and functional diversity. Firstly, proteins may interact with proteins of either
identical or non-identical chains; these interactions generate either homo- or heterooligomers, respectively [82]. In turn, oligomers formed by homologous proteins can join
in either an isologous or heterologous fashion. Isologous associations are formed on the
equivalent surfaces of each protein unit, whereas heterologous connections occur at
alternative interfaces [82]. Secondly, protein complexes may be functionally obligate;
the individual protein components cannot exist alone, as they may not be stable without
their specific binding partners. In contrast, non-obligate interactions are those produced
from the assembly of proteins which can exist independently from one another [82;83].
A prime example of a non-obligate interactions are cellular signalling cascades; the
individual proteins are generally not co-localized until the moment of interaction, and
therefore must be stable on their own. Nonetheless, co-localized proteins, particularly
homo-oligomers, can participate in non-obligate interactions [82]. Lastly, proteinprotein interactions may be either permanent and form very stable complexes, or they
can be transient and provide dynamic associations and disassociations in response to
the environment or external factors [82;83]. These interactions may also be regulated
by post-translational modifications, such as glutathionylation and carbonylation [84-86].
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Despite the discrete types of protein complexes which can form, it is unusual for a
particular interaction to be neatly categorized, as these complexes can vary in stability
according to their surrounding environment.
Na+/K+-ATPase has several known binding partners and participates in various
protein-protein interactions. The individual alpha and beta subunit isoforms of Na+/K+ATPase, themselves, also interact and assemble to produce the functional enzyme. Thus,
this enzyme is an example of a hetero-oligomer, or in this particular instance a
heterodimer; it is also an example of a non-obligate and usually permanent interaction.
Both alpha and beta subunits are produced independently, but the beta subunit is
required for the successful insertion of the alpha subunit into the plasma membrane. It
interacts with the alpha subunit via a heptad repeat motif, in order to form the αβ
hetero-oligomer [87]. The beta subunit can exist within the plasma membrane
regardless of alpha expression, although independent roles of this subunit are unknown
[27]. It is, however, fundamentally important in cell-cell adhesion, as Na+/K+-ATPase β1
also contains a glycine zipper motif which allows homo-oligomerization between beta
subunits [87]. As a transmembrane protein of the plasma membrane, Na+/K+-ATPase has
the potential to associate with cytosolic, extracellular, and other transmembrane
proteins. Isozymes may also have unique or shared binding partners. Each of these types
of associations is depicted in Figure 4.2.
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Figure 4.2 Potential protein-protein interactions involving Na+/K+-ATPase
+

+

Many unknown proteins may form complexes with Na /K -ATPase, or act as protein binding partners. The
+ +
six heterodimeric forms of Na /K -ATPase, known to exist in the myelin membrane, are illustrated above.
The dashed lines indicate the potential connections between the various subunit isoforms and other
+ +
unknown proteins. Protein-protein interactions of the Na /K -ATPase alpha and beta subunit isoforms
may include cytosolic, extracellular and/or other transmembrane proteins. The indicated associations are
+ +
provided as examples and do not necessarily represent actual associations of these Na /K -ATPase
isozymes.

4.3.1 Structural and Functional Properties
Co-immunoprecipitation of the three Na+/K+-ATPase alpha subunit isoforms
revealed their involvement in several protein-protein interactions, within the myelin
membrane. When analyzed by LC-MS/MS, a total of 13 major proteins were identified,
with 100% probability and a minimum of two unique peptides recognized using the
Scaffold 4 proteome software. The α1 and α2 isoforms were successfully detected within
their respective isolated protein complexes; the remaining protein binding partners
included additional Na+/K+-ATPase subunit isoforms, myelin specific proteins, and other
protein types. The identified binding partners of each alpha isoform are listed in Table
4.3, along with their proposed structural and/or functional roles. Due to the transient
nature of certain protein-protein interactions, it is likely that the number of identified
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binding partners in myelin has been underestimated. Similarly, the conditions of the coimmunoprecipitation could have potentially disrupted various protein associations. For
example, TX-100, although not used in this co-IP, has been reported to disrupt the
Na+/K+-ATPase α1β2 isozyme but not α1β1 or α2β2 [31].
Table 4.3 Known physiological functions of binding partners identified by coimmunoprecipitation and mass spectrometry in this study
+

+

Protein-protein interactions within the myelin membrane, which involved Na /K -ATPase, were identified
+ +
by mass spectrometry. Each alpha isoform of Na /K -ATPase had both unique and shared binding
partners. These binding partners are listed, along with their proposed structural and/or functional
properties from the literature.

Na+/K+ATPase α
Isoform

Identified
Binding Partner
Sodium/potassiumtransporting
ATPase subunit
alpha-3
Sodium/potassiumtransporting
ATPase subunit
beta-1

α1

Abbreviation
+

+

Na /K -ATPase
α3
+

+

Na /K -ATPase
β1

Serine/arginine
repetitive matrix
protein 2

SRRM2

Peripheral myelin
protein 22

PMP-22

Spermatogenesisassociated protein
7

SPAT7

2’,3’-cyclic
nucleotide 3’phosphodiesterase

CNP

Proteolipid protein
1

PLP1

Structural and Functional
Properties
+

+

Ion transport of Na and K ;
+
lower affinity for Na

[24;72]

Transport and insertion of the α
subunit into the plasma
+
membrane; lower affinity for K

[27;72]

RNA splicing factor; binds
components of pre-mRNA and
the splicesome; plays a role in
cell migration
Minor tetraspan membrane
protein of PNS myelin; provides
structural support and
maintains compact myelin;
component of membrane
junctions with involvement in
cell-cell interactions and cell
proliferation
Involved in normal retinal
function; possible interactions
with chromatin and the
initiation of meiotic
recombination in testis
Forms stable associations with
tubulin and anchors
microtubules to membranes;
regulates tubulin polymerization
Major tetraspan membrane
protein of CNS myelin; provides
structural support and
maintains compact myelin;
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References

[88]

[1;89;90]

[91;92]

[11;93]

[12;94]

possible ionophore

α2

α3

Sodium/potassiumtransporting
ATPase subunit
alpha-3

+

+

+

+

Na /K -ATPase
α3

Ion transport of Na and K ;
+
lower affinity for Na

[24;72]

Cullin-associated
NEDD8-dissociated
protein 1

CAND1

Regulates the assembly and
activity of Cullin-RING E3
ubiquitin-ligases; role in protein
degradation pathways

[95-97]

Sodium/potassiumtransporting
ATPase subunit
beta-1

Na /K -ATPase
β1

Transport and insertion of the α
subunit into the plasma
+
membrane; lower affinity for K

[27;72]

+

+

Brain acid soluble
protein 1

BASP1

Protein MRVI1

MRVI1

Peripheral myelin
protein 22

PMP-22

Serine/arginine
repetitive matrix
protein 2

SRRM2

Proteolipid protein
1

PLP1

Krueppel-like factor
6

KLF6

Co-localizes with raft proteins;
possible involvement in cell-cellinteractions; transcription
regulator
Component of cGMP kinase
signalling complexes; interacts
with inositol 1,4,5-triphosphate
receptor 1; mediates nitric oxide
dependent inhibition of calcium
signalling
Minor tetraspan membrane
protein of PNS myelin; provides
structural support and
maintains compact myelin;
component of membrane
junctions with involvement in
cell-cell interactions and cell
proliferation
RNA splicing factor; binds
components of pre-mRNA and
the splicesome; plays a role in
cell migration
Major tetraspan membrane
protein of CNS myelin; provides
structural support and
maintains compact myelin;
possible ionophore
Contain zinc finger motifs that
bind promoter and enhancer
regions; regulate proliferation,
differentiation and apoptosis

[98;99]

[100-103]

[1;89;90]

[88]

[12;94]

[104]

Na+/K+-ATPase interacts with an array of proteins within the myelin membrane.
Its association with several myelin specific proteins alludes to the possibility of its direct
or indirect involvement in the maintenance of myelin. Other binding partners may
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provide significant structural and functional roles when associated with Na+/K+-ATPase,
or vice versa. For example, SRRM2 is a RNA splicing factor which can bind sequence
elements on pre-mRNA, as well as components of the splicesome, to form the
complexes needed in excision-splicing [88]. The interaction of Na+/K+-ATPase with
proteins involved in transcriptional processing is logical as the alternative splicing of the
alpha and beta isoforms has been implicated in the generation of various Na+/K+-ATPase
isozymes [3]. KLF6, one of the proteins associated with Na+/K+-ATPase α3, is a
transcription factor with proposed roles in promoting apoptosis in Schwann cells,
following nerve injury; it appears to increase the susceptibility of a cell to apoptotic
stressors [104]. Overexpression of KLF6 has also been linked to increased neurite growth
[104]. Another binding partner, CAND1, is known to interact with diverse families of
proteins, and consequently participate in a wide range of cellular processes. More
specifically, CAND1 regulates Cullin3-mediated E3 ligase activity and suppresses CullinRING ubiquitin ligases by sequestering unneddylated Cullin1 [96]. Cullin-RING ubiquitin
ligases are critical for targeting cellular proteins for ubiquitin-mediated degradation;
hence, CAND1 delays or prevents the destruction of cellular proteins which are targeted
for ubiquitination [97]. And lastly, MRVI1, also known as inositol 1,4,5-trisphosphate
receptor-associated cGMP kinase substrate, not only interacts with Na+/K+-ATPase α3
but has known associations with inositol 1,4,5-triphosphate receptor 1 [101].
Interestingly, inositol 1,4,5-triphosphate receptor 1 was a predicted functional partner
of the α1 and α2 isoforms, but not α3; these protein-protein interactions were revealed
using STRING 9.1 (http://string-db.org/) [59]. Refer to Appendix C for more information.
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Many of the proteins identified as Na+/K+-ATPase binding partners are
responsible for cell to cell interactions, signal transduction, and the mediation of cellular
responses. These proteins were also indicative of the distribution of Na+/K+-ATPase
between the various microdomains of the myelin membrane. Specifically, PLP1 is a
protein marker of the tetraspanin-enriched microdomain of compact myelin [16]; its
association with both the α1 and α3 isoforms suggests that Na+/K+-ATPase also exists
within this microdomain. Likewise, the partnership between the Na+/K+-ATPase α3 and
BASP1 indicates that this isoform is likely present in the lipid raft microdomains of the
myelin membrane, as lipid rafts are found in all cell types and seem to sequester BASP1
in endothelial cells [99]. This result corresponds with the detection of Na+/K+-ATPase α3
in the DRMs of mouse myelin, as demonstrated by Western blot analysis. Na+/K+-ATPase
has also been identified in kidney caveolae; it forms complexes with caveolin-1 and
associates with annexin-2 [58]. Caveolin-1 is also enriched in microdomains of the outer
loop of myelin, in the PNS [16]. It is therefore possible that Na+/K+-ATPase could interact
with caveolin-1 in the myelin membrane, and become localized to these caveolin-1
enriched microdomains.
The co-expression of the Na+/K+-ATPase beta subunit and E-cadherin is essential
for the formation of tight junctions and desmosomes [105]. Similarly, in renal epithelia,
Na+/K+-ATPase demonstrates co-localization with E-cadherin but not occludin; as a
result, Na+/K+-ATPase has been proposed to regulate cellular junctions, including
adherens junctions, via ion transport and signal transduction [58]. In particular, Na+/K+ATPase has known involvement in EGFR/Src-Ras-Raf-ERK and PI3K-PDK-Akt cell
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signalling pathways [24;58]. Ouabain can initiate the carbonylation of two amino acid
residues in the A-domain of Na+/K+-ATPase α1, which results in stimulation of Src
signalling; however, this process appears to be regulated by reactive oxygen species, as
signalling is prevented by pre-treatment with N-acetyl-L-cysteine [86]. Finally, the
association of CNP with tubulin in brain tissue, and its roles in microtubule assembly and
organization, corresponds with the known interactions of Na+/K+-ATPase with
components of the cytoskeleton [93]. The non-random distribution of Na+/K+-ATPase
within biological membranes has been attributed to interactions with ankyrin, fodrin,
actin, and uvomorulin; these are cytoskeletal proteins which provoke the assembly of
the cytoskeleton together with Na+/K+-ATPase, in addition to mediating the specific
distribution of Na+/K+-ATPase within the plasma membrane [70;72].
The ability of Na+/K+-ATPase to respond to changes in physiological requirements
largely relies on its interaction with other cellular proteins. As previously mentioned,
reactive oxygen species can initiate signal transduction by Src, via Na+/K+-ATPase [86].
The induction of these signalling cascades can trigger a variety of cellular processes,
likely in response to oxidative stress. Similarly, cysteine residues in Na+/K+-ATPase
become S-glutathionylated when exposed to oxidized glutathione. S-glutathionylation
results in enzyme inhibition, as glutathione disrupts the ability of Na+/K+-ATPase to bind
adenine nucleotides [84]. This inhibition is not observed at high ATP levels, suggesting
that S-glutathionylation regulates Na+/K+-ATPase activity in situations of oxidative stress
and ATP depletion, such as in cases of hypoxia [84]. S-glutathionylation of Na+/K+ATPase can also be reversed by enzymes such as glutaredoxin 1; this deglutathionylation
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has been demonstrated in the β1 subunit following superoxide scavenging by superoxide
dismutase [85]. The reversible glutathionylation of Na+/K+-ATPase by glutaredoxin 1
indicates that it is an oxidative regulator of Na+/K+-ATPase activity.
The major isozymes of Na+/K+-ATPase which were identified in this study, by
Western blot analysis, included α1β1, α2β3, and α3β1. Of these, both the α1β1 and α3β1
associations were confirmed by mass spectrometry, as the Na+/K+-ATPase β1 subunit
isoform was detectable in both the α1 and α3 isoform isolated protein complexes.
Interestingly, the α1 and α2 isoforms demonstrated the ability to interact with other
alpha subunits, specifically the α3 isoform. This finding was anticipated, as the
promiscuous nature of Na+/K+-ATPase alpha and beta subunits permits the assembly of
oligomeric complexes. Different alpha isoforms have demonstrated the ability to form
stable oligomers, proving the complexity of Na+/K+-ATPase and its molecular
heterogeneity; however, the influence of Na+/K+-ATPase supracomplexes on enzymatic
function remains unclear [3].

4.4 Na+/K+-ATPase Involvement in Demyelination
4.4.1 Temporal Na+/K+-ATPase Expression
The subunit isoforms of Na+/K+-ATPase not only demonstrate tissue specificity,
but also display changes in expression over the stages of development. Of course,
Na+/K+-ATPase provides important cellular functions that are required for normal
development; therefore, patterns of expression are expected as a consequence of
responding to changing physiological requirements. This enzyme has proven critical
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during morphogenesis; in embryonic development the sodium-potassium pump
collaborates with other sodium exchangers of trophoblasts, to produce the
transepithelial flow of water and Na+ ions necessary for the formation of the fluid or
yolk-filled component of what eventually becomes the blastula [72]. In experiments
which disrupted Na+/K+-ATPase activity during blastocyst formation, pre-natal
development ceased.
Hormones, specifically thyroid hormones and glucocorticoids, appear to
influence alpha isoform expression at various stages of development [106]. Thyroid
hormone stimulates an increase in α2 and α3 isoform mRNA levels, whereas
glucocorticoids have shown to suppress α3 isoform gene transcription [70]. Combined,
these two types of hormones adjust isoform expression in cardiac tissue; the α3 isoform
is transcribed to the greatest extent during fetal and neonatal development, while the
α2 isoform appears to take over during post-natal development [70]. Regardless, Na+/K+ATPase α1 remains the predominant alpha isoform at all stages of development. Similar
changes in the gene transcription of the alpha isoforms have been observed in other
tissues; for example, neuronal Na+/K+-ATPase α3 mRNA and protein levels are
significantly reduced with normal aging [36].
Both β1 and β2 isoforms are expressed in the CNS of rats at varying stages of
post-natal development. The β1 isoform is expressed equally with the β2 isoform, in
neurons, during the neonatal stage of development; its expression significantly
increases after birth, and reaches mature levels as quickly as 6 days later [107]. In
contrast, β2 expression decreases continuously over post-natal development and
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eventually becomes undetectable in the fully mature adult rat neurons [107]. Thyroid
hormones appear to have limited or no effect on the transcription of these beta subunit
isoforms [70]. Transcriptional regulation of the beta isoforms is possible; however, it
seems to be primarily driven by immediate physiological needs, rather than major
developmental changes. For example, myoblasts induce beta subunit biosynthesis in
response to increased intracellular Na+ ion concentrations; as a result, Na+/K+-ATPase
alpha subunits can be promptly transported to the plasma membrane to restore ionic
balance [70]. Conversely, in situations where Na+ entry becomes impaired, the Na+/K+ATPase isozymes are internalized in order to maintain ionic homeostasis [70].
Regardless of the transcriptional regulation of the Na+/K+-ATPase beta subunit,
these isoforms demonstrate developmental changes in their glycosylation. Bear in mind
that all isoforms of the beta subunit are heavily glycosylated, and that each isoform
varies in its number of potential N-glycosylation sequences according to its species of
origin [3;27]. In mammals, the β1 subunit has three possible extracellular N-glycosylation
sites; on the other hand, the β2 subunit of chicken, human, and mouse origin have four,
eight, and nine potential N-glycosylation sites, respectively [3;108]. The β3 subunit is
much more variable between species, and little information is known regarding its
glycosylation. The fully glycosylated forms of each beta subunit are classically identified
as the mature beta subunits, whereas the unglycosylated core protein is, by definition,
the immature form. In this study, variations in expression of each glycosylation state of
the β1 subunit were noted over post-natal development in mice. Unsurprisingly, the
unglycosylated core of Na+/K+-ATPase β1 demonstrated limited expression in the later
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months of development and was the least abundant of all forms. Conversely, the
Na+/K+-ATPase β1 subunits containing either one or two N-glycans were found in the
greatest abundance. It is possible that these glycosylated, yet immature, β1 subunits are
held in reserve and become glycosylated when the mature form is needed.

4.4.2 Modifications to Na+/K+-ATPase Expression in a Demyelinating
Model
Demyelination, as modelled by ND4 transgenic mice, is characterized by the
destruction of the myelin sheath [1]. It is one of the fundamental causes of multiple
sclerosis, and contributes significantly to the development of symptoms. This study
identified several important dissimilarities in Na+/K+-ATPase expression between healthy
CD1 control mouse myelin and transgenic ND4 mouse myelin. Although the patterns of
expression for each subunit isoform evaluated using the ND4 model were relatively akin
to those observed in the CD1 mouse myelin, when compared side-by-side the individual
protein levels at each stage of development were strikingly different; these variations
are illustrated in Figure 4.3. Na+/K+-ATPase α1, α2, and α3 levels were 1.5 to 3.2 times
higher at 3.00 months of age in the demyelinating model; however, this elevation was
followed by a rapid decrease, with levels dropping below those observed in the healthy
myelin over varying stages of post-natal development. The β1 isoform had reduced
expression in the ND4 myelin, with the exception of a spike at 9.00 months of age; here,
the expression of β1 was more than 2.5 times that measured in the CD1 myelin.
Alternatively, β2 isoform expression fluctuated throughout development but remained
relatively close to levels demonstrated in healthy myelin. And lastly, expression of the β3
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isoform was extremely similar in both CD1 and ND4 myelin until 13.02 months of age,
when levels in ND4 myelin slightly increased.

Figure 4.3 Ratio of corrected intensities for each Na+/K+-ATPase subunit isoform in
ND4 myelin, relative to CD1 myelin, with aging
+

+

Intensity of each Na /K -ATPase subunit isoform in ND4 myelin relative to CD1 myelin, ensuring nonsaturation and subtracting background. Data corresponds with the Western blots shown in Figure 3.8.
Intensity was measured at 3.10, 7.65, 9.00 and 13.02 months of age. Each value was corrected by
+ +
normalization with a β-actin protein loading control, and the CD1 myelin Na /K -ATPase subunit isoforms
have relative intensities equal to 1.0.
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Figure 4.4 Ratio of corrected intensities for each Na+/K+-ATPase β1 glycosylation state
in ND4 myelin, relative to CD1 myelin, with aging
+

+

Intensity of each Na /K -ATPase β1 glycosylation state in ND4 myelin relative to CD1 myelin, ensuring nonsaturation and subtracting background. Data corresponds with the Western blots shown in Figure 3.8.
+ +
Bands 1 to 4 represent the highest molecular mass form of Na /K -ATPase β1 (3 N-glycans) to the lowest
molecular mass form (core, non-glycosylated), respectively. Intensity was measured at 3.10, 7.65, 9.00
and 13.02 months of age. Each value was corrected by normalization with a β-actin protein loading
+ +
control, and the CD1 myelin Na /K -ATPase β1 glycosylation states have relative intensities equal to 1.0.

In the mouse model of demyelination, Na+/K+-ATPase β1 demonstrated
noteworthy differences in the expression of its various glycosylation states. These
changes in expression are displayed in Figure 4.4. Aside from the mature, fully
glycosylated form of Na+/K+-ATPase β1, expression appears increased in the ND4 myelin
at 9.00 months. Very little of the mature β1 isoform exists in the ND4 myelin; at 9.00
months it reaches maximum expression, yet it remains to be only half as much as the
protein levels observed in CD1 myelin. Ultimately, Na+/K+-ATPase β1 does not reach full
maturation in the demyelinating mouse model.
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Mutated Na+/K+-ATPase beta subunits, with altered N-glycosylation sites, are
able to maintain enzyme activity as well as their affinity for K+ ions and their sensitivity
to ouabain; however, these non-glycosylated subunits demonstrate an impaired ability
to assemble into αβ complexes, and also increase the susceptibility of Na+/K+-ATPase to
proteolysis [3]. This experimental observation suggests that glycosylation of the beta
subunit may contribute to protein folding events necessary for maintaining proper
Na+/K+-ATPase structures. An absence of the normal N-glycans of the β1 isoform has also
proven to disrupt its role in adherens junctions, by destroying its ability to bind ankyrin
and increasing its susceptibility to endocytosis [109]. Respectively, a lack of Na+/K+ATPase β1 N-glycans has been held responsible for the impairment of mature cell-cell
associations [110]. There is substantial evidence supporting the role of β-β interactions
between the caveolar Na+/K+-ATPase αβ complexes of adjacent cells [58]; thus,
glycosylation is not only vital for proper assembly of the alpha and beta Na+/K+-ATPase
subunits, but is also important for the maintenance of cell-cell communication and
adhesion. As interactions between unglycosylated beta subunits and components of
adherens junctions and cytoskeletal elements can be more easily disrupted, the limited
expression of mature Na+/K+-ATPase β1 could potentially contribute to the formation of
demyelinating lesions in ND4 mice. Glycosylation has also been proposed as a
therapeutic target for the treatment of viral infections, cancer, and an array of human
disorders [111;112]. By understanding the glycosylation changes of the Na+/K+-ATPase
beta subunits in instances of demyelination, it may be possible to eventually establish
methods for the therapeutic manipulation of N-glycans, as a treatment of MS.
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Aside from demyelinating disorders, Na+/K+-ATPase has also been implicated in
other neurological disorders, as it is ubiquitously expressed in the CNS. It has proposed
involvement in the pathophysiology of bipolar mood disorder as well as potentially
acting as a molecular target of prion infections, such as Creutzfeld-Jakob disease. Firstly,
individuals with bipolar mood disorder are known to experience both generalized
decreases in CNS glucose metabolism and ATP synthesis; these two processes could
easily correspond to decreased, or impaired, Na+/K+-ATPase activity [72]. In fact,
patients who have experienced digoxin or digitalis neurotoxicity, and animals
administered ouabain, exhibit mania-like hyperactivity and symptoms of depression
[72;113]. With regards to prion infections, animals injected with ouabain experience
similar neurological changes to those observed in various spongiform encephalopathies
[72].

4.4.3 Considerations for Evaluating Protein Expression
Evaluating and comparing Na+/K+-ATPase protein expression between myelin
samples of different genetic backgrounds can present several challenges. To begin with,
Na+/K+-ATPase expression is highly influenced by circadian rhythms, dehydration or
over-hydration, diet, and hormonal changes [36]. Na+/K+-ATPase demonstrates diurnal
patterns of expression; the neurons of the ventral suprachiasmatic nucleus experience
increased enzymatic activity during the day and decreased activity at night [114].
Alternatively, extreme changes in ionic environments, such as those accompanying
dehydration or over-hydration, can directly control Na+/K+-ATPase activity. It has also
been claimed that a diet with increased saturated fatty acid composition, or decreased
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polyunsaturated fatty acids, is able to inhibit Na+/K+-ATPase activity by becoming
incorporated into biological membranes [36]. The influence of thyroid hormones and
glucocorticoids on Na+/K+-ATPase expression was discussed previously; they appear to
influence alpha isoform expression at various stages of development [106]. Similarly,
estrogens have been implicated in increased Na+/K+-ATPase activity; it has been
suggested that Na+/K+-ATPase becomes activated by estrogen-mediated signal cascades
or by estrogen-dependent changes in membrane fluidity [36]. With particular regards to
this study, Na+/K+-ATPase expression may also vary in ND4 myelin as efforts to
remyelinate transpire. Injury to the myelin membrane may trigger changes in Na+/K+ATPase subunit isoform expression. A similar effect has been documented in neurons;
Na+/K+-ATPase α3 expression increases post-axonal damage, and remains elevated
during the period of regeneration [115]. Unfortunately, in this particular strain of ND4
mice, any remyelination or compensation mechanisms eventually become overwhelmed
and lead to death.
Undoubtedly there are many factors, both environmental and endogenous,
which can alter Na+/K+-ATPase activity and expression in a living animal model. Thus,
standardized housing conditions for laboratory animals are imperative for
reproducibility and minimizing bias [116]. Housing conditions such as animal feed and
water, caging, bedding material, lighting, ventilation, temperature, noise, and sanitation
must all be considered in animal research. Likewise, animals need to be euthanized
under equivalent conditions, following a standard operating procedure. For the
comparison of Na+/K+-ATPase expression in myelin isolated from both CD1 and ND4
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mice, it was particularly important for all of the animals to be housed and sacrificed
identically; samples from each mouse line needed to be euthanized at an equivalent
age. Nonetheless, all efforts to maintain comparable standards of living can still not
account for the fact that two genetically distinct lines (control and transgenic) of mice
were compared; therefore, it is possible that innate differences may exist which could
alter Na+/K+-ATPase activity and expression.
Finally, all densitometric data obtained in this study, by chemiluminescent or
fluorescent detection, was normalized using β-actin. This housekeeping protein is one of
many commonly used protein loading controls; others include β-tubulin, glyceraldehyde
3-phosphate dehydrogenase, cyclophillin, etc. [60;62]. As these proteins perform
housekeeping roles, they are typically constitutively expressed. The use of an internal
control takes technical artifacts, like pipetting errors during gel loading and inconsistent
protein transfer to blotting membranes, into account [60]. Normalization using these
controls can be easily applied to data, pending that all replicates destined for
comparison contain the control protein band [61]. For all densitometric measurements
of both samples and controls, non-saturation was ensured when measuring signal
intensities, in addition to performing background subtraction. Unfortunately, variability
in the expression of housekeeping proteins in certain tissues and disease states could
undermine the validity of β-actin as an internal control. Specifically regarding the ND4
transgenic mice used in this study, by 10 months of age total myelin protein content can
be reduced to as little as 17% of that found in normal healthy mice [23]. It is therefore
difficult to imagine that when the total myelin protein content is disrupted to such an
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extent, that β-actin levels remain normal. As a result, innovative approaches for the
accurate quantification of protein expression using densitometric analysis may need to
be developed.
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Chapter 5 – Conclusions and Future Studies
In 1981, the question of whether or not Na+/K+-ATPase is a myelin-associated
enzyme was put forth by Reiss et al. [117]. They found that Na+/K+-ATPase activity in
purified myelin was significantly more than expected as a result of microsomal
contamination. Other studies using electron microscopic cytochemistry, in addition to
other subcellular fractionation techniques, were also suggestive of an association
between Na+/K+-ATPase and myelin [118]. Now, over 30 years later, this study aimed to
answer that original question by comprehensively examining the expression of myelinassociated Na+/K+-ATPase, and its individual subunit isoforms, using a mouse model.
Mouse myelin closely resembles human myelin; in fact, they share 308 common
proteins [119]. As a result, the study of myelin proteins using a mouse model can
provide relevant information pertaining to human demyelinating diseases.
It was discovered that Na+/K+-ATPase α1, α2, and α3, as well as the
complementary β1, β2, and β3 subunits, are expressed in mouse myelin prepared by
both sucrose and Percoll gradient isolation methods. These six subunit isoforms
represent all known forms of Na+/K+-ATPase in the CNS; they are uniquely co-expressed
within the myelin sheath, when compared with neurons, astrocytes and
oligodendrocytes [34;75;78-81]. Similarly, six different isozymes of Na+/K+-ATPase were
identified in myelin; these included α1β1, α2β1, α2β3, α3β1, α3β2, and α3β3. The most
abundant isozymes were α1β1, α2β3, and α3β1. All six αβ complexes were also distinct
when compared with neurons and glia; more specifically, α2β3 and α3β3 are unique to
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myelin, whereas α1β2, α1β3, and α2β2 are known to exist in neurons and/or glia but were
not identified in the myelin membrane [72].
Several protein-protein interactions involving Na+/K+-ATPase were revealed using
mouse myelin. In particular, the various alpha isoforms demonstrated interactions with
other Na+/K+-ATPase alpha and beta subunit isoforms, in addition to associating with
certain myelin-specific proteins and other protein types. These protein binding partners
of Na+/K+-ATPase have known cellular functions, including RNA splicing, involvement in
cell-cell migration and adhesion, the mediation of cytoskeletal interactions, and the
regulation of protein degradation and apoptosis. Furthermore, several of these binding
partners are known to localize in adherens junctions, tight junctions and caveolae.
Na+/K+-ATPase also demonstrated associations with protein markers of lipid raft and
tetraspanin-enriched microdomains [32;58;73;74]. The results of this study suggest that
Na+/K+-ATPase likely localizes in the corresponding microdomains of the myelin
membrane.
When the temporal expression of each subunit isoform of Na+/K+-ATPase was
examined by Western blot analysis, this protein displayed noticeable changes over the
course of normal development. This result corresponds with the known variations in
Na+/K+-ATPase expression and activity observed in other tissues and cell types; these
fluctuations occur in response to physiological demands, as well as normal aging
processes [36;70]. The Na+/K+-ATPase subunit isoforms of the myelin membrane also
showed differences in expression between healthy and diseased myelin. The divergence
in the expression levels of the Na+/K+-ATPase subunit isoforms, in ND4 mouse myelin,
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may be a contributing factor to the demyelinating processes which occur in these
transgenic mice; alternatively, it could be consequence of other biochemical changes
which take place during demyelination. Regardless of cause or effect, ND4 myelin
exhibited severe impairment in Na+/K+-ATPase β1 subunit maturation. Expression of its
mature, fully glycosylated form was drastically reduced over the post-natal
development of ND4 mice; at maximum expression, the diseased myelin only contained
approxmately 50% as much of the mature Na+/K+-ATPase β1, as measured in the healthy
CD1 mouse myelin.
Ultimately, the experimental evidence suggests that Na+/K+-ATPase provides
significant structural and functional roles within the myelin membrane. The coexpression of all six CNS isoforms, in addition to several different heterodimeric forms,
implies that this enzyme is essential to the normal physiology of the myelin sheath. It is
likely that each isoform and isozyme confers distinctive properties required to meet the
unique physiological demands of the myelin membrane. Likewise, the observed
disruption of Na+/K+-ATPase expression in ND4 mice may indicate Na+/K+-ATPase
involvement in demyelinating processes.
In the future, differences in Na+/K+-ATPase expression between various control
and demyelinating animal models should be further evaluated. By examining myelin
from a greater range of developmental timepoints, in addition to performing more
replicates and using different models of demyelination, the significance of the changes
in Na+/K+-ATPase subunit isoform expression will be established. Similarly, an
investigation pursuing the effects of beta subunit N-glycosylation on demyelination
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would be worthwhile. As changes in the N-glycans of Na+/K+-ATPase β1 have been noted
between healthy and diseased myelin, it would be beneficial to test whether or not
manipulation of these carbohydrate constituents can trigger a diseased state
reminiscent of demyelination, or specifically multiple sclerosis. Alternatively,
manipulation of the N-glycans or N-glycosylation sequences of the Na+/K+-ATPase beta
subunits could offer therapeutic benefit in the treatment of demyelination.
Glycosylation has been previously proposed in the literature as a medicinal target for
the treatment of a variety of human disorders [111;112].
Lastly, the characterization of Na+/K+-ATPase in the myelin membrane needs to
continue with the development of an effective method for evaluating its enzymatic
activity. To date, typical enzymatic assays for Na+/K+-ATPase, such as the p-nitrophenyl
phosphatase activity assay, have not been validated for measuring Na+/K+-ATPase
activity in preparations of myelin vesicles. A preliminary investigation into the enzymatic
activity of Na+/K+-ATPase, in the myelin membrane, is described in Appendix E. Na+/K+ATPase inhibitors, aside from ouabain, need to be identified such that enzymatic activity
can be accurately measured. Recall that although Na+/K+-ATPase is generally inhibited
by cardiac glycosides, Na+/K+-ATPase α2 and α3 are ouabain-sensitive, whereas the α1
isoform is ouabain-resistant [75]. Therefore, the measurement of the total Na+/K+ATPase activity, as well as the activity of each individual catalytic alpha subunit isoform,
will require the use of several different inhibitors.
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Appendix A – Structure, Physical and Chemical Properties
of Detergents
Table A.1 Structure, physical and chemical properties of detergents used in this study

Structure

Molecular
mass
(g/mol)

Critical
Micelle
Concentration
(mM)

Detergent

Type

CHAPS

Zwitterionic

614.9

6-10

SDS

Anionic

288.4

7-10

Tween-20

Non-ionic

1228

0.059

TX-100

Non-ionic

650

0.2-0.9
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Appendix B – Protein Sequence Analysis of Na+/K+-ATPase
B.1 The Alpha Subunit
CLUSTAL O(1.2.1) multiple sequence alignment
Alpha1 MGKGVGRDKYEPAAVSEHGDKKGKKAKKERDMDELKKEVSMDDHKLSLDELHRKYGTDLS
Alpha2 MGRGAGRE-YSPAAT-TAENGGGKKKQKEKELDELKKEVAMDDHKLSLDELGRKYQVDLS
Alpha3 MGDKKDDK-SSP---------KKSKAKERRDLDDLKKEVAMTEHKMSVEEVCRKYNTDCV
**
. .*
.* ::.:::*:*****:* :**:*::*: *** .*

60
58
50

Alpha1 RGLTPARAAEILARDGPNALTPPPTTPEWVKFCRQLFGGFSMLLWIGAILCFLAYGIRSA
Alpha2 KGLTNQRAQDILARDGPNALTPPPTTPEWVKFCRQLFGGFSILLWIGALLCFLAYGILAA
Alpha3 QGLTHSKAQEILARDGPNALTPPPTTPEWVKFCRQLFGGFSILLWIGAILCFLAYGIQAG
:*** :* :*******************************:******:******** :.

120
118
110

Alpha1 TEEEPPNDDLYLGVVLSAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIRNGEKMSI
Alpha2 MEDEPSNDNLYLGIVLAAVVIVTGCFSYYQEAKSSKIMDSFKNMVPQQALVIREGEKMQI
Alpha3 TEDDPSGDNLYLGIVLAAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIREGEKMQV
*::* *:****:**:****:****************:**************:****.:

180
178
170

Alpha1 NAEDVVVGDLVEVKGGDRIPADLRIISANGCKVDNSSLTGESEPQTRSPDFTNENPLETR
Alpha2 NAEEVVVGDLVEVKGGDRVPADLRIISSHGCKVDNSSLTGESEPQTRSPEFTHENPLETR
Alpha3 NAEEVVVGDLVEIKGGDRVPADLRIISAHGCKVDNSSLTGESEPQTRSPDCTHDNPLETR
***:********:*****:********:.********************: *.:******

240
238
230

Alpha1 NIAFFSTNCVEGTARGIVVYTGDRTVMGRIATLASGLEGGQTPIAEEIEHFIHLITGVAV
Alpha2 NICFFSTNCVEGTARGIVIATGDRTVMGRIATLASGLEVGQTPIAMEIEHFIQLITGVAV
Alpha3 NITFFSTNCVEGTARGVVVATGDRTVMGRIATLASGLEVGKTPIAIEIEHFIQLITGVAV
** *************:*: ****************** *:**** ******:*******

300
298
290

Alpha1 FLGVSFFILSLILEYTWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKN
Alpha2 FLGVSFFVLSLILGYSWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKN
Alpha3 FLGVSFFILSLILGYTWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKN
*******:***** *:********************************************

360
358
350

Alpha1 LEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTENQSGVSFDKTSATWFA
Alpha2 LEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTEDQSGATFDKRSPTWTA
Alpha3 LEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTEDQSGTSFDKSSHTWVA
********************************************:***.:*** * ** *

420
418
410

Alpha1 LSRIAGLCNRAVFQANQENLPILKRAVAGDASESALLKCIEVCCGSVMEMREKYSKIVEI
Alpha2 LSRIAGLCNRAVFKAGQENISVSKRDTAGDASESALLKCIELSCGSVRKMRDRNPKVAEI
Alpha3 LSHIAGLCNRAVFKGGQDNIPVLKRDVAGDASESALLKCIELSSGSVKLMRERNKKVAEI
**:**********:. *:*: : ** .**************:..*** **:: *:.**

480
478
470

Alpha1 PFNSTNKYQLSIHKNPNASEPKHLLVMKGAPERILDRCSSILLHGKEQPLDEELKDAFQN
Alpha2 PFNSTNKYQLSIHEREDSPQS-HVLVMKGAPERILDRCSTILVQGKEIPLDKEMQDAFQN
Alpha3 PFNSTNKYQLSIHETEDPNDNRYLLVMKGAPERILDRCATILLQGKEQPLDEEMKEAFQN
*************: : : ::**************::**::*** ***:*:::****

540
537
530

126

Alpha1 AYLELGGLGERVLGFCHLLLPDEQFPEGFQFDTDDVNFPVDNLCFVGLISMIDPPRAAVP
Alpha2 AYMELGGLGERVLGFCQLNLPSGKFPRGFKFDTDELNFPTEKLCFVGLMSMIDPPRAAVP
Alpha3 AYLELGGLGERVLGFCHYYLPEEQFPKGFAFDCDDVNFTTDNLCFVGLMSMIDPPRAAVP
**:*************: **. :**.** ** *::** .::******:***********

600
597
590

Alpha1 DAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVNQVNPRDA
Alpha2 DAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPREA
Alpha3 DAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPRDA
****************************************************.*****:*

660
657
650

Alpha1 KACVVHGSDLKDMTSEELDDILRYHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVN
Alpha2 KACVVHGSDLKDMTSEQLDEILRDHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVN
Alpha3 KACVIHGTDLKDFTSEQIDEILQNHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVN
****:**:****:***::*:**: ************************************

720
717
710

Alpha1 DSPALKKADIGVAMGIVGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTL
Alpha2 DSPALKKADIGIAMGISGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTL
Alpha3 DSPALKKADIGVAMGIAGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTL
***********:**** *******************************************

780
777
770

Alpha1 TSNIPEITPFLIFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEQAESDIMKRQPRNPK
Alpha2 TSNIPEITPFLLFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEAAESDIMKRQPRNSQ
Alpha3 TSNIPEITPFLLFIMANIPLPLGTITILCIDLGTDMVPAISLAYEAAESDIMKRQPRNPR
***********:**:*********:******************** ************ :

840
837
830

Alpha1 TDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPFHLLGIRETWDDRWVNDVED
Alpha2 TDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPSRLLGIRLDWDDRTTNDLED
Alpha3 TDKLVNERLISMAYGQIGMIQALGGFFSYFVILAENGFLPGNLVGIRLNWDDRTVNDLED
***************************:************ .*:*** **** .**:**

900
897
890

Alpha1 SYGQQWTYEQRKIVEFTCHTAFFVSIVVVQWADLVICKTRRNSVFQQGMKNKILIFGLFE
Alpha2 SYGQEWTYEQRKVVEFTCHTAFFASIVVVQWADLIICKTRRNSVFQQGMKNKILIFGLLE
Alpha3 SYGQQWTYEQRKVVEFTCHTAFFVSIVVVQWADLIICKTRRNSVFQQGMKNKILIFGLFE
****:*******:**********.**********:***********************:*

960
957
950

Alpha1 ETALAAFLSYCPGMGAALRMYPLKPTWWFCAFPYSLLIFVYDEVRKLIIRRRPGGWVEKE
Alpha2 ETALAAFLSYCPGMGVALRMYPLKVTWWFCAFPYSLLIFIYDEVRKLILRRYPGGWVEKE
Alpha3 ETALAAFLSYCPGMDVALRMYPLKPSWWFCAFPYSFLIFVYDEIRKLILRRNPGGWVEKE
************** .******** :*********:***:***:****:** ********

1020
1017
1010

Alpha1 TYY
Alpha2 TYY
Alpha3 TYY
***

1023
1020
1013

Figure B.1 Multiple sequence alignment of mouse Na+/K+-ATPase α subunits
Alignments were generated with Clustal Omega (1.2.1) on the EMBL-EBI website using UniProtKB
accession numbers, Q8VDN2, Q6PIE5, and Q6PIC6 for alpha 1, 2, 3, respectively. The amino acids are
coloured as follows: red (small and/or hydrophobic, i.e., A, V, F, P,M, I, L, W, and G), blue (acidic, i.e., D
and E), magenta (basic, i.e., R and K, and including H), and green (polar, i.e., S, T, N, Q, and C). In the
alignment, the consensus symbol asterisk (*) indicates positions which have a single, fully conserved
residue; symbol colon (:) indicates conservation between groups of strongly similar properties; and
symbol period (.) indicates conservation between groups of weakly similar properties.
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3 (96.3%) 7 (100%) 9 (100%) 21 (78%) 22 (83.7%) 24 (92.9%) 25 (87.5%) 27 (90.5%) 28 (8
4.6%) 30 (89.7%) 36 (82.6%) 37 (84.6%) 45 (100%) 53 (100%) 54 (84.3%) 61 (100%) 67 (1
00%) 74 (100%) 91 (100%) 94 (100%) 118 (100%) 153 (100%)156 (100%) 162 (100%) 173
(100%) 177 (100%) 194 (94.4%) 198 (94.1%) 204 (100%) 212 (100%) 227 (100%) 240 (10
0%) 255 (100%) 264 (100%) 269 (100%) 349 (87.3%) 350 (100%) 353 (95.3%) 354 (100%)
359 (85.7%) 377 (100%) 385(100%) 413 (100%) 423 (100%) 430 (100%) 444 (91.8%) 445
(100%) 458 (100%) 471 (100%) 473 (92.8%) 476 (100%) 487 (100%) 494 (100%) 502 (100
%) 508 (90.7%) 513 (75.6%) 517 (90.8%) 526 (100%) 535 (86.4%) 551 (94.1%) 596 (100%)
605 (100%) 607 (90.7%) 612 (100%) 625 (95.4%) 629 (100%) 647 (100%) 658 (100%) 661
(95.4%) 671 (86.4%) 683 (100%) 692 (100%) 698 (100%) 707 (100%) 726 (82.6%) 727 (87
.5%) 743 (100%) 766 (100%) 773 (82.6%) 774 (90.9%) 833(100%) 834 (100%) 837 (100%)
840 (100%) 843 (76.8%) 848 (100%) 887 (98.5%) 893 (100%) 911 (100%) 912 (100%) 938
(100%) 940 (90.9%) 941 (100%) 950 (100%) 952 (100%) 979 (100%) 984 (49.7%) 1005 (1
00%) 1006 (83.7%) 1010(82.6%) 1011 (30.6%) 1012 (30.4%) 1019 (79.9%)
Figure B.2 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase α1
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the
+ +
UniProtKB accession number Q8VDN2 for Na /K -ATPase α1. Cleavage is predicted to occur on the right
side (C-terminal direction) of the indicated amino acids.

3 (100%) 7 (100%) 22 (92.9%) 23 (78%) 24 (75.5%) 26 (84.3%) 28 (79.9%) 34 (82.6%) 35 (
84.6%) 43 (100%) 51 (90.9%) 52 (84.3%) 59 (93.9%) 65 (100%) 72 (100%) 89 (100%) 92 (1
00%) 151 (100%) 154 (100%) 160 (100%) 171 (98.5%) 175(100%) 192 (94.4%) 196 (100%
) 202 (100%) 210 (100%) 225 (100%) 238 (100%) 253 (100%) 262 (100%) 267 (100%) 347
(87.3%) 348 (100%) 351 (95.3%) 352 (100%) 357 (85.7%) 375 (100%) 383 (100%) 411 (73
.9%) 412 (100%) 421 (100%)428 (100%) 432 (86.4%) 442 (65%) 443 (100%) 456 (100%) 4
66 (100%) 467 (75%) 469 (100%) 471 (100%) 474 (100%) 485 (100%) 493 (78.4%) 505 (9
0.7%) 510 (75.6%) 514 (90.8%) 523 (100%) 529 (83.8%) 548 (94.1%) 561 (100%) 564(100
%) 567 (100%) 579 (94.7%) 593 (100%) 602 (100%) 604 (90.7%) 609 (100%) 622 (95.4%)
626 (100%) 644 (100%) 655 (100%) 658 (95.4%) 668 (86.4%) 680 (91.8%) 689 (100%) 695
(100%) 704 (100%) 723 (82.6%) 724 (87.5%) 740(100%) 763 (100%) 770 (82.6%) 771 (90
.9%) 830 (100%) 831 (100%) 834 (100%) 840 (76.8%) 845 (100%) 879 (100%) 884 (100%)
890 (100%) 908 (100%) 909 (84.5%) 935 (100%) 937 (90.9%) 938 (100%) 947 (100%) 949
(100%) 976 (100%)981 (92.4%) 1002 (100%) 1003 (83.7%) 1007 (100%) 1008 (87.3%) 10
16 (79.9%)
Figure B.3 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase α2
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the
+ +
UniProtKB accession number Q6PIE5 for Na /K -ATPase α2. Cleavage is predicted to occur on the right side
(C-terminal direction) of the indicated amino acids.
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4 (78%) 5 (84.6%) 8 (100%) 12 (86.6%) 13 (90.9%) 15 (100%) 17 (82%) 19 (100%) 20 (100
%) 26 (82.6%) 27 (84.6%) 35 (100%) 43 (45.3%) 44 (84.3%) 57 (100%) 64 (100%) 81 (100
%) 84 (100%) 143 (100%) 146 (100%) 152 (100%) 163 (98.5%)167 (100%) 184 (100%) 188
(100%) 194 (100%) 202 (100%) 217 (100%) 230 (100%) 245 (100%) 254 (100%) 259 (100
%) 271 (100%) 339 (87.3%) 340 (100%) 343 (95.3%) 344 (100%) 349 (85.7%) 367 (100%)
375 (100%) 403 (100%) 420(100%) 424 (100%) 434 (91.8%) 435 (100%) 448 (100%) 458 (
100%) 461 (100%) 463 (100%) 465 (84.1%) 466 (79.6%) 477 (100%) 492 (100%) 498 (90.7
%) 503 (75.6%) 507 (90.8%) 516 (100%) 525 (100%) 541 (94.1%) 557 (94%) 586 (100%)59
5 (100%) 597 (90.7%) 602 (100%) 615 (95.4%) 619 (100%) 637 (100%) 648 (100%) 651 (9
5.4%) 661 (86.4%) 682 (100%) 688 (100%) 697 (100%) 716 (82.6%) 717 (87.5%) 733 (100
%) 756 (100%) 763 (82.6%) 764 (90.9%) 823 (100%) 824(100%) 827 (100%) 830 (100%) 8
33 (76.8%) 838 (100%) 877 (100%) 883 (100%) 901 (100%) 902 (84.5%) 928 (100%) 930 (
90.9%) 931 (100%) 940 (100%) 942 (100%) 969 (100%) 974 (49.7%) 995 (84.6%) 996 (83.
7%) 1000 (100%) 1001(100%) 1009 (79.9%)
Figure B.4 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase α3
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the
+ +
UniProtKB accession number Q6PIC6 for Na /K -ATPase α3. Cleavage is predicted to occur on the right side
(C-terminal direction) of the indicated amino acids.

B.2 The Beta Subunit
CLUSTAL O(1.2.1) multiple sequence alignment
Beta1 -----MARGKAKEEGSWKKFIWNSEKKEFLGRTGGSWFKILLFYVIFYGCLAGIFIGTIQ 55
Beta2 MVIQKEKKSCGQVVEEWKEFVWNPRTHQFMGRTGTSWAFILLFYLVFYGFLTAMFSLTMW 60
Beta3 -MTKTEKKSFHQSLAEWKLFIYNPSSGEFLGRTSKSWGLILLFYLVFYGFLAALFTFTMW 59
:. :
.** *::* . :*:***. ** *****::*** *:.:* *:
Beta1 VMLLTISELKPTYQDRVAPPGLTQIPQIQK-TEISFRPNDPKSYEAYVLNIIRFLEKYKD 114
Beta2 VMLQTVSDHTPKYQDRLATPGLMIRPKTEN-LDVIVNISDTESWGQHVQKLNKFLEPYND 119
Beta3 AMLQTLNDEVPKYRDQIPSPGLMVFPKPQTALEYTFSMSEPQTYKKLVEDLESFLKPYSV 119
.** *:.: *.*:*:: ***
*: :. : . .: :::
* .: **: *.
Beta1 SAQKDDMIFEDCGNVPSEPKERGDINHERGERKVCRFKLDWLGNCSGLND-DSYGYREGK 173
Beta2 SIQAQKNDV--CR--PGRYYEQPDNGVLNYPKRACQFNRTQLGDCSGIGDPTHYGYSTGQ 175
Beta3 EEQKNL-TS--CP--DGAPFIQH-----GPDYRACQFPVSLLEECSGVTD-ANFGYSKGQ 168
. * :
*
.
:
:.*:*
* :***: *
:** *:
Beta1 PCIIIKLNRVLGFKPKPPKNESLETYPLMMKYNPNVLPVQCTGKRDEDKDKVGNIEYFGM 233
Beta2 PCVFIKMNRVINFYAGANQ----------------SMNVTCVGKRDEDAENLGHFVMFPA 219
Beta3 PCILVKMNRIIDLIPDGYP------------------QISCLPKEE-----NATIATYPE 205
**:::*:**:: :
: * *.:
. : :

129

Beta1 GGYYGFPLQYYPYYGKLLQPKYLQPLLAVQ--FTNLTVDTEIRVECKAYGE-N-IGYSEK 289
Beta2 NG--SIDLMYFPYYGKKFHVNYTQPLVAVK--FLNVTPNVEVNVECRINA-ANIATDDER 274
Beta3 FG--VLDLKYFPYYGKKRHVGYRQPLVAVQVKFDSGLNKKEVTVECHIAGTRNLKNKNER 263
*
: * *:***** : * ***:**: * .
. *: ***: . *
.*:
Beta1 DRFQGRFDVKIEIKS- 304
Beta2 DKFAGRVAFKLRINKT 290
Beta3 DKFLGRVSFKVTARA- 278
*:* **. .*: .

Figure B.5 Multiple sequence alignment of mouse Na+/K+-ATPase β subunits
Alignments were generated with Clustal Omega (1.2.1) on the EMBL-EBI website using UniProtKB
accession numbers, P14094, P14231, and P97370 for beta 1, 2, 3, respectively. The amino acids are
coloured as follows: red (small and/or hydrophobic, i.e., A, V, F, P,M, I, L, W, and G), blue (acidic, i.e., D
and E), magenta (basic, i.e., R and K, and including H), and green (polar, i.e., S, T, N, Q, and C). In the
alignment, the consensus symbol asterisk (*) indicates positions which have a single, fully conserved
residue; symbol colon (:) indicates conservation between groups of strongly similar properties; and
symbol period (.) indicates conservation between groups of weakly similar properties.

3 (100%) 5 (100%) 7 (82%) 13 (100%) 14 (100%) 21 (87.3%) 22 (84.6%) 27 (100%) 34 (10
0%) 65 (49.7%) 71 (100%) 85 (100%) 91 (51%) 96 (100%) 107 (100%) 111 (92.8%) 113 (87
%) 118 (100%) 134 (90.7%) 136 (100%) 143 (100%) 146(88.4%) 147 (84.5%) 150 (100%) 1
52 (100%) 170 (85.3%) 173 (51.9%) 179 (100%) 182 (100%) 187 (40.6%) 189 (8.1%) 192 (
100%) 204 (100%) 217 (84.7%) 218 (100%) 222 (37.7%) 224 (89.7%) 249 (100%) 254 (100
%) 274 (100%) 278 (100%)289 (83.2%) 291 (100%) 295 (100%) 299 (100%) 303 (100%)
Figure B.6 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase β1
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the
+ +
UniProtKB accession number P14094 for Na /K -ATPase β1. Cleavage is predicted to occur on the right
side (C-terminal direction) of the indicated amino acids.

5 (84.3%) 7 (87.3%) 8 (90.9%) 18 (100%) 25 (100%) 32 (100%) 72 (100%) 76 (79.4%) 85 (3
4.9%) 87 (100%) 109 (100%) 112 (91.4%) 125 (88.7%) 130 (32.6%) 133 (100%) 147 (90.7
%) 148 (100%) 154 (100%) 181 (100%) 184 (100%) 203(84.7%) 204 (100%) 233 (92.9%) 2
34 (100%) 247 (100%) 262 (100%) 274 (89.7%) 276 (64.2%) 280 (100%) 284 (100%) 286 (
100%) 289 (100%)
Figure B.7 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase β2
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the
+ +
UniProtKB accession number P14231 for Na /K -ATPase β2. Cleavage is predicted to occur on the right
side (C-terminal direction) of the indicated amino acids.
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3 (93.1%) 6 (87.3%) 7 (90.9%) 17 (100%) 31 (100%) 34 (100%) 71 (100%) 73 (90.6%) 86 (8
.1%) 104 (100%) 105 (82%) 115 (49.7%) 123 (88.7%) 142 (100%) 166 (93.9%) 174 (100%)
177 (100%) 194 (90.7%) 212 (100%) 219 (92.9%) 220(54.5%) 221 (70%) 226 (100%) 235 (
100%) 242 (84.1%) 243 (84.6%) 255 (100%) 258 (100%) 260 (80.3%) 263 (89.7%) 265 (64.
2%) 269 (100%) 273 (89.5%) 277 (100%)
Figure B.8 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase β3
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the
+ +
UniProtKB accession number P97370 for Na /K -ATPase β3. Cleavage is predicted to occur on the right
side (C-terminal direction) of the indicated amino acids.
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Appendix C – Predicted Functional Partners
C.1 Predicted Functional Partners of Na+/K+-ATPase Subunits
Table C.1 Predicted functional partners of Na+/K+-ATPase α and β subunits
+

+

Functional partners predicted for Na /K -ATPase α and β subunits in mice, using STRING 9.1 (http://stringdb.org/). Each suggested protein partner is listed in order of greatest evidence to least evidence.

Na+/K+ATPase
Subunit

Alpha 1

Alpha 2

Predicted Functional Partner
Protein

Gene

Sodium/potassium-transporting
ATPase subunit beta-1

Atp1b1

FXYD domain-containing ion
transport regulator 2

Fxyd2

Sodium/potassium-transporting
ATPase subunit beta-2

Atp1b2

Sodium/potassium-transporting
ATPase subunit beta-3

Atp1b3

Sodium/potassium-transporting
ATPase subunit alpha-2

Atp1a2

Sodium/potassium-transporting
ATPase subunit alpha-3

Atp1a3

Sodium/potassium-transporting
ATPase subunit alpha-4

Atp1a4

Solute carrier family 8
(sodium/calcium exchanger),
member 1

Scl8a1

Klotho

KI

Inositol 1,4,5-triphosphate receptor
1
Sodium/potassium-transporting
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Itpr1
Atp1b2

Evidence
Co-expression
Experiments
Databases
Textmining
Experiments
Databases
Textmining
Databases
Textmining
Experiments
Databases
Textmining
Co-occurrence
Co-expression
Databases
Textmining
Homology
Co-occurrence
Databases
Textmining
Homology
Co-occurrence
Databases
Homology
Experiments
Textmining
Experiments
Textmining
Experiments
Textmining
Co-expression

ATPase subunit beta-2
Sodium/potassium-transporting
ATPase subunit beta-1

Atp1b1

FXYD domain-containing ion
transport regulator 2

Fxyd2

Sodium/potassium-transporting
ATPase subunit beta-3

Atp1b3

Sodium/potassium-transporting
ATPase subunit alpha-3

Atp1a3

Sodium/potassium-transporting
ATPase subunit alpha-4

Atp1a4

Sodium/potassium-transporting
ATPase subunit alpha-1

Atp1a1

Solute carrier family 8
(sodium/calcium exchanger),
member 1
Inositol 1,4,5-triphosphate receptor
1
Potassium inwardly-rectifying
channel, subfamily J, member 9

Alpha 3

Slc8a1

Experiments
Textmining

Itpr1

Experiments
Textmining

Kcnj9

Textmining

FXYD domain-containing ion
transport regulator 2

Fxyd2

Sodium/potassium-transporting
ATPase subunit beta-2

Atp1b2

Sodium/potassium-transporting
ATPase subunit beta-3

Atp1b3

Sodium/potassium-transporting
ATPase subunit beta-1

Atp1b1
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Databases
Textmining
Co-expression
Databases
Textmining
Experiments
Databases
Textmining
Experiments
Databases
Textmining
Co-occurrence
Co-expression
Databases
Textmining
Homology
Co-occurrence
Databases
Textmining
Homology
Co-occurrence
Co-expression
Databases
Textmining
Homology

Experiments
Databases
Textmining
Co-expression
Databases
Textmining
Experiments
Databases
Textmining
Co-expression
Databases

Beta 1

Sodium/potassium-transporting
ATPase subunit alpha-2

Atp1a2

Sodium/potassium-transporting
ATPase subunit alpha-1

Atp1a1

Sodium/potassium-transporting
ATPase subunit alpha-4

Atp1a4

Agrin

Agrn

BR serine/threonine kinase 2

Brsk2

Dynein, axonemal, heavy chain 8

Dnahc8

Sodium/potassium-transporting
ATPase subunit alpha-1

Atp1a1

FXYD domain-containing ion
transport regulator 2

Fxyd2

Sodium/potassium-transporting
ATPase subunit alpha-2

Atp1a2

Sodium/potassium-transporting
ATPase subunit alpha-3

Atp1a3

Sodium/potassium-transporting
ATPase subunit alpha-4

Atp1a4

Sodium/potassium-transporting
ATPase subunit beta-2

Atp1b2

Sodium/potassium-transporting
ATPase subunit beta-3

Atp1b3

Sodium/potassium transporting
ATPase interacting 1
FXYD domain-containing ion
transport regulator 7
Sodium/potassium transporting
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Nkain1
Fxyd7
Nkain4

Textmining
Co-occurrence
Co-expression
Databases
Textmining
Homology
Co-occurrence
Databases
Textmining
Homology
Co-occurrence
Databases
Textmining
Homology
Textmining
Co-expression
Textmining
Textmining
Co-expression
Experiments
Databases
Textmining
Experiments
Databases
Co-expression
Databases
Textmining
Co-expression
Databases
Textmining
Databases
Textmining
Databases
Textmining
Homology
Databases
Textmining
Homology
Textmining
Experiments
Textmining
Textmining

ATPase interacting 4
Sodium/potassium-transporting
ATPase subunit alpha-2

Atp1a2

Sodium/potassium-transporting
ATPase subunit alpha-1

Atp1a1

Sodium/potassium-transporting
ATPase subunit alpha-3

Atp1a3

Sodium/potassium-transporting
ATPase subunit alpha-4
FXYD domain-containing ion
transport regulator 2

Atp1a4
Fxyd2

Beta 2
Sodium/potassium-transporting
ATPase subunit beta-3

Atp1b3

Sodium/potassium-transporting
ATPase subunit beta-1

Atp1b1

WD repeat containing, antisense to
TP53
Lymphocyte antigen 6 complex, locus
G6C
Rabaptin, RAB GTPase binding
effector protein 2

Beta 3

Wrap53

Textmining

Ly6g6c

Textmining

Rabep2

Textmining

Sodium/potassium-transporting
ATPase subunit alpha-3

Atp1a3

Sodium/potassium-transporting
ATPase subunit alpha-2

Atp1a2

Sodium/potassium-transporting
ATPase subunit alpha-1

Atp1a1

Sodium/potassium-transporting
ATPase subunit alpha-4
FXYD domain-containing ion
transport regulator 2
Sodium/potassium-transporting
ATPase subunit beta-2
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Co-expression
Databases
Textmining
Databases
Textmining
Co-expression
Databases
Textmining
Databases
Textmining
Experiments
Databases
Co-expression
Databases
Textmining
Homology
Databases
Textmining
Homology

Atp1a4
Fxyd2

Atp1b2

Experiments
Databases
Textmining
Experiments
Databases
Textmining
Experiments
Databases
Textmining
Experiments
Databases
Experiments
Databases
Co-expression
Databases
Textmining
Homology

Sodium/potassium-transporting
ATPase subunit beta-1

Atp1b1

Cartilage associated protein
RAS related protein 1b

Crtap
Rap1b

Databases
Textmining
Homology
Co-expression
Co-expression

C.2 Predicted Protein-Protein Interactions of Na+/K+-ATPase
Subunits

Figure C.1 The predicted functional partners of Na+/K+-ATPase α1
Image generated using STRING 9.1.

Figure C.2 The predicted functional partners of Na+/K+-ATPase α2
Image generated using STRING 9.1.
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Figure C.3 The predicted functional partners of Na+/K+-ATPase α3
Image generated using STRING 9.1.

Figure C.4 The predicted functional partners of Na+/K+-ATPase β1
Image generated using STRING 9.1.
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Figure C.5 The predicted functional partners of Na+/K+-ATPase β2
Image generated using STRING 9.1.

Figure C.6 The predicted functional partners of Na+/K+-ATPase β3
Image generated using STRING 9.1.
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Appendix D – Raw Data for Densitometric Analyses
Table D.1 Western blot intensity data for CD1 and ND4 myelin comparison
+

+

Raw data from densitometric analysis of CD1 and ND4 Western blot analysis. Intensities are provided for each Na /K -ATPase subunit isoform, as well as each
glycosylation state of the β1 subunit; Band 1 to Band 4 represent the highest molecular mass protein band to the lowest molecular mass (unglycosylated core)
protein band, respectively. Intensities were normalized to β-actin protein loading controls, and standard deviation of the pixel intensities in each sample was
calculated by Image Lab Version 5.0 (Bio-Rad).
Subunit Isoform
Age

Type of
Data

Raw Data

CD1
Control
Myelin

3.10
months

Normalized
Data

7.65
months

Raw Data

Measurement

Intensity of
Fluorescent Signal
(β-Actin control)
Standard Deviation
of Fluorescent
Signal
Intensity of
Enhanced
Chemiluminescent
Signal (Sample)
Standard Deviation
of
Chemiluminescent
Signal
Relative Intensity
Factor
Relative Intensity of
Enhanced
Chemiluminescent
Signal
Standard Deviation
of Relative Intensity
Intensity of
Fluorescent Signal

Alpha 1

Alpha 2

Alpha 3

Beta 1

Beta 2

Beta 3

Beta 1
Band 1

Beta 1
Band 2

Beta 1
Band 3

Beta 1
Band 4

1964105

2708061

1851844

1851844

1964105

2708061

1851844

1851844

1851844

1851844

799.0206

979.5301

801.8033

801.8033

799.0206

979.5301

801.8033

801.8033

801.8033

801.8033

483129.5

36782.64

1083381

1856270

2225996

3205753

250723

162529

176851

47232

3024.82

824.3722

4967.65

763.5356

7210.989

8782.518

979.4812

637.9062

625.3855

421.3716

0.25

0.34

0.23

0.23

0.25

0.34

0.23

0.23

0.23

0.23

1961504

108311.6

4665167

7993317

9037536

9439782

1079643

699869.2

761541.4

203386.6

12306.66

2427.794

21486.45

4773.681

29506.54

26085.77

4243.588

2763.564

2713.095

1816.612

7974260

6808667

1760731

1760731

7974260

6808667

1760731

1760731

1760731

1760731
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(β-Actin control)

Normalized
Data

Raw Data

9.00
months

Normalized
Data

Standard Deviation
of Fluorescent
Signal
Intensity of
Enhanced
Chemiluminescent
Signal (Sample)
Standard Deviation
of
Chemiluminescent
Signal
Relative Intensity
Factor
Relative Intensity of
Enhanced
Chemiluminescent
Signal
Standard Deviation
of Relative Intensity
Intensity of
Fluorescent Signal
(β-Actin control)
Standard Deviation
of Fluorescent
Signal
Intensity of
Enhanced
Chemiluminescent
Signal (Sample)
Standard Deviation
of
Chemiluminescent
Signal
Relative Intensity
Factor
Relative Intensity of
Enhanced
Chemiluminescent
Signal
Standard Deviation
of Relative Intensity

2567.282

2207.072

734.084

734.084

2567.282

2207.072

734.084

734.084

734.084

734.084

1175295

925577.6

2333128

1352819

6709981

6613303

94498.76

285076.6

367779.1

70889.52

9068.39

8504.181

10404.16

2258.68

18604.01

12467.35

1004.61

1836.48

3503.16

811.3904

1.00

0.85

0.22

0.22

1.00

0.85

0.22

0.22

0.22

0.22

1175295

1084030

10566615

6126846

6709981

7745452

427980

1291097

1665653

321054.9

9076.281

9966.23

47325.39

10543.55

18729.01

14815.96

4553.324

8334.723

15880.82

3677.182

4012486

4145130

4702827

4702827

4012486

4145130

4702827

4702827

4702827

4702827

1796.694

1850.12

2090.94

2090.94

1796.694

1850.12

2090.94

2090.94

2090.94

2090.94

1248363

694249.2

3619293

455475.7

5135876

3998997

45878.65

145469.6

87800.8

5208.42

8557.57

5894.32

12913.14

570.544

12736.53

8775.83

263.1928

649.2042

607.0426

116.3775

0.50

0.52

0.59

0.59

0.50

0.52

0.59

0.59

0.59

0.59

2480948

1335573

6136986

772318.8

10206841

7693134

77793.27

246662.7

148877.8

8831.559

17043.23

11354.95

22065.28

1026.566

25721.39

17228.29

447.6162

1106.26

1031.447

197.3724
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Raw Data

13.02
months

Normalized
Data

Raw Data
ND4
Transgenic
Myelin

3.10
months

Normalized
Data

Intensity of
Fluorescent Signal
(β-Actin control)
Standard Deviation
of Fluorescent
Signal
Intensity of
Enhanced
Chemiluminescent
Signal (Sample)
Standard Deviation
of
Chemiluminescent
Signal
Relative Intensity
Factor
Relative Intensity of
Enhanced
Chemiluminescent
Signal
Standard Deviation
of Relative Intensity
Intensity of
Fluorescent Signal
(β-Actin control)
Standard Deviation
of Fluorescent
Signal
Intensity of
Enhanced
Chemiluminescent
Signal (Sample)
Standard Deviation
of
Chemiluminescent
Signal
Relative Intensity
Factor
Relative Intensity of
Enhanced
Chemiluminescent
Signal

2266047

1818010

1281897

1281897

2266047

1818010

1281897

1281897

1281897

1281897

1123.899

789.0717

929.5972

929.5972

1123.899

789.0717

929.5972

929.5972

929.5972

929.5972

2697860

676230.2

3598350

650954.6

4566681

1653301

47033.25

198043

82480.5

49149.06

17006.02

5156.71

14758.39

1029.21

10633.07

4943.56

586.7155

1153.26

1489.24

421.3461

0.28

0.23

0.16

0.16

0.28

0.23

0.16

0.16

0.16

0.16

9493819

2966119

22384155

4049375

16070232

7251803

292578.4

1231960

513084.1

305740.2

60029.45

22655.26

93231.07

7043.682

38257.44

21910.97

3655.926

7229.464

9271.542

2630.416

2317390

3653502

1234209

1234209

2317390

3653502

1234209

1234209

1234209

1234209

958.5079

1127.46

736.5056

736.5056

958.5079

1127.46

736.5056

736.5056

736.5056

736.5056

873924.1

161674.6

1630287

842295.5

1510235

4864355

570

55844

258577

76477

4653.235

1382.791

7264.35

595.6856

4815.513

12951.38

381.5696

404.2201

938.8458

383.2174

0.29

0.46

0.15

0.15

0.29

0.46

0.15

0.15

0.15

0.15

3007218

352876.6

10533328

5442093

5196798

10617108

3682.785

360809.6

1670673

494119.9
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Raw Data

7.65
months

Normalized
Data

Raw Data
9.00
months

Normalized
Data

Standard Deviation
of Relative Intensity
Intensity of
Fluorescent Signal
(β-Actin control)
Standard Deviation
of Fluorescent
Signal
Intensity of
Enhanced
Chemiluminescent
Signal (Sample)
Standard Deviation
of
Chemiluminescent
Signal
Relative Intensity
Factor
Relative Intensity of
Enhanced
Chemiluminescent
Signal
Standard Deviation
of Relative Intensity
Intensity of
Fluorescent Signal
(β-Actin control)
Standard Deviation
of Fluorescent
Signal
Intensity of
Enhanced
Chemiluminescent
Signal (Sample)
Standard Deviation
of
Chemiluminescent
Signal
Relative Intensity
Factor
Relative Intensity of
Enhanced
Chemiluminescent

16060.26

3020.092

47354.18

5035.797

16709.26

28457.38

2465.332

2620.537

6147.289

2493.474

6932256

5945920

969985.3

969985.3

6932256

5945920

969985.3

969985.3

969985.3

969985.3

2417.751

1938.347

504.4575

504.4575

2417.751

1938.347

504.4575

504.4575

504.4575

504.4575

813033.6

455770

1621032

609532.3

6395463

6002612

2926.9

166333.5

168380.8

21381.14

6539.262

3467.39

7943.9

902.6996

18032.15

11167.67

205.0394

911.4549

1151.38

227.9837

0.87

0.75

0.12

0.12

0.87

0.75

0.12

0.12

0.12

0.12

935242.6

611247.5

13326520

5010972

7356780

8050291

24062.08

1367430

1384260

175774.6

7529.263

4654.493

65673.62

7865.382

20900.7

15205.5

1685.677

7526.752

9492.845

1876.484

5854361

5618304

6088181

6088181

5854361

5618304

6088181

6088181

6088181

6088181

2544.906

2239.23

2174.6

2174.6

2544.906

2239.23

2174.6

2174.6

2174.6

2174.6

2500319

1152316

5814317

1562077

8893667

5939907

31243.42

466539.3

461119.8

15398.23

15829.75

9213.09

16031.52

2536.84

20138.52

13223.55

305.6617

2257.18

3513.76

332.7187

0.73

0.70

0.76

0.76

0.73

0.70

0.76

0.76

0.76

0.76

3405699

1635523

7615554

2045998

12114115

8430721

40922.43

611070.1

603971.7

20168.5
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Signal

Raw Data

13.02
months

Normalized
Data

3.10
months

Normalized ND4
to CD1
Myelin
Ratios

7.65
months

Normalized
Data

Normalized
Data

9.00
months

Normalized
Data

13.02
months

Normalized
Data

Standard Deviation
of Relative Intensity
Intensity of
Fluorescent Signal
(β-Actin control)
Standard Deviation
of Fluorescent
Signal
Intensity of
Enhanced
Chemiluminescent
Signal (Sample)
Standard Deviation
of
Chemiluminescent
Signal
Relative Intensity
Factor
Relative Intensity of
Enhanced
Chemiluminescent
Signal
Standard Deviation
of Relative Intensity
Ratio of Diseased to
Healthy Relative
Intensities
Standard Deviation
of Normalized Ratio
Ratio of Diseased to
Healthy Relative
Intensities
Standard Deviation
of Normalized Ratio
Ratio of Diseased to
Healthy Relative
Intensities
Standard Deviation
of Normalized Ratio
Ratio of Diseased to
Healthy Relative

21612.56

13092.7

21173.44

3402.153

27931.7

19067.07

400.6204

2964.485

4607.353

435.8523

2821045

2185337

2443929

2443929

2821045

2185337

2443929

2443929

2443929

2443929

1343.626

970.8208

1115.91

1115.91

1343.626

970.8208

1115.91

1115.91

1115.91

1115.91

2998635

1148146

4201894

993252.2

6297561

3457138

25295

425775.8

178040.8

50861.83

17870.8

7724.68

14417.33

1622.31

14580.09

10064.49

344.8458

1964.29

1961.05

357.1174

0.35

0.27

0.31

0.31

0.35

0.27

0.31

0.31

0.31

0.31

8476252

4189565

13710298

3240868

17801338

12615038

82534.68

1389258

580926.5

165956.3

50676.52

28248.61

47456.8

5496.362

42076.66

37150.28

1125.823

6440.567

6404.176

1167.694

1.53

3.26

2.26

0.68

0.58

1.12

0.00

0.52

2.19

2.43

0.01

0.08

0.01

0.00

0.00

0.00

0.00

0.00

0.01

0.02

0.80

0.56

1.26

0.82

1.10

1.04

0.06

1.06

0.83

0.55

0.01

0.01

0.01

0.00

0.00

0.00

0.00

0.01

0.01

0.01

1.37

1.22

1.24

2.65

1.19

1.10

0.53

2.48

4.06

2.28

0.01

0.01

0.01

0.01

0.00

0.00

0.01

0.02

0.04

0.07

0.89

1.41

0.61

0.80

1.11

1.74

0.28

1.13

1.13

0.54
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Intensities
Standard Deviation
of Normalized Ratio

0.01

0.01

0.00
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0.00

0.00

0.01

0.01

0.01

0.02

0.01

Appendix E – Na+/K+-ATPase Endpoint and Kinetic Enzyme
Assays
E.1 Introduction
Evaluation of the enzymatic activity of Na+/K+-ATPase is a necessary step in the
characterization of this protein within the myelin membrane. The specific enzymatic
activity of Na+/K+-ATPase has been determined in other tissue and cell types by using
the K+-dependent p-nitrophenyl phosphatase (pNPPase) activity assay; it measures the
enzymatic activity of phosphatases [2]. This assay takes advantage of the chemical
reaction depicted in Figure E.1. The presence of phosphatases, such as Na+/K+-ATPase,
catalyzes the conversion of 4-nitrophenyl to 4-nitrophenol [4]. This chromogenic
product absorbs strongly at 410 nm, when deprotonated to produce p-nitrophenolate
[4]. Without deprotonation, 4-nitrophenol only weakly absorbs light at 405 nm. Thus,
this reaction can be manipulated by the addition of a strong base, such as sodium
hydroxide (NaOH), to ensure full deprotonation and allow an endpoint measurement of
absorption, such that Na+/K+-ATPase activity can be determined.

Figure E.1 The reaction utilized in the K+-dependent p-nitrophenyl phosphatase
activity assay
Alternatively, the evaluation of enzyme kinetics using the pNPPase assay
requires that the pH conditions of the reaction maximize both enzymatic activity and
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spectrophotometric detection. Although the pKa of 4-nitrophenol is approximately 7.2,
it is expected that physiological pH will provide the greatest Na+/K+-ATPase activity [6].
Studies of Na+/K+-ATPase activity in other tissue and cell types also generally use
inhibitors to distinguish between the total ATPase activity and Na+/K+-ATPase activity.
More specifically, the difference in enzyme activity between a reaction containing Na+,
K+, and Mg2+, and one without K+ but with 10-4 M ouabain, is often considered the
enzymatic activity attributed to Na+/K+-ATPase [7].

E.2 Materials and Methods
E.2.1 Materials
Ouabain octahydrate, sodium azide (NaN3) and p-nitrophenyl phosphate di(tris)
(pNPP) were purchased from Sigma-Aldrich (St. Louis, MO, USA). NaOH was obtained
from VWR Scientific Products (West Chester, PA, USA). All other materials were sourced
as previously described in section 2.1.

E.2.2 Methodology
Myelin was isolated from CD1 mouse brains using a modified version of the
sucrose gradient method developed by Norton [5]; this protocol was described
previously in section 2.3.1. The K+-dependent p-nitrophenyl phosphatase activity assay
was conducted using 96-well microplates, with 50 mM pNPP always prepared fresh
using ultrapure water. Blanks consisted of 75 µL of 2X reaction buffer (100 mM Tris/HCl,
0.1 mM EGTA, 5 mM MgCl2, and 15 mM KCl) and 65 µL of water; the pH of the reaction
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buffer was adjusted as needed for each experiment; ranging from 7.4 to 8.2. Samples
included 75 µL of 2X reaction buffer, 1-65 µL myelin protein (30 µg total), and were
brought to a total volume of 140 µL with water. In samples with inhibitor, 10 µL of water
was omitted and replaced with 10 µL of varying concentrations of either Na 3VO4, NaN3,
or ouabain; the sample or sample and inhibitor mixtures were incubated at 37 oC for 10
minutes prior to initiating the reaction. The reaction was initiated by the addition of 10
µL of 50 mM pNPP; it was also added to blanks. For endpoint measurements, the
reactions were incubated at 37oC for 20 minutes, stopped with the addition of 50 µL of
2N NaOH, and immediately measuring the absorbance at 410 nm. Alternatively, kinetic
measurements were taken every 30 seconds at 410 nm, over a 30 minute period, while
the reaction mixtures were maintained at 37oC. After 30 minutes, the reactions were
stopped by the addition of 50 µL of 2N NaOH, and the absorbance was measured again
at 410 nm. Controls which contained myelin protein but omitted the addition of 10 µL of
50 mM pNPP, by substituting it with water, were also prepared. The extinction
coefficient of p-nitrophenolate at 410 nm (18300 M-1cm-1) was used to calculate enzyme
activity.

E.3 Results
The enzyme activity of Na+/K+-ATPase in myelin, was evaluated kinetically at pH
7.6, 7.8, 8.0 and 8.2, over a 30 minute period. The results of this kinetic pNPPase activity
assay are shown in Figure E.2. The activity of Na+/K+-ATPase at each pH was determined
using the slope of the line of best fit of the linear portion of each reaction curve. These
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values, along with the activities determined using the absorbances at 410 nm after
samples were stopped with NaOH, are shown in Table E.1. There was no significant
change in absorbance over time in the blanks.

Figure E.2 Determination of the rate of change in absorbance over time, in myelin
samples of varying pH, at 410 nm
As expected, the blanks showed little or no enzymatic activity. Likewise, the
control samples without pNPP did not demonstrate an increase in absorbance over
time. The determined enzyme, and specific, activities from the pNPPase activity assays
suggests that pH 7.8 is optimal for the continued kinetic analysis of Na+/K+-ATPase; this
pH provides not only the highest measured absorbances, but also the greatest slope.
The final measured absorbances at 410 nm established that alterations in the pH of the
reaction buffer have little influence on the final measurement, post-addition of NaOH.
Table E.1 Calculated enzymatic activity of Na+/K+-ATPase, over a range of pH values

pH 7.6

Endpoint Assay
Enzyme Activity
Specific Activity
-1
(µmol min )
(µmol min-1 mg-1)
3.64E-04
1.21E-02
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Kinetic Assay
Enzyme Activity
Specific Activity
-1
(µmol min )
(µmol min-1 mg-1)
3.03E-03
1.01-01

pH 7.8
pH 8.0
pH 8.2

3.71E-04
3.56E-04
3.55E-04

1.24E-02
1.19E-02
1.18E-02

5.94E-03
4.24E-03
2.82E-03

1.98E-01
1.41E-01
9.41E-02

Endpoint pNPPase activity assays demonstrated that not only was phosphatase
activity greater in brain homogenate samples when compared to purified myelin
samples of equal protein content, but that enzyme activity exhibited a positive doseresponse; increased total myelin protein generated a linear increase in enzyme activity
(results not shown). The addition of 100 mM Na3VO4, 15 mM NaN3, or 10 mM ouabain
to the purified myelin samples also generated little or no change in enzyme activity,
although it did demonstrate significant decreases in the phosphatase activity of brain
homogenate samples of equal protein content (results not shown).

E.4 Discussion and Conclusions
Steady-state kinetics offers a very good approximation of the rates of enzymatic
reactions [3]. Although pH 7.8 appears to be ideal for kinetic evaluation of Na+/K+ATPase using the pNPPase activity assay, the kinetic lag observed in Figure E.2 dictates
that further method development is required. The kinetic lag may be a consequence of
investigating Na+/K+-ATPase activity within vesicles; recall that the isolated myelin exists
as vesicles and for the reaction substrate (pNPP) to interact with Na+/K+-ATPase, a
membrane protein, it may need to be incorporated into these vesicles [8]. The substrate
must be able to reach the active site of the enzyme, in order for this assay to be
successfully applied. A delay in pNPPase activity may therefore be the result of the time
requirement of this integration. The myelin vesicles themselves may also cause light
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scattering during spectrophotometric analysis, which would in turn cause fluctuations in
the measured absorbances at 410 nm. As a result, it may be necessary to further purify
Na+/K+-ATPase from the myelin membrane, such that its activity can be more accurately
assessed.
Ouabain-sensitivity has historically been used to identify the phosphatase
activity of a sample which is attributable to Na+/K+-ATPase [7]. Unfortunately, this does
not account for any enzymatic activity associated with the α1 isoform, as it is ouabainresistant. Only Na+/K+-ATPase α2 and α3 are ouabain-sensitive and will be successfully
inhibited [1]. Other inhibitors need to be examined for the accurate determination of
Na+/K+-ATPase activity within the myelin membrane. These may include sodium
vanadate, sodium azide, and potassium nitrate; they are inhibitors of P-type ATPase
activity, F0F1-type ATPase activity, and V-type ATPase activity, respectively. By using a
variety of phosphatase or ATPase inhibitors, it may also be possible to determine the
enzymatic activity attributable to each of the three Na+/K+-ATPase alpha isoforms in
myelin.
Once a kinetic activity assay for Na+/K+-ATPase of myelin origin has been
successfully developed, the reactions can be manipulated, and a variety of analyses can
be performed using the acquired data. Specific enzymatic activity, as well as initial rates,
Vmax, and the apparent Michaelis constant (KM) will be calculated. Dose-response
experiments may be performed using a range of substrate concentrations. Similarly, the
half maximal inhibitory concentration (IC50) of ouabain and other ATPase inhibitors can
be determined.
150

E.5 References
1. S. Alberti, E.A. Gregorio, C.T. Spadella & C. Cojocel, Localization and irregular
distribution of Na,K-ATPase in myelin sheath from rat sciatic nerve, Tissue Cell 39 (2007)
195-201.
2. M.L. Caspers, M. Bussone, M.J. Dow, L.J. Ulanski & P. Grammas, Alterations of
cerebromicrovascular Na +, K +- ATPase activity due to fatty acids and acute
hypertension, Brain Res. 602 (1993) 215-220.
3. A. Fersht, Enzyme Structure and Mechanism, W. H. Freeman and Company, San
Francisco, 1977.
4. M.G. Marichal, A.R. Delcastillo, P.M. Vasallo & E.B. Arias, Characterization of K+dependent and K+-independent p-nitrophenylphosphatase activity of synaptosomes,
Neurochem.Res. 18 (1993) 751-758.
5. W.T. Norton, Isolation of myelin from nerve tissue, Meth. Enzymol. 31 (1974) 435444.
6. S. Nouri & F. Haghseresht, Adsorption of p -Nitrophenol in Untreated and Treated
Activated Carbon, Adsorption 10 (2004) 79-86.
7. K. Renkawek, W.O. Renier, J.H.H.M. Pont, O.J.M. Vogels & F.J.M. Gabreels, Neonatal
Status Convulsivus, Spongiform Encephalopathy, and Low Activity of Na /K ‐ATPase in
the Brain, Epilepsia 33 (1992) 58-64.
8. Siegel, G.J., B.W. Agranoff, R.W. Albers, S.K. Fisher & M.D. Uhler. Basic
Neurochemistry: Molecular, Cellular and Medical Aspects. Philadelphia: LippincottRaven (1999).

151

Appendix F – Peptide Fragmentation in Mass Spectrometry

Figure F.1 Peptide fragmentation in mass spectrometry
The major y and b ions generated during protein identification by mass spectrometry are produced by
fragmentation at amide bonds. The assignment of y and b ion values to amino acid residues or peptide
fragments is indicated in red.

Table F.1 Residue masses of amino acids for protein identification in mass
spectrometry
The monoisotopic masses of amino acid residues are used for the sequencing of peptides in mass
spectrometry. The 20 common amino acids often fragment at amide bonds generating the major y and b
fragment ions which have mass-to-charge ratios that correspond to these monoisotopic masses.

Structure

Monoisotopic Mass
of Residue

Amino Acid

Symbol

Type

Alanine

A

Non-polar,
aliphatic

71.03711

Arginine

R

Positively
charged

156.10111

Asparagine

N

Polar,
uncharged

114.04293
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Aspartate

D

Negatively
charged

115.02694

Cysteine

C

Polar,
uncharged

103.00919

Glutamine

Q

Polar,
uncharged

128.05858

Glutamate

E

Negatively
charged

129.04259

Glycine

G

Non-polar,
aliphatic

57.02146

Histidine

H

Positively
charged

137.05891

Isoleucine

I

Non-polar,
aliphatic

113.08406

Leucine

L

Non-polar,
aliphatic

113.08406

Lysine

K

Positively
charged

128.09496

Methionine

M

Non-polar,
aliphatic

131.04049

Phenylalanine

F

Aromatic

147.06841
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Proline

P

Non-polar,
aliphatic

97.05276

Serine

S

Polar,
uncharged

87.03203

Threonine

T

Polar,
uncharged

101.04768

Tryptophan

W

Aromatic

186.07931

Tyrosine

Y

Aromatic

163.06333

Valine

V

Non-polar,
aliphatic

99.06841
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Appendix G – Additional Western Blots

Figure G.1 Protein expression in myelin isolated using sucrose and Percoll gradient
methods
Enhanced chemiluminescent Western blot detection of MCT1, VDAC, NQO1, and MBP in partially
delipidated myelin samples, of equivalent protein content, from sucrose-gradient and Percoll-gradient
isolation methods. Equal volumes (12.5 µL), and therefore equal protein (approximately 50 µg of total
myelin protein), of each sample were separated on 14% SDS-PAGE and transferred to nitrocellulose
membrane. The corresponding primary and secondary antibodies used are described in Table 2.3. Each
Western blot was imaged using the VersaDoc 4000 (Bio-Rad) with an exposure time of 30-400 seconds,
ensuring non-saturation.

Figure G.2 Comparison of isolated myelin with brain homogenate
Enhanced chemiluminescent Western blot detection of: A) Na+/K+-ATPase and VDAC; B) MCT1; in
partially delipidated brain homogenate and myelin samples, of equivalent protein content, from sucrosegradient and Percoll-gradient isolation methods. Equal volumes (18.75 µL), and therefore equal protein
(approximately 75 µg of total myelin protein), of each sample were separated on 14% SDS-PAGE and
transferred to nitrocellulose membrane. The corresponding primary and secondary antibodies used are
described in Table 2.3. Each Western blot was imaged using the VersaDoc 4000 (Bio-Rad) with an
exposure time of 30-400 seconds, ensuring non-saturation.
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Figure G.3 Detection of Na+/K+ATPase subunit isoforms in
myelin DRMs
Enhanced chemiluminescent Western
+ +
blot detection of: A) Na /K -ATPase α2
+ +
and β3; B) Na /K -ATPase α2 and β3; C)
+ +
Na /K -ATPase β1. Equal volumes (20
µL) of each acetone-precipitated lipid
raft fraction (B1-10, C1-10, and D110), isolated as CHAPS DRMs, were
separated on 12% SDS-PAGE and
transferred to nitrocellulose
membrane. Fractions B3, B4, C3, C4,
D3 and D4 represent the low density,
raft fractions; alternatively, fractions
B9, B10, C9, C10, D9 and D10
represented the non-raft, high density
fractions. The corresponding primary
and secondary antibodies used are
described in Table 2.3. Each Western
blot was imaged using the VersaDoc
4000 (Bio-Rad) with an exposure time
of 30-200 seconds, ensuring nonsaturation.
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Appendix H – Comparison of Densitometric Data Without β-Actin Control
Table H.1 Western blot intensity data for alternate sample sets without a β-actin control

+

+

Raw data from densitometric analysis of CD1 and ND4 Western blot analysis, without normalization to β-actin. Intensities are provided for each Na /K -ATPase
subunit isoform, as well as each glycosylation state of the β 1 subunit; Band 1 to Band 4 represent the highest molecular mass protein band to the lowest
molecular mass (unglycosylated core) protein band, respectively. Standard deviation of the pixel intensities in each sample was calculated by Image Lab
Version 5.0 (Bio-Rad).
Subunit Isoform
Age

Data
Set

1
3.10
months
2

CD1 Control
Myelin

1
7.65
months
2

9.00
months

1

Measurement

Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal

Alpha 1

Alpha 2

Alpha 3

Beta 1

Beta 2

Beta 3

Beta 1
Band 1

Beta 1
Band 2

Beta 1
Band 3

Beta 1
Band 4

949982

177210.5

3338678

369958.2

3736108

2786185

54978.14

68599

55692.29

29271

6188.159

2576.144

13824.59

588.9315

10654.79

7338.029

496.1169

572.695

762.3669

312.121

483129.5

36782.64

1083381

1856270

2225996

3205753

250723

162529

176851

47232

3024.82

824.3722

4967.65

763.5356

7210.989

8782.518

979.4812

637.9062

625.3855

421.3716

2385123

17775.33

3762310

1212395

6004631

3298992

43489.79

290223.8

473463.4

143777.6

15042.21

2149.99

16047.69

2054.5

14520.01

8695.68

363.794

1350.82

3290.72

806.4366

1175295

925577.6

2333128

1352819

6709981

6613303

94498.76

285076.6

367779.1

70889.52

9068.39

8504.181

10404.16

2258.68

18604.01

12467.35

1004.61

1836.48

3503.16

811.3904

455076.3

366972

2568857

317021.5

5010588

4812661

28243.8

113739.1

81498.15

11115.8

2195.755

2800.039

13599.17

623.7382

11997.7

9867.872

335.1071

750.8703

938.0963

155.6221
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2

1
13.02
months
2

1
3.10
months
2

ND4
Transgenic
Myelin

1
7.65
months
2

1
9.00
months
2

Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)

1248363

694249.2

3619293

455475.7

5135876

3998997

45878.65

145469.6

87800.8

5208.42

8557.57

5894.32

12913.14

570.544

12736.53

8775.83

263.1928

649.2042

607.0426

116.3775

2545489

34753.5

2764283

312825.4

3780305

3199185

44710.23

123206.2

35265.69

391.9821

17300.53

1325.992

11451.41

536.1424

10378.71

9319.39

472.5498

560.7273

521.9172

49.98207

2697860

676230.2

3598350

650954.6

4566681

1653301

47033.25

198043

82480.5

49149.06

17006.02

5156.71

14758.39

1029.21

10633.07

4943.56

586.7155

1153.26

1489.24

421.3461

2791077

166966.3

4204345

413235.6

2247258

4700973

6645.86

79621.71

176561

30409.86

18301.66

4499.504

16928.69

1009.66

6156.039

11436.92

204.3782

580.6925

1912.33

317.0696

873924.1

161674.6

1630287

842295.5

1510235

4864355

570

55844

258577

76477

4653.235

1382.791

7264.35

595.6856

4815.513

12951.38

381.5696

404.2201

938.8458

383.2174

1426324

87658.67

2845655

414859.3

5230054

4985924

-6062.7

205027.6

133935

11218.42

9267.994

1842.78

13517.72

908.0418

13567.35

10727.75

153.5906

1039.3

1163.36

173.7648

813033.6

455770

1621032

609532.3

6395463

6002612

2926.9

166333.5

168380.8

21381.14

6539.262

3467.39

7943.9

902.6996

18032.15

11167.67

205.0394

911.4549

1151.38

227.9837

1804484

483497.7

3350180

855650.9

10624075

6537429

28272.75

260014.3

346565.8

19455

7956.94

2906.148

16027.87

1930.13

19336.02

13971.82

370.173

1394.09

3616.76

265.9338

2500319

1152316

5814317

1562077

8893667

5939907

31243.42

466539.3

461119.8

15398.23
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1
13.02
months
2

3.10
months

Ratio (CD1
Control
Myelin to
ND4
Transgenic
Myelin)

7.65
months

9.00
months

13.02
months

1
2
1
2
1
2
1
2

Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Intensity of Enhanced
Chemiluminescent Signal
(Sample)
Standard Deviation of
Chemiluminescent Signal
Ratio of Diseased to Healthy
Intensities
Ratio of Diseased to Healthy
Intensities
Ratio of Diseased to Healthy
Intensities
Ratio of Diseased to Healthy
Intensities
Ratio of Diseased to Healthy
Intensities
Ratio of Diseased to Healthy
Intensities
Ratio of Diseased to Healthy
Intensities
Ratio of Diseased to Healthy
Intensities

15829.75

9213.09

16031.52

2536.84

20138.52

13223.55

305.6617

2257.18

3513.76

332.7187

1550445

338870.9

2635873

669467.8

7384027

4600099

55969.46

319809

90608.92

9454.8

9899.051

3626.769

12132.26

1128.22

16507.52

12479.78

602.2975

1287.1

923.8873

101.5365

2998635

1148146

4201894

993252.2

6297561

3457138

25295

425775.8

178040.8

50861.83

17870.8

7724.68

14417.33

1622.31

14580.09

10064.49

344.8458

1964.29

1961.05

357.1174

2.938031

0.942192

1.259284

1.116979

0.601497

1.687244

0.120882

1.160683

3.170295

1.038907

1.808882

4.395406

1.504814

0.453757

0.678454

1.517383

0.002273

0.343594

1.462118

1.619178

0.598009

4.931479

0.756358

0.342182

0.871003

1.511348

-0.13941

0.706446

0.282883

0.078026

0.69177

0.492417

0.694789

0.450565

0.953127

0.907657

0.030973

0.583469

0.457831

0.301612

3.965235

1.317533

1.304152

2.699031

2.120325

1.358381

1.001025

2.28606

4.252437

1.750211

2.002878

1.659801

1.606479

3.429549

1.731675

1.485349

0.681001

3.207126

5.251886

2.956411

0.609095

9.750699

0.953547

2.140069

1.953288

1.437897

1.251827

2.595722

2.569322

24.12049

1.111486

1.697862

1.167728

1.525839

1.379024

2.091051

0.537811

2.149917

2.15858

1.034848
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Figure H.1 Compared intensities of each Na+/K+-ATPase subunit isoform, between two
sets of CD1 and ND4 myelin samples, in each age group
+

+

Intensity of each Na /K -ATPase subunit isoform, ensuring non-saturation and subtracting background.
Comparisons were for CD1 and ND4 myelin at: A) 3.00 months of age; B) 7.65 months of age; C) 9.00
months of age; D) 13.02 months of age.
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Figure H.2 Compared intensities of each Na+/K+-ATPase β1 glycosylation state,
between two sets of CD1 and ND4 myelin samples, in each age group
+

+

Intensity of each Na /K -ATPase β1 glycosylation state, ensuring non-saturation and subtracting
+ +
background. Bands 1 to 4 represent the highest molecular weight form of Na /K -ATPase β1 (3 N-glycans)
to the lowest molecular weight form (core, non-glycosylated), respectively. Comparisons were for CD1
and ND4 myelin at: A) 3.00 months of age; B) 7.65 months of age; C) 9.00 months of age; D) 13.02 months
of age.
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Figure H.3 Ratio of intensities for each Na+/K+-ATPase subunit isoform in ND4 myelin,
relative to CD1 myelin, with aging
+

+

Intensity of each Na /K -ATPase subunit isoform in ND4 myelin relative to CD1 myelin, ensuring nonsaturation and subtracting background. Results from two separate Western blot data sets are shown
(Sample 1 and Sample 2). Intensity was measured at 3.10, 7.65, 9.00 and 13.02 months of age.
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Figure H.4 Ratio of intensities for each Na+/K+-ATPase β1 glycosylation state in ND4
myelin, relative to CD1 myelin, with aging
+

+

Intensity of each Na /K -ATPase β1 glycosylation state in ND4 myelin relative to CD1 myelin, ensuring nonsaturation and subtracting background. Bands 1 to 4 represent the highest molecular weight form of
+ +
Na /K -ATPase β1 (3 N-glycans) to the lowest molecular weight form (core, non-glycosylated),
respectively. Results from two separate Western blot data sets are shown (Sample 1 and Sample 2).
Intensity was measured at 3.10, 7.65, 9.00 and 13.02 months of age.
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